<SEC-DOCUMENT>0000875045-15-000012.txt : 20150424
<SEC-HEADER>0000875045-15-000012.hdr.sgml : 20150424
<ACCEPTANCE-DATETIME>20150424071113
ACCESSION NUMBER:		0000875045-15-000012
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150423
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150424
DATE AS OF CHANGE:		20150424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		15789948

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>q12015earnings8-k.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Q1 2015 Earnings 8-K</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s84CA93C3E229486035B96BDF2660536F"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">Date of Report (Date of earliest event reported):  </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">April 24, 2015</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:24pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:16pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter) </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="38%"></td><td width="31%"></td><td width="31%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">0-19311</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">33-0112644</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of incorporation)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Commission File Number)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(IRS Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">225 Binney Street, Cambridge, Massachusetts 02142</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address of principal executive offices; Zip Code)</font></div><div style="line-height:120%;text-indent:348px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Registrant&#8217;s telephone number, including area code:  </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(617) 679-2000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Former name or former address, if changed since last report.)</font></div><div style="line-height:120%;text-indent:348px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s84CA93C3E229486035B96BDF2660536F"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 24, 2015, Biogen Inc. issued a press release announcing its results of operations and financial condition for the first quarter ended March 31, 2015.  A copy of the press release is furnished as Exhibit 99 and is incorporated herein by reference. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</font></div><div style="line-height:120%;text-align:justify;text-indent:45px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibit listed on the Exhibit Index immediately preceding such exhibit is furnished as part of this Current Report on Form 8-K.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s84CA93C3E229486035B96BDF2660536F"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:348px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:348px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">By: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Steven N. Avruch</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-indent:372px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Steven N. Avruch</font></div><div style="line-height:120%;text-indent:372px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Corporation Counsel and Assistant Secretary</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date:  April 24, 2015</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s84CA93C3E229486035B96BDF2660536F"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:69.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="28%"></td><td width="72%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;text-decoration:underline;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's press release dated April 24, 2015.</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>q12015pressrelease.htm
<DESCRIPTION>EXHIBIT 99
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Q1 2015 Press Release</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sB544DC7CCE6AC17DB3EC6BDF2489D9A7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;"><img src="biogenlogostandardrgb01.jpg" style="font-size:12pt;height:57px;width:173px;"></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Biogen Media Contact:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Biogen Investor Contact:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Kate Niazi-Sai </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Ben Strain </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Biogen Inc. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Biogen Inc. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tel: (781) 464-3260</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Tel: (781) 464-2442</font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Carlo Tanzi, Ph.D.</font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Biogen Inc. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">Tel: (781) 464-2442</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BIOGEN REPORTS FIRST QUARTER 2015 REVENUES OF $2.6 BILLION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">Multiple sclerosis portfolio gains share globally with ongoing TECFIDERA</font><font style="font-family:inherit;font-size:12pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#32;rollout in Europe and launch of PLEGRIDY</font><font style="font-family:inherit;font-size:12pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup>&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">Company advances research pipeline and development efforts in Alzheimer&#8217;s disease, secondary progressive MS and neurological repair for MS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cambridge, Mass., April 24, 2015 -- </font><font style="font-family:inherit;font-size:12pt;">Biogen Inc. (NASDAQ: BIIB) today reported first quarter 2015 results, including revenues of $2.6 billion, a 20% increase compared to the first quarter of 2014.  Non-GAAP diluted earnings per share (EPS) for the first quarter of 2015 were $3.82, an increase of 55% over the first quarter of 2014.  Non-GAAP net income attributable to Biogen for the first quarter of 2015 was $900 million, an increase of 53% over the first quarter of 2014.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On a reported basis, GAAP diluted EPS for the first quarter of 2015 were $3.49, an increase of 73% over the first quarter of 2014.  GAAP net income attributable to Biogen for the first quarter of 2015 was $823 million, an increase of 71% versus the same period in the prior year.  (A reconciliation of GAAP to Non-GAAP quarterly financial results can be found in Table 3 at the end of this release).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;In the first quarter, we continued to gain share in the MS market and we believe that our MS product portfolio is well positioned to provide patients the breadth of choices that they need,&#8221; said Chief Executive Officer George A. Scangos, Ph.D.  &#8220;While we saw moderating patient growth of our oral MS therapy TECFIDERA in the U.S. and Germany, the launch of PLEGRIDY continued to go well, and we have seen continued strong performance from TYSABRI.  We believe that our portfolio offers patients leading choices among oral, interferon, and high-efficacy therapies, and we look forward to continued growth in our global market share.&#8221;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Last month we presented compelling data for aducanumab (BIIB037), and we are planning to initiate Phase 3 studies later this year,&#8221; Dr. Scangos continued. &#8220;In January we reported top line results of our phase 2 study of anti-LINGO in acute optic neuritis, which we believe demonstrate this compound&#8217;s ability to remyelinate damaged neurons, and we presented detailed results of this study at AAN earlier this week.  For the remainder of 2015, we look forward to continued pipeline progress, including a Phase 3 readout for TYSABRI in secondary progressive MS and Phase 2 data for both TYSABRI in acute ischemic stroke and Neublastin in neuropathic pain.&#8221;&#160;&#160; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">First Quarter 2015 Performance Highlights </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB544DC7CCE6AC17DB3EC6BDF2489D9A7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Total multiple sclerosis product sales were $2.1 billion compared to $1.7 billion in the same quarter last year.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">TECFIDERA revenues were $825 million compared to $506 million in the same quarter last year.  These results consisted of $648 million in U.S. sales and $177 million in sales outside the U.S. compared to $460 million and $46 million, respectively, in the first quarter of 2014.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">TECFIDERA revenues in the first quarter of 2015 decreased 10% versus the fourth quarter of 2014.  This decline was partially impacted by one fewer shipping week in the U.S. versus the prior quarter, increased discounts and allowances specific to the first quarter of 2015 and updated pricing assumptions in Germany.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Interferon revenues, including AVONEX</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;and PLEGRIDY, were $755 million compared to $761 million in the same quarter last year. These results consisted of $518 million in U.S. sales and $236 million in sales outside the U.S. compared to $476 million and $285 million, respectively, in the first quarter of 2014.  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">TYSABRI</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;revenues were $463 million compared to $441 million in the same quarter last year. These results consisted of $273 million in U.S. sales and $190 million in sales outside the U.S. compared to $234 million and $207 million, respectively, in the first quarter of 2014.  TYSABRI U.S. sales include 13 shipping weeks in the first quarter of 2015 versus 12 in the first quarter of 2014.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Net revenues relating to RITUXAN</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;and GAZYVA</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;from our unconsolidated joint business arrangement were $331 million compared to $297 million in the same quarter last year.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ELOCTATE</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;revenues were $54 million and ALPROLIX</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;revenues were $43 million.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Other Financial Highlights</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Revenues for FAMPYRA</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;and FUMADERM&#8482; were $34 million compared to $35 million in the same quarter last year.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Royalty revenues were $20 million compared to $38 million in the same quarter last year.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Corporate partner revenues were $32 million compared to $52 million in the same quarter last year.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Non-GAAP SG&amp;A expense was $560 million compared to $509 million in the same quarter last year.  GAAP SG&amp;A expense was $560 million compared to $512 million in the same quarter last year.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Non-GAAP R&amp;D expense was $461 million compared to $527 million in the same quarter last year.  GAAP R&amp;D expense was $461 million compared to $529 million in the same quarter last year.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">As of March 31, 2015, Biogen had cash, cash equivalents and marketable securities totaling approximately $3.5 billion.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Neurology Highlights</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In January 2015, Biogen announced positive top-line results from the Phase 2 acute optic neuritis (AON) RENEW trial in which treatment with anti-LINGO-1 showed evidence of biological repair of the visual system.  Anti-LINGO-1 also demonstrated an acceptable safety profile.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB544DC7CCE6AC17DB3EC6BDF2489D9A7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In January 2015, Biogen and Google[x] Life Sciences began a partnership to explore drivers of multiple sclerosis disease progression through investigational technologies and methods, such as novel sensor platforms, advanced laboratory science, and bio-analytical tools.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In February 2015, an international consortium that includes scientists and clinicians from Columbia University Medical Center (CUMC), Biogen and HudsonAlpha Institute for Biotechnology announced the identification of a new gene that is associated with sporadic amyotrophic lateral sclerosis, or Lou Gehrig&#8217;s disease.  The study was published in the online edition of </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Science</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In March 2015, Biogen announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037), in which the compound demonstrated an acceptable safety profile and positive results on radiologic and clinical measurements in patients with prodromal or mild Alzheimer&#8217;s disease.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In March 2015, the European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) for ZINBRYTA&#8482; for the treatment of relapsing forms of multiple sclerosis.  ZINBRYTA is being jointly developed by Biogen and AbbVie.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In April 2015, Biogen initiated a Phase 3 study of TECFIDERA in secondary progressive multiple sclerosis.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This week, Biogen is presenting new clinical data supporting the Company&#8217;s marketed and investigational therapies for neurological diseases at the 67th American Academy of Neurology Annual Meeting.  The 73 company-sponsored platform and poster presentations include subgroup efficacy data for TECFIDERA, long-term safety and efficacy data for PLEGRIDY, full results from the Phase 2 RENEW trial of anti-LINGO-1 in acute optic neuritis, subgroup data from the PRIME study of aducanumab in Alzheimer&#8217;s disease, and data from the Phase 3 DECIDE study of ZINBRYTA in relapsing-remitting multiple sclerosis.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Hemophilia Highlights</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In January 2015, Biogen, Fondazione Telethon and Ospedale San Raffaele announced they entered into a worldwide collaboration to jointly develop gene therapies for the treatment of both hemophilia A and B.  The agreement will combine San Raffaele - Telethon Institute for Gene Therapy&#8217;s extensive expertise in creating new gene therapy strategies and developing them from the bench to bedside with Biogen&#8217;s deep understanding of hematology to potentially treat the underlying causes of hemophilia A and B. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In February 2015, Biogen and Swedish Orphan Biovitrum AB announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of ALPROLIX</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt"> </sup></font><font style="font-family:inherit;font-size:12pt;">in children under age 12 with severe hemophilia B.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In March 2015, ELOCTATE was launched in Japan, becoming the first available recombinant hemophilia A therapy in Japan that has prolonged circulation in the body.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Immunology Highlights</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In February 2015, Biogen&#8217;s collaboration partner UCB announced that dapirolizumab pegol (Anti-CD40 Ligand) was well tolerated in a Phase 1b trial in systemic lupus erythematosus.  The compound is expected to progress to Phase 2 in 2016.</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB544DC7CCE6AC17DB3EC6BDF2489D9A7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Other Events </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In January 2015, Biogen and Columbia University Medical Center formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to identify new treatment approaches.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In January 2015, Samsung Bioepis, a joint venture (JV) between Samsung Biologics and Biogen, received EMA acceptance and validation of its MAA for its etanercept biosimilar candidate.  In March 2015, the EMA also accepted and validated the MAA for the JV&#8217;s infliximab biosimilar candidate.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In February 2015, Biogen completed its acquisition of U.K.-based Convergence Pharmaceuticals.  Convergence is a clinical-stage biopharmaceutical company with an innovative portfolio of ion channel-modulating product candidates for neuropathic pain including CNV1014802, a product candidate being developed for trigeminal neuralgia, a chronic orphan disease.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Conference Call and Webcast </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company's earnings conference call for the first quarter will be broadcast via the internet at 8:00 a.m. EDT on April 24, 2015, and will be accessible through the Investors section of Biogen&#8217;s homepage, </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.biogen.com</font><font style="font-family:inherit;font-size:12pt;">.  Supplemental information in the form of a slide presentation will also be accessible at the same location on the internet at the time of the conference call and will be subsequently available on the website for at least one month.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Biogen</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.  Founded in 1978, Biogen is the world&#8217;s oldest independent biotechnology company and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.  For product labeling, press releases and additional information about the Company, please visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.biogen.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Safe Harbor </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This press release contains forward-looking statements, including statements about the prospects of our product portfolio, the potential and progress of our pipeline and business development activities, and anticipated clinical trials and data readouts.  These forward-looking statements may be accompanied by such words as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;will&#8221; and other words and terms of similar meaning. You should not place undue reliance on these statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our dependence on sales from our principal products; failure to compete effectively due to significant product competition in the markets for our products; failure to protect and enforce our data, intellectual property and other proprietary rights and the risks and uncertainties relating to intellectual property claims; difficulties in obtaining adequate coverage or changes in pricing or the availability of reimbursement for our products; the occurrence of adverse safety events, restrictions on use with our products or product liability claims; uncertainty of success in developing, licensing or acquiring other product candidates or additional indications for existing products, including the risk that unexpected concerns may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies or may fail to </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB544DC7CCE6AC17DB3EC6BDF2489D9A7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">approve or may delay approval of our drug candidates; results in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; our dependence on collaborators and other third parties for the development and commercialization of products and other aspects of our business, which are outside of our control; failure to manage our growth and execute our growth initiatives; problems with our manufacturing processes or capacity; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including exchange rate fluctuations; charges and other costs relating to our properties; currency fluctuations; fluctuations in our effective tax rate; the market, interest and credit risks associated with our portfolio of marketable securities; environmental risks; and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the SEC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">###</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB544DC7CCE6AC17DB3EC6BDF2489D9A7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE 1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENT OF INCOME</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-style:italic;font-weight:bold;">(unaudited, in thousands, except per share amounts)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:644px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="438px"></td><td width="9px"></td><td width="86px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="86px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,172,322</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,742,765</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">330,611</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">296,885</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19,814</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37,856</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate partner</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">32,216</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52,245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,554,963</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,129,751</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Cost and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">312,431</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">279,245</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">460,549</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">528,884</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">560,361</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">511,674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">95,903</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143,258</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,844</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(799</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,437,088</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,462,262</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain on sale of rights</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,859</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,117,875</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">671,348</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14,986</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5,601</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,102,889</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">665,747</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">281,881</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">178,414</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">834</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">820,174</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">479,728</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Net income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,367</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(228</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">822,541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">479,956</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.02</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">234,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236,786</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235,630</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB544DC7CCE6AC17DB3EC6BDF2489D9A7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE 2</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-style:italic;font-weight:bold;">(unaudited, in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:613px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="388px"></td><td width="9px"></td><td width="97px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="97px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">March 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#2573ba;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,151,997</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,845,384</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,389,995</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,292,445</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">825,349</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804,022</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">891,555</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">730,822</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,258,896</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,672,673</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,377,325</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,470,652</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,739,628</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,765,683</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,353,123</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,028,507</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,849,852</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,760,249</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">640,630</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">618,795</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TOTAL ASSETS</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15,219,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14,316,559</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#2573ba;font-weight:bold;">LIABILITIES AND EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,254</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,136</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,942,977</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,216,570</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">580,672</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">582,061</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">130,564</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50,656</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">892,529</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">650,096</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,669,458</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,814,040</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TOTAL LIABILITIES AND EQUITY</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15,219,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14,316,559</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB544DC7CCE6AC17DB3EC6BDF2489D9A7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE 3</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">GAAP TO NON-GAAP RECONCILIATION:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NET INCOME ATTRIBUTABLE TO BIOGEN INC. AND DILUTED EARNINGS PER SHARE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-style:italic;font-weight:bold;">(unaudited, in millions, except per share amounts)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">An itemized reconciliation between diluted earnings per share on a GAAP basis and on a non-GAAP basis is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:679px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="512px"></td><td width="9px"></td><td width="67px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="67px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Ended  March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GAAP earnings per share - Diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.49</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.02</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to GAAP net income attributable to Biogen Inc. (as detailed below)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.33</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.45</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-GAAP earnings per share - Diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.47</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;color:#2573ba;">An itemized reconciliation between net income attributable to Biogen Inc. on a GAAP basis and on a non-GAAP basis is as follows:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Ended  March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GAAP net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">822.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">480.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">92.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">139.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SG&amp;A:  Stock option expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">R&amp;D:  Stock option expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect related to reconciling items</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-GAAP net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">900.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">586.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#2573ba;font-weight:bold;">Use of Non-GAAP Financial Measures </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We supplement our consolidated financial statements presented on a GAAP basis by providing additional measures which may be considered &#8220;non-GAAP&#8221; financial measures under applicable SEC rules. We believe that the disclosure of these non-GAAP financial measures provides additional insight into the ongoing economics of our business and reflects how we manage our business internally, set operational goals and forms the basis of our management incentive programs. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be viewed in isolation or as a substitute for reported, or GAAP, net income attributable to Biogen Inc. and diluted earnings per share. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our &#8220;Non-GAAP net income attributable to Biogen Inc.&#8221; and &#8220;Non-GAAP earnings per share - Diluted&#8221; financial measures exclude the following items from GAAP net income attributable to Biogen Inc. and diluted earnings per share: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">1. Purchase accounting and merger-related adjustments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude certain purchase accounting related items associated with the acquisition of businesses, assets and amounts in relation to the consolidation of variable interest entities for which we are the primary beneficiary. These adjustments include charges for in-process research and development, the amortization of certain acquired intangible assets and fair value remeasurement of our contingent consideration obligations.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB544DC7CCE6AC17DB3EC6BDF2489D9A7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">2. Stock option expense recorded in accordance with the accounting standard for share-based payments. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">3. Other items.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We evaluate other items on an individual basis, and consider both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to our ongoing business operations, and (iii) whether or not we expect it to occur as part of our normal business on a regular basis. We also include an adjustment to reflect the related tax effect of all reconciling items within our reconciliation of our GAAP to Non-GAAP net income attributable to Biogen Inc. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB544DC7CCE6AC17DB3EC6BDF2489D9A7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE 4</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PRODUCT REVENUES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-style:italic;font-weight:bold;">(unaudited, in millions)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:454px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="294px"></td><td width="9px"></td><td width="63px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="63px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#2573ba;font-weight:bold;">PRODUCT REVENUES</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">824.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">505.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">692.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">761.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">PLEGRIDY</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">462.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">441.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">20.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,172.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,742.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>biogenlogostandardrgb01.jpg
<TEXT>
begin 644 biogenlogostandardrgb01.jpg
M_]C_X``02D9)1@`!`@$`E@"6``#_[0`L4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``E@````$``0"6`````0`!_^%2)&AT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N
M,30U-C8Q+"`R,#$R+S`R+S`V+3$T.C4V.C(W("`@("`@("`B/@H@("`\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@("`@("`\<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@("`@("`@("`@("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B/@H@("`@("`@("`\9&,Z9F]R;6%T/FEM86=E
M+VIP96<\+V1C.F9O<FUA=#X*("`@("`@("`@/&1C.G1I=&QE/@H@("`@("`@
M("`@("`\<F1F.D%L=#X*("`@("`@("`@("`@("`@/')D9CIL:2!X;6PZ;&%N
M9STB>"UD969A=6QT(CY":6]G96Y?3&]G;U\Q,C`S,30\+W)D9CIL:3X*("`@
M("`@("`@("`@/"]R9&8Z06QT/@H@("`@("`@("`\+V1C.G1I=&QE/@H@("`@
M("`\+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z>&UP/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O(@H@("`@("`@("`@("!X;6QN<SIX;7!'26UG
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O9R]I;6<O(CX*("`@("`@
M("`@/'AM<#I-971A9&%T841A=&4^,C`Q-"TQ,BTP-50Q,#HT.3HR,"TP-3HP
M,#PO>&UP.DUE=&%D871A1&%T93X*("`@("`@("`@/'AM<#I-;V1I9GE$871E
M/C(P,30M,3(M,#54,34Z-#DZ,C=:/"]X;7`Z36]D:69Y1&%T93X*("`@("`@
M("`@/'AM<#I#<F5A=&5$871E/C(P,30M,3(M,#54,3`Z-#DZ,C`M,#4Z,#`\
M+WAM<#I#<F5A=&5$871E/@H@("`@("`@("`\>&UP.D-R96%T;W)4;V]L/D%D
M;V)E($EL;'5S=')A=&]R($-3-B`H36%C:6YT;W-H*3PO>&UP.D-R96%T;W)4
M;V]L/@H@("`@("`@("`\>&UP.E1H=6UB;F%I;',^"B`@("`@("`@("`@(#QR
M9&8Z06QT/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'AM<$=);6<Z=VED=&@^
M,C4V/"]X;7!'26UG.G=I9'1H/@H@("`@("`@("`@("`@("`@("`\>&UP1TEM
M9SIH96EG:'0^.#@\+WAM<$=);6<Z:&5I9VAT/@H@("`@("`@("`@("`@("`@
M("`\>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B`@("`@
M("`@("`@("`@("`@(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!
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M=5DR9T%!04%!04%!04%!04%!0EI*4E5-9V%(4C!C1&]V3#-D,V1Y-7`F(WA!
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M=F)I0G`F(WA!.V)I0DI254TR351K,DYI,'E,:D5!04%!04%!04%!04%!04-X
M4UI76FQC;59U63)59U9M;&QD,FQU6GE"1&(R-6MA6%)P8C(T9V%7-&<F(WA!
M.U-55D1.:D4U3FI9=$UI-'A!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!0C)A5U8S04%!04%!051P4#1!1D8X=4%"1%`F(WA!.T9!040W8W=!
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M.TUP<WDQ1$U.33!9>F9Z3S1-+T4P2WI2;$Y*-#`R1%543E4P,6AZ6$-.9C`R
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M4$%%.4HF(WA!.U0U3E`S5D%N54A&474Q14=55D)2;3%(;55J1E-F1DQ(57A.
M5%@Q3W%5+UI546Q34%9.=%9+1E8Q5F-*5T0Q6F-6<6Q7.3%D158U2E@F(WA!
M.S1&9W972#%9>3%K85=7;%IU1F](5VQ:87!L<C%7,%9B;%9V;%A$5F-H;'I7
M6%-D9&5&,TI8:'!E8D8V.5AW.6995BMZ64%69U8R0W$F(WA!.UE0>&A4,D=I
M6696:5-72V-9=D)J43)/6%DK=&M11U-56D]L;%!75U-:961M4%=A4UIU:&Y0
M5V546BML;U`R:5=A3WAP43)M86%F1G$F(WA!.U-'<69A=F1R5#)U;F$O.7-6
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M,&(W4U`Y3$(P,%14>'122C%-=E94=%A2,6Q85S).9&,F(WA!.S$K1%E:3FIO
M,E=Z6CAD<#(R=G9B9TYW1C-)<F1%3C)7,VAZ96]T.'`S-B]G3G5#.3155&AZ
M3TI4-'1V:EDK4'(U2%!K+T]7135G,VTF(WA!.VQU8V8U-FYO375I.#958G`P
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M.W`W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6G%B;DHR96XU
M2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1544F(WA!.T)1645#04U$
M8E%%04%H141"0T53355%1E523FA)9UIX9UI%>6]B2'=&34A2-%-.0T962FEC
M=D5Z2D121&=H85-5>5=I63=,0T(S4%,F(WA!.TYE2D5G>&15:W=G2D-H9UI*
M:EI&1VED:V1&53,X<4]Z=WEG<#`K4'IH2E-K=$U453504FQD65=6<&)81C%E
M6#%2;%IM9&]A5W!R8D<F(WA!.S%U8C)2,61N9#1E6'`W9D@Q*V8S3T5H66%(
M:4EM2VDT>4YJ;RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R
M<2MV+V$F(WA!.T%!=T1!44%#15%-4D%$.$$Y43,Y+V)71G$Y>F-T>&I4=S-*
M2C9!1'54:V]236I167EK26EY.#`Q+W=!-#8W8S-+>3(X<E=C151";V\F(WA!
M.UEZ,4E0-UHO82M85$YL:3`X04XY,UA:33AI9'1M3BM99E!V;4<O;6%/-'57
M9V=04S-G2FI3;G91.&TK:S5D2%,T=TMQ,G%E;VY,<7@F(WA!.VAY1UES1TQC
M=#9N<CE/8W!R.4=C138O:%!*67ET3TY%.#)E63E+;%9R3SEK15DV=U-%=D52
M-&-'<5!U>D=H;6Q(:U<R1U-1-48W0C4F(WA!.U`X-U<R=E)E:DUG='12459E
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M=DQ&<71X64Q+-2MW>%$F(WA!.V=$=T%0-FIN2#ET=T5-*S,X478Y2#9(33`T
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M,4(W:D]D,4=!-'`X2F5G=UIX;&IX0C1F*V)/=F$U82\F(WA!.VU"<7-&<G%.
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M=VUE=VTF(WA!.T=Y1F@K-EEB14U84%$Y46-Y.%=U9TDK<S`T;6)3>31V5'E5
M9$TO2W%/;VLQ4S0R-BMH0C$K;'E0,41-3%`R=T]50CA3,EDY168T:7HF(WA!
M.T=X,#=4=$UT>&(R34-14D1Q1D<U23=S5'5X*V5A4$YN;FM.>4YU9$-!:4M#
M;&5145A(.31T5TA2:#%(,#5I5$%,26AD<%=H=%!/04,F(WA!.V9253%D<61"
M-&902C9F5$=C=DI&57I&5E9&0W%+2V]O04]W1V(P0VA3=FUJ.#1V+T%#62MR
M+SA!4G8X03E1<U=D5#)D+V-2*U`S;#4F(WA!.W)T1"LK;#A0=40Q+SAL=B]!
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M.V=B:DMT3G`X.&]!=VQ59F57,U5A:D)'6D5O,TPS0FUF:V95=$(Q3'DU0F0V
M1F%'>#`Q,FM%5G-Y2D=62W51>#1O>G)U,B]834Q646XF(WA!.T=:17IC;DXP
M,#139T1!545X,6I7.4LP87AE*S%/-5,Q=%4R3'5E<#=+<6EP62MW1F-R>#1P
M5$Y21FQS>5I)=T9Y3D(U,V4O.#5!95<F(WA!.UEP:6QP65A6>D=#4C9P-%)G
M*S9G;&I4-3!Z67@W2FU2=5%(6%,W5F=$<T-56&]V-39E56(K9%E,>$HY3EIJ
M4EI:9TAI<5115EI#4U`F(WA!.W!7;G9K379:95-)<U9*;FHW5'AY3DA:-DI&
M3$9,1VMS5')*1DE!>4]P1$MY;F-%16)%2$YC4E1S06)5-S(Y=$Q',&QU-WE:
M24QA1F4F(WA!.U5S,&@T<6](:51H:D5Y3D1M:55H15=E5'IJ5E!Z.#AQ,C!R
M4C).<F,S+T@O04AA07-56BM833@O=E5:<V]D;%I$>DE$<G`Y<5EX>4(F(WA!
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M.V)Z9C4W.'8K5EE%9E5P5V$T;$)-1G!#03!R9V)6;U-!1CDR3UEU;C!S.'`Y
M4$IY8RMP:&E(<5E:8F8X04]16&PQ-6Q7-#`R-FAI2F\F(WA!.UI&36)K9357
M<35M>3=*;E=X1&AJ=%=&-V=V4CE',7)3.6$P*U!53DUU1G5B5U0W36DQ1D-/
M<7-P;U9).$1M='E9<%%.4T9&,D]02D<F(WA!.UEU2G-),TLR8G-68U%#2T56
M0C9J16A51F-A5VML5$<S02M",T=9=5139SAT:S)G6#!3.$HR94]N>F(K;5EX
M,%4K.$QA*T1Y*V])864F(WA!.U1L+VMR="M*>6-.0U`T:71P=$9&2$5G4TY1
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M2%1M;&XU469L-7!V;5=3-C%(5F<P;&A:<W-59'-R1F95:TDU2&UY,&)I;W`P
M3SEF=G0W43%K<U92:GHF(WA!.TQ6;TY*2$I:;'E$,%AZ1BM49FLK+W="36QJ
M,#)Z1FAF<6@K<E1X=3E/64=W9%=99V<Y*RMA,T0R:FMJ3#%'=S=(3#)F:FQ(
M,&EI*V4F(WA!.TQ+-49T95$S0FE38U)/<FU'5E%Y3T9.4W)!.5%E;61(2TYI
M;FYO;6IB-DXX,V599$HX;F535W8Y1G,T3$MF54]!<V]);VMJ6#%:57(F(WA!
M.S9J2V=!2E)"6#=H;DXV9D1,3FQQ4DIR;3E&;GEX=S1R:4%,-5!$+TM(;&Y5
M=D]F;5@V<3`W8W!/5GAF,VML6%E*56-M3F9T37AA9SDF(WA!.S@S=6]Z>'=W
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M4U9(0E!S.'$Y9D4Q>E@U9%9$5%)%26EY-T1(<'`V9VUC:E%3;CAX9GDF(WA!
M.W9U+TM+43-K5GHY9#`R9"]4.55R=V5/4VA)5F=#=TE)0F]C=#!E=4=B87%K
M,6%V4DA&=F1H3F9Y1S%Q93(X,%1A5UA0,6$O9UIV5#<F(WA!.V5R1#A3="]W
M2$E:5C)R:D)X.%A51G,W37E%5#1E:&4O6GIZ=C-9<3=&6%EQ-T9867$W1EA9
M<2M:+W=!-'8O2FHV=CA!.4<O+T%&0W@F(WA!.UHQ2%HS.7A(-"]E6&UU,%`W
M-EAW*S1*,35(+THR,CAY*UA)3EAF5DAT;6UA4E1#<TEC1#`S2R]A3'(Q<&Q'
M<3=23TM::E9T*VTW4$<F(WA!.U-!;&1*-B\O041J=F$X5'<Q>'<S66TS0D@O
M2G=::B]Y=V8U=C)T+SAK:BMD.6IZ>GI:-5$X=V539%9H17-X55-697DQ0S-:
M:T1C858F(WA!.V]24FQ:86EO>EIA9E51>G@K.$]U>C9E94=8,T8V>BM4,S5I
M6&9M0TMB4CE79C%.4W1%.5='-#9'5T5%2V58*U5P23,W9RMX>E5D;S8F(WA!
M.TU9+U9(-E,W8G,O5FY*-EIF54AM6#5X9BM42#%F+V\S+W=#;U=,3G`R9"]C
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M9'5M64](<VU1;&-Y2SAN3GDY<5)-86E$9FTX,#AK*U0F(WA!.TY4.#`V=DAA
M,C!B3%IO=TXW9#`K0TM/=2LO5&M2.6QF-%9Z6C9N57AX4G,X*VIR9$YP-5I:
M54]85FYN+T%$:T9.-F,K:&%F1T]&=D0F(WA!.T9+-F]/;3521BLT2FUV-TI&
M:5(V=60R<60T:#4O=T-69D]M="M6-4QI6%-J17-L,$975G!%1#=)4U%"6'`Q
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M04-I9TQ(-E=*3V-P<4IC5U-2.'DY4G`T.$]/23AM3"\F(WA!.T%*-"\X;TA,
M+W=!>$U0-GIM5C):+V9F075.,FPO9&9&-5HK4S,O:W=B2"]J2%`X03AM5WIB
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M6FIN5S5Z,5!Y+UDS:E)90C`K,6QU;C)M;C)T;VM';G<F(WA!.WA15VDO=T(S
M2$%Q<D=01V=88DU/8VE48W5B;'AI04M(2C5(+T%--41A835J,&95,5@Y,G!L
M='!7.$-W5C1X+W=R-75/>4HO5D@T=7`F(WA!.S=7:#E-:W8O04]C9F159V<Q
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M.R]W0UEA3"]I07IK8W8Q2#-V5C0O<$AU65HK95`O2T)Y+W=$351$*W,U;3EM
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M4V9S670U82]-9GIB-61T5&%A9&1J-G`F(WA!.U5L8F5:0DEI:S=K<%AD82M!
M3DUY.#)J>#5$8VAU-'5(5C5-66](6D-A>C5G.#!E8G13:"MU>7DS.3$Y:3)T
M;VLR5W954GAO2V(P,S(F(WA!.W%C;FIW-#A-9'1G>'E:6C5:8C=L-U@K52]W
M0U<P;FQU,V)63E559G!I-E1I26A1*VA'9'ET4C%D=C)Q9DQ.2'(Y8C1P-%DO
M4U!T9'HF(WA!.V]D2#19-'!F569S65`K971X-6)N.'=21WEL6CE::5%286EQ
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M4$4O9CA!5T\K8G)&;&@F(WA!.VUJ='5/-3`R5$901$QF63DW230O>GDX.7)B
M0T5Y5WIU0E0V=S!)-3$X9&E%<B]S8WAJ,EAH=3DS24AA5U=U:D@Y4#!V>E8U
M,S$Q,FHF(WA!.T5L.694<T1C,V-M,&-9-F-N641I:6=D05!K0FU24$IJ=U$W
M9S!1:&MZ5#=Y*VMF2B]L97HX<S9$8C968DAM639V8U15;UI*5RLR-4@F(WA!
M.S1$=T9--7)56GIL;5I&-E!4-%)J9TEH.'1A,2]X,F(O05`U:4IF.$%I6GIQ
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M<U9D:7)S5F1I<G-69&ER<U9F+SEK/3PO>&UP1TEM9SII;6%G93X*("`@("`@
M("`@("`@("`@/"]R9&8Z;&D^"B`@("`@("`@("`@(#PO<F1F.D%L=#X*("`@
M("`@("`@/"]X;7`Z5&AU;6)N86EL<SX*("`@("`@/"]R9&8Z1&5S8W)I<'1I
M;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@
M("`@("`@('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C`O;6TO(@H@("`@("`@("`@("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*("`@("`@("`@
M("`@>&UL;G,Z<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(^"B`@("`@("`@(#QX;7!-33I);G-T86YC
M94E$/GAM<"YI:60Z,#@X,#$Q-S0P-S(P-C@Q,3@R,D$Y0S4U,#$P0S$P,D8\
M+WAM<$U-.DEN<W1A;F-E240^"B`@("`@("`@(#QX;7!-33I$;V-U;65N=$E$
M/GAM<"YD:60Z,#@X,#$Q-S0P-S(P-C@Q,3@R,D$Y0S4U,#$P0S$P,D8\+WAM
M<$U-.D1O8W5M96YT240^"B`@("`@("`@(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@("`@("`@("`\>&UP34TZ4F5N
M9&ET:6]N0VQA<W,^<')O;V8Z<&1F/"]X;7!-33I296YD:71I;VY#;&%S<SX*
M("`@("`@("`@/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*("`@("`@("`@("`@/'-T4F5F.FEN<W1A;F-E240^=75I9#HV
M839F9#DR9"UD-#DQ+34V-#<M8C5B8BUB8S!E9CDX-&0S9C`\+W-T4F5F.FEN
M<W1A;F-E240^"B`@("`@("`@("`@(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD
M:60Z,#,X,#$Q-S0P-S(P-C@Q,3@P.#-%144Q040S0T1$034\+W-T4F5F.F1O
M8W5M96YT240^"B`@("`@("`@("`@(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12
M968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@("`@("`@("`@("`\<W12968Z<F5N
M9&ET:6]N0VQA<W,^<')O;V8Z<&1F/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*
M("`@("`@("`@/"]X;7!-33I$97)I=F5D1G)O;3X*("`@("`@("`@/'AM<$U-
M.DAI<W1O<GD^"B`@("`@("`@("`@(#QR9&8Z4V5Q/@H@("`@("`@("`@("`@
M("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@
M("`@("`@("`@/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M("`@("`@("`@("`@("`@("`\<W1%=G0Z:6YS=&%N8V5)1#YX;7`N:6ED.D9%
M-T8Q,3<T,#<R,#8X,3$X,C)!1C$S0D4T0T(X.38U/"]S=$5V=#II;G-T86YC
M94E$/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z=VAE;CXR,#$T+3$R+3`R
M5#$T.C,P.C$Q+3`U.C`P/"]S=$5V=#IW:&5N/@H@("`@("`@("`@("`@("`@
M("`\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@
M*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^"B`@("`@("`@("`@
M("`@("`@(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B`@("`@
M("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@("`@("`@("`@("`@
M("`@("`\<W1%=G0Z:6YS=&%N8V5)1#YX;7`N:6ED.C`X.#`Q,3<T,#<R,#8X
M,3$X,C)!.4,U-3`Q,$,Q,#)&/"]S=$5V=#II;G-T86YC94E$/@H@("`@("`@
M("`@("`@("`@("`\<W1%=G0Z=VAE;CXR,#$T+3$R+3`U5#$P.C0Y.C(P+3`U
M.C`P/"]S=$5V=#IW:&5N/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*$UA8VEN=&]S:"D\
M+W-T179T.G-O9G1W87)E06=E;G0^"B`@("`@("`@("`@("`@("`@(#QS=$5V
M=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B`@("`@("`@("`@("`@(#PO
M<F1F.FQI/@H@("`@("`@("`@("`\+W)D9CI397$^"B`@("`@("`@(#PO>&UP
M34TZ2&ES=&]R>3X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@("`@('AM;&YS
M.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R
M+S$N,"\B/@H@("`@("`@("`\:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^
M4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@("`@("`\+W)D
M9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*("`@("`@("`@("`@>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!D9B\Q+C,O(CX*("`@("`@("`@/'!D9CI0<F]D=6-E<CY!9&]B92!0
M1$8@;&EB<F%R>2`Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@("`@("`\+W)D9CI$
M97-C<FEP=&EO;CX*("`@/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2)W(C\^_^(,6$E#0U]0
M4D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`,0``
M86-S<$U31E0`````245#('-21T(``````````````````/;6``$`````TRU(
M4"`@````````````````````````````````````````````````````````
M```````18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````48FMP
M=````@0````4<EA96@```A@````49UA96@```BP````48EA96@```D`````4
M9&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P```]0`
M```D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E120P``
M!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`````
M````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V,3DV
M-BTR+C$`````````````````````````````````````````````````````
M`````````````%A96B````````#S40`!`````1;,6%E:(```````````````
M``````!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4``!C:
M6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO+W=W
M=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````
M````````````````````````````````````````````````````````9&5S
M8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="`````````````````````````````&1E
M<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V
M,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ``````````````````````````````````!V
M:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@``````!,
M"58`4````%<?YVUE87,``````````0````````````````````````*/````
M`G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`*``M
M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`
MGP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3
M`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!
ML0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q
M`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#
M9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$<01^
M!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U!<4%
MU07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/
M!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)
M$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS
M"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-
M)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z
M#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2
M)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P
M%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8
M&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC
M&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?
M$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=
M(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G
M&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI
M*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP
M-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43
M-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z
M=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B
M0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%
MWD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB
M3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2
M?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:
M66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8`5@
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MB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1
MJ)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5
MFT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:D
MQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZA
MKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y
M2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4
MQ%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/
M-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IV
MVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WF
MEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,
M\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_
M;?___^X`#D%D;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!
M`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!(@-H`P$1``(1`0,1`?_$`/T``0`"
M`P$``P$!```````````)"@8'"`4#!`L"`0$!``$%`0$!``````````````<$
M!08("0,!`A````8!`P("`P@(#0T+"@<```$"`P0%!A$'""$2$PDQ02)1,A1V
MMU@Y"O!A<2,5UI<8@:'A0C,DE-46EC@9&I'14F)#TS34M1=WAWC!\6-SDR65
M-E8W5[&"PE-D-;;G:*B2HL0FQTB($0`!`P,!!`4&!0T,"`8"`@,!``(#$00%
M!B$Q$@=!46$3"'&!(G.S-Y$R0A15H5)B<I+2(Y.4%187&+'1@J*R,U/3=(2T
M=?#!0V.C)#0VX52DY"5E-2;$1<*#9/_:``P#`0`"$0,1`#\`O\`B`B`B`B_A
MQQMEM;KJT---(4XZZXI*&VVT)-2UK6HR2A"$D9F9GH1#Z`7$-:*N*^$@"IV`
M*.3D%YB^WFVIS\=VMB1MSLN92\PJU;DJ;P6JEI[D)-VRC*^$9(;2R)1MP5(8
M<3T*6E6I%*NF.5>4RW#=9EQL[$T/#3\,X=C3LCKUOJ1]80HUU%S)QN,XK;$@
M75X-G%7\$T_;#:_R-H#]>"MO\0>5%3R4PM\[%N#3[EXN3+.88]$\1J(^T^:D
MP\CH6I#\F0NFGFDT+0IQ;L20DVW#-*F7';%KG1DVD\@.Z+I,3-4Q/.TBF]CZ
M`#C&\&@#F[1M#@V\Z-U9#J>Q/>\+,I%LD8-QKN>RI)X3N(J2UVP["TGKU2DH
M2I:U)0A"34M:C)*4I26JE*4>A)2DBU,S]`P<`DT&]9D2`*G<N$=Z?,6XX;0.
M3*J%D#^YN515+971X`4>S@QI*>Y/AV.4//,X^PEMU)H=3'>ER6E%HIG7H)'T
M_P`K-5YT-FDB%G9.V\<U6DC[&,`O/6.(-:?KE@&<YDZ:PQ="R0W5V/DQ4<`?
MLGU#!VT+B/K5%]NIYL._N4_"XVUU%B6UL)2'"A2GHK>:Y&VLRT0IRPO8[..F
MKI[)'5=J5*]HU$0R75_(K*MTE<.TA?N=K"-O''QLC$,O"#6(!_%P/?\`(D<\
ML#@`\!I+FQK=<WLO<W'#;0Q6UH=E?YQX[:N`:?)P?"H]LVY8\G,[>D(RW?'<
MZ2AQ;J9-7$RFTQ^I-9FI+B'*&@>JJA)IU-)%X!=I&9%H1F0YK9C/ZN%W+8Y>
MZO([N*1S)(BYT?`]I+7-=&WA`+2"""-AJ%Y3Z@S-Z.*6ZF<P]`<6M/F;0?46
MA;&UM+=\Y5M93[24?=K)L9DB:^?>M3B]7I+CKA]SBS4?7JHS/TF,:DEDE=Q2
MN<YW622?JJV/>^0\4A+G=IK^ZOH#\+\K9&.;R;NX<ZA_$]TMQ<9=;7WH70YK
MDE29*,S,S,H-DPE1*U/N(R,E$9D>NHN-OF,M9GBM+JXB(^MD>W]PA5D.1R%N
M:V\\S#]B]P_<*ZTV\\S3E_@"HS;VX<3/JV-V:56X=#7WB7B0>IE)NX":?+'O
M$+HHSL==/09'U&58_F3JVP(!N!/&/DRM#J^5PX7_`,=7ZTUIJ"TH#,)6#HD:
M'?"X4?\`QE)+LUYQ^W=ZY%J][]O[?`I3BFV5Y3B#SF5XV2E:>)+GTSK<3(ZJ
M*@M?8C%;.GH7NGI(V'YOX^<B+-6[X'?7Q^FSRENQ[1Y.,K,L=S#M)2(\G$Z)
MWUS/2;Y2-C@/)Q%2S[>;G[>[LX^SE.VV8T&9T+QI0<^BL&9A1GC3W_!+",DR
MEUDY*>JF)+;3R/UR2$JX_)X_*VXNL;-'-`>EIK3L(WM/80#V+/;2]M+^(3V<
MC)(CTM-?,>D'L-"L[%<JI`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`
M1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`
M1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`
M1`1`1`1`1`1`1`1`1`1`1`1`1`1`18/N'N/A^UN,S<LS6W9JJJ(1I;(_OLVQ
MEFDS9KJN$@_&G3Y!E[*$%HDM5K-*$J4FXXO%7V9NVV6/87S.\P:.ESCN`'7Y
MA4D!4&2R=EB;5UY?/#(6_"3T!HWDGJ\YH`2H..2?+?<#>]R9052Y6&[;][C;
M>.0I"D3[U@CT0_E4YA1?#/$+VBAMZ1&]2(R>6@G3V)TGHC%Z>#;F8"XRU/CD
M>BP]48.[[8^D?L0>%0-J?6.1SI=;PU@QGU@.UXZY"-_VH]$?9$<2X1G0="5[
M/Z0D>.18#(R@7L[6[GY9LCN%0[B8=)\&TI)/[8AN+6F%=53RDILJ2R0C0W8%
MBP7:K]<VLDN(T<0A1>&9P]EJ'%R8N_%89!L/2QP^*]O46G;V[0=A(7OB<K=X
M+(QY*R-)6':.AS3\9KNL$?!L(V@+W.3/.7>W?R=94ES;KPS`5NJ*-M_B\E^+
M5R(GM$U_"&R(F;'*75MF1K*0:8?BI[VXS1EH5#I3E_IW2[&SP1_.,F!MFD`+
M@?L&[6QCJX?2IL+W*NU+K?/:C>Z&9_<X\[H8R0TC[-V]_;7T:[0T+BH[)O[7
MZ)C/.\"PK@*_I-BV?N?U0XPG`:KZ-DPW8I)U@B.6VGM))%[<E"="2T?7VW6T
M^\_7*+V"U]@BT_\`$SR*;J^RDU]I*'_]JMHZW$3!MNX6#XS0-]Q$T>B`.*6,
M<&US8VF]XJ_,)%M,?P1.P]1ZO(?J>18J.::RA`1`1`1?,TWW'J/R3\"_0%5M
M+;/<C<+:;(HV5[;Y?>8;?QS1^WJ6:Y'*2TA9+^"640^^#;0%K+VXTIIYAST*
M09"HL,MD<1<"[QLTD-P.EII4=1&YP['`@](5RL;N[L91/9R.CE'2#2O81N([
M"".Q3Y<4/-`Q_/%U>#<@F:[#,K?-F'!W`A%\$PR[?/[VW^'X[JU'BDYY7;W/
MDI=<M:E*/X(@DH.=M)<V;2_<S'ZD#8+LT`F&R)Q^S'^S)Z]K*UKP#8I4P>LH
M[KAMLH!'.=@>-C#]L/DGM^+]JI=D+0ZA#K2T.-N(2MMQ"B6A:%D2D+0M)FE2
M%)/4C+H9"9P014;05G>_:-R_L?40$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$6LMV=UL9V?Q&7E61N*=,C.-3T\=:$S[
MVT6A2F($,EZD@M$FMYTR-++1&HR,]$JN^$PMWG;YME:BG2YQ^*QO2X_N`=)V
M=HM68R]KA;,W=T:]#6C>]W0!_K/0-O8H.-X-SLQWJRA_),JDK3&:4ZU14##K
MJJG'H#BD_M6`RO1*GW4MI.1(-).R%I(U:)2A"-B,%B+'3]F+2R'IFA>\CTGG
MK)ZAMX6[FC=M))@7-96^SEV;F[)X1\1@)X6#J`Z^L[R>R@&D9E7H1^S[OJ&1
M1S*POBV+!;.#V]Q:>[ZA<89*JBD8M=V<;3NZ>[]GI%UA>K=*U:?S*H<EQ%R(
MJ3.9$)2VTI+53[1=7&.G4U:=4?VW3UF+BQQX=BH7`5VK0IV^AZ=WV?HAWO6O
MG=K^T6_7WWZ?4.]7WNUZ#-OZ/:_3'[$J_!C7W'7&Y1'(;U\0M#D%[XM3,DD^
M1EU(EJ,B5K^O,CU/NT3S@\4/)INF,D>8.FHN'3M[+2YC8/1M[AY^.`/BPSG^
M"R:K:@21L&1XR[,K.XE/X5HV=H_?"^N-/U=D!%\B$&H_M#\DKZ`O5CLZ^H>3
MG+W8U9!%C:Z=/ZHI7O59&Q93#B>CH*21ZK8XU*5PNYPY#LR[6[=[F2K#(MJ'
M5LQ*Z6XIV9<;?]RD-I>KM2<D3\9:1^RP"U4PDN^*1&2F7I0T#S0N-.2,Q6:<
M^;!$@-.]\'15N\NC'2S>-[-M6NSC`9Z:QI:W1+[/<.DL\G6WLZ.CJ-@>JM:R
M]K(%U2SXEK4VL2//K;*!(;E0IT*4VEZ-*BR65+:>8>:62DJ29D9&-JK>X@NX
M&75J]LEO(T.:YI!:YI%001L((4D,>V1H>P@L(J"-Q"]`>R_2`B`B`B`B`B`B
M`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B
M`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B
M`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`BQO+\LH\&QNWRO(
MYB85/31%RI3O13KAD9(8BQ6S4GQYDQ]:6F6R,C6XM*?6*NQLKC(W;+*T;Q3R
M.H!^Z3U`#:3T`*EO;RWL+5]Y=.X8&"I_U`=9)V`=)4)&ZVX^1;TYC)R>[-;$
M%KQ(F.T:7#7$I*GQ34U';T)*7IC_`$7)?T)3SOJ2A*$(V#PN*M<!8"SMZ&0[
M7OZ7NZ^P#<T=`ZR23!&8RESG+TW4^Q@V,9T,;U=I/RCTGL``P,Z71/O?5Z-/
MU!<OG&U6[N=FY8Y9U7:E7LZ>GU?[XJX9ZE4TD2UA<P>WNT+[.HO%O+7>K9,Q
M:FN(^G?T%[@<K5,U:TLVM#5^B+M"5;)0N4-SJE='8IM(Z#37V:U=^A>Q'G=5
MK;Z=$ID)(UI^V2B]!$/Q<@QD/'Q3^ZOU`>,<)^,%K1%M_;?I_9H*7O54&/8O
M38MNI>W^F/1LJ_!C610;;M6A6I*T,M4F:B)1?KDJ-*DJ[5%T/0R/04>7Q>-U
M!BKC"9>)L^,NHG1R,=N<UPH>T$;VN'I-<`YI!`*_#>*-XD9L<#598VZV\A+C
M9D:5EW$1+):D=3+L7H23):3+UD6OI+H9&.07-3EWD.66L)]-W9,EG_.6TI%.
M^MW$\#N@<;2"R0#8)&NI5O"3E%O.VXB$@W](ZBOE2DU&(X)50!5>DPSKIT'D
MYR]F-JO?BQCZ=!3/<JMC%D\.+KIT%)(]5L<:R^##]'04,CU<(HUFE?"][T%#
M)(KE%$I2."O)V3MO:0]I\ZL3/;Z\F&WC]C,</PL,O)SRE]ANJ,TQ\=N9;I^.
M1_>XTE?CZH0J0HYBY3<R3@KQFF\U)_\`"3/I&]QV02./7T1/<?2Z&./'L!>5
MF.#OW6Y%K,?P!W?8G]XGX#MZU-\-N%F*`B`B`B`B`B`B`B`B`B`B`B`B`B`B
M`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B
M`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B
M`B`B`B`B`B`B`B`B`B`B`B`B`B`B`BB?Y;[O.9[FG^;VBEJ5BN%S'&K)3#AF
MQ<92V1LRW5D1%XC-%W+C-EZ/&-Y1:D:#*:=$8,8VP_.ERW_G;AOHUWMCWCSO
MV./9PC9M4/ZRS1R%]^;;<_\`*0.]*FYTFX^9FUH[>(]2T#3TO<E/L^HO4?09
M-/<;5C<,-0LG<HM&]?#]7N"C%S4[U5&#8L%NZOL2OV?N"XV\U2%03Q46E,@A
M]OB%I[OV?H#(;:2M"K+<,6D[QG0U_HC(;=RLL[5J>U01&KI[O^Z+U"2K3*%J
MG+:1C(*B?52-$E):5X+NFJH\E'MQI"?61M/$1G_9)U+T&8KG1MFB,9Z1\!ZU
M2M>8I`\="X+F2)57/EULU)LRX,EV+);,_>NLK-"B(_0I)F6J5%T,NI=#&-.<
MZ-Y8_8X&A5\`:]H>WXI%5]J-:ZZ>T/VV1?DL63PK/T>U]KT_U14,D7BYBV'0
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MUYI*-(5Z5$32U&:W%#<KDGKTZGPIP>1?7-6#`*G?)!\5C^US-C'G[1Q)+BLN
ML93)$&/^.WZHZ%V:)O5<@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(M(\AMS"VIVLR#(HSR6KV8A%#C"3+52KVU2XVP^A)D:5'61
M4/2S(^BBCFGTF1'D.E\1^>LS%:O%;9OIR?:-WC^$:-_A*Q:DROYHQ,ERTTN'
M>@S[=VX_P15WF4,^-0UO+)QTU...+-;CBU&M:UK,U*6M2M5*4I1F9F9ZF)ZO
M)`T4&P=2@ZV87&IWKH7':7O2C1/I(O5]SH,7NKBA606\-5F4JA[&3,T>KW/M
M>G[@H&7-7;U6OMZ-6G<GKR;)?L]=#]S]$7ZSEJK/<QTJN=<F8T-ST>L93:.W
M+';EN]:#R!'5?Z/^^,FM3L"L-P%I^W26J_L]P7V`JSS=:U[.Z&?V>L7.-6]^
MY<8\A<=.MGP<OB(T8L5(K;7M+HF<RT:H4A6GKDQ&E-F?0B-E/K4+)FH#&YMT
MW<[8?+T'SC9YE=L7+QM-N[>-H\G3]7]U:`B6>IE[7K]W[/6+,V17-S%E]?8Z
MZ>UZ14L>O![%G5;.U[?:]P5L;U2O:N@L3GE:PB[S-4F-VMO&9FI2R,OO3RC/
M]<XE)D9F9F:DF8YG>*;EN-(:Q&JL7&6X',%SW4'HQW8VS-[!+LF;4[7.E#0&
ML`&18J?OXN[<?PC/JCH/^I;%B1==.@U3>]7^-A66P8GHZ>YZA12/5?%&LQ@0
MO>]/60H9)%<8HUG%=!][T]S[/M"WRR*YPQ+/:V![WV?<]706Z6176&);$J*M
M;RVVT([EJ/0B,ONF?Z!$6HMLCRX\(WJ[P0UV+JO9G*']K\OQ_(H9N+9ARB;M
MV4F>L^LF$3%FQV%[!J.,9J:UU)+J$*ZFG49CH;44VD=1VN:AJ8HWTE:/EQ/]
M&1M-U>':VNYP:=M%>H&B.E%-=&D,2X[$N,ZA^-*9:D1WFSU0\P^A+C3J#]:'
M&U$9?:,=$X9HKB)L\+@Z%[0YI&XM(J".P@U5>OF'HB`B`B`B`B`B`B`B`B`B
M`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B
M`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B
M`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`BBHYXYNNUS_`!+;V,\9P\8J%7ED
MVA>J%6]^[X<=I]LCT\6#504+09]23,5[HF?EOCQ#C)\H\?A)G\#?M6;Z>5Q(
M/VH41<P;_OLC#C6GT(F<;OMG[J^1H!'VRYXQ&,2C:U+^Q^Z,HOGTJL8LV[EU
M;AM<ETFB-/I[?5[HPN_EX:K*K..M%L2_J$Q8G5)%JWKKI[I=/5Z.HM5M/QO\
MZN$\(:Q<P9BTE/BZ%Z-?L_2&86!)HL9O`!6BY=RK3[Y[O7_=&96/0L7NMY7/
M>0'U7^B,HMEC]STK3=N?58OL'0K--U+7D[TG]GK%TC5O?N6M<[QIK+\6N\?<
M)).3H:_@;B^A,6#&DB`\:M#-*6Y;2.[3J:-2]!C[=VXNK9\!WD;.P]'U5]MY
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M[%(D3`0'#<LR@P^I=/TA;))%<HH]JS>O@^]]GW/L^T+?+(KG#$L[K8'O?9]S
MU"W2R*ZPQ+8]-4.R%)2VC7JGN6?1""/UJ/0R+T'T])Z="%ND?Q;MRNT$))H%
MMNHK&H22[/;<46BG#+0S(C]Z1:GVEK_5T'X8T5JKQ%&&#M6:PV_1^J*^)JJF
MA2M<;<H5D>V%7$?<-<W&'GL>>-6G<<6,EM^K,B_]6W72&V2/UFR8WDY-YPYC
M1,,$IK<V3C;G[5M'1^81N:P?:%5+=RWZ)57Z0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$4`V]62*RS?C="X4X;K99A9U$9PSZ+A8X
MXG'H*D>XVJ'5H-)>G0^O4;+Z?M!9:<LX*4/S=KCY7^F?JN*UWSMU\\U!=SDU
M'?N:/(ST!]1H64X@9$;6OH]GT_<]8H[^NU>]GT+J[#93;)-J,R+0D^LNGH&%
M7["ZH65V;P%FF3W"7XQD:O0C0NNOH+3U&*"S@+755;<S!S5RMF4I*C=Z_P!D
M,SL&$46*WCZU7+V4OD9N?H_9Z]!F%FTT"QBZ=OHN?,A<U-S]$91:C8%C]P5I
MVW5J:OT1?8-BL\Q6OYI]3^Z?_D%TC5`\KQ%>DQ4#<O!1F[Y4Q8YNMD+;2?#C
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M3@EYJ?\`P_T_T*NC&-:*-W+)HC?H^S[.@JHPO=H64PFNI=!<(FKV:%V[Q(ME
M1[O**%2]&["IBVC:%="\:KE?!E^'J>G>MJTU,BZF2-?UHV/Y`9$Q96^Q+CZ,
MUNV4#MB?PFG:1+MZP.Q>[=R[J&TB_2`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B
M`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B
M`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B
M`B`B`B`B`B`B`B`B`B`B`BK0P+1=I:SK1W4G+&PEV#A*-)J[YDER0ON-*4),
M^YSKH1%]H;;2P"&%L(W-:&_`*+5QDIEF=*=[G$_":K?.+2B1X?7W/T!C5XRM
M5?;5]*+H*BN":;1[6G0O7]A#&+F"I*R"":@7H6U]WM*]OU>[]KUCR@MJ.7I+
M<5"T/E-D2R<]KW?7]G49)9Q4HK%=2UJN=,EE]QN=?=^X,JM&;ECERY:'OG]3
M<Z^Z,EMF[`K%.5J2U<U-77W1>X0K3*5@LQ6IGU%Q8J%Y7DGZ3^Z/<;EY%<(\
MKXJ$9?B<TD:.2,?D15+]GVD1+)UUM'0N_P!A4Y1]>GM=/6,.U*W_`)J)W26$
M?`?_`!638)WX"1O0'U^$?^"T55$?LZ^X7^X+-$KG)O6SJC7V?T/ZHN,2HWT6
MT*C7V?L]0N$2HI=VQ=4["O/.93^!6DFZNYAJ;880A2G'I<362TE&FNG;&)XS
MUZ:$-6/&5IB++\I/TB`:+G#WL4O$=_<SN%M(P'H#I)('N]6*K(-'3.&8^:`$
M]\P@#[)OI#Z@<I"J+;N89(=LW$0T=#\%OM>D&7M:D9D9M-'T+UKZ'Z"'(N?(
MPC8RKSV;!\)_U`@]:F^VQ,N^8AHZMY6T:ZGKZM';$82E>FBGE^V\OHDCU<5U
M)*C01]I:)U]!"T2W,LVQQHWJ&[H^'=7;T[E>X;>*$>@-O7TKVFDZ_HF/)H50
M%[49'H^S[7]053`OV`LDAM^C]`5T87LT++(37O?]\7&)J]VA=,\<WU1-SJ1L
MCT3.B7$19]"(TE52IB2,S].KL1.GKUT$O\G)S;ZZM6#8V6.9A_%/?^ZP>>B]
MP-BD=&YJ^("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"*KSC\G0T=?<&X5TQ:I6[J+>%!8=I(]KW/7^J,=N8JJ^6\E%MFONNU!>WZO=
M%DEMZFJNT<U!M7]3[W5"O;]W3KT"*WVI)/L6J;^U[B7[1GZ?6+U;0T5IN):K
M1N03N[OZ^G7U^Z,BM8U9+AZTQ=2=>_K[HO\`;M5FG=5:PLW=35U]T7B%JM<I
M6'25:F?V>@5[1L5&[>O/'HOPN"N3EBS8Y]5UC)DM5)0LHE&1=42K"2]+\%7W
M(?@K+_C!AFH9!)>MC'R&;?*37]RBRC#,++5SS\IVSR#9^[5:BJHYEV]/<^SJ
M+9&U5[RME5+)EV]/<%?$%1R%;-J6O>_H"XQA44A72>QTM5=N9@L@B,S7D=9!
M/MTUTM'TUJE>T1EVDF69GZ]/1U$:\],=#DN2VJK><!S&X&]E`/UT$#YV'RA\
M;2.H@*Y::F=!J.R>W>;F-OF>X-/U'*7L<#%M`GI'U?5]]A'H'JP+]!>]%;]'
MV?9T%9&%Z-63PV_0*^)J]VA9?!:]'3](7*)J]VA=`[&M=NY6*'IZ)4O_`"9.
M$G<KF_\`[QCS_O'^R>O:GHJ2,;KK\("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("*K_`)#"7C><9?C[B?"<HLKR&F6WVDWX:ZRWEPE(
M\-))2CM-C30B(B]&@W`M9!=XZ"Z&T20L=]TT'_6M5+F,VM]-;G88YGM^Y<1_
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MYZ'EF1EVD4AAM):GH:U$7KT$.>)#4-MIGD9J2]N33YQC9+1@V5<^]I:@`'?3
MO2YU-H8USNA7O2%JZ]U/9QM%>"42'L$?IU^%M!VD*5D<(%LVO[06I_<'Z"^K
MU8Z/1]GI_K$*A@7["R*(WZ!6QM7LT+*X37H_WQ<(FKV:%F,!GWO07.%JJ&A=
M&;"P?'W&H5FG5$1JTDK+0^G;53&FSU(^G:\\D^O0_0)8Y2VW?:XLW4JV-LKS
MYHG@'[HA>I^(I!1N,O)`1<S<N^3%'Q$V+R7?3(\9MLOJ<:L<;KGZ*DF0X-C)
M7DE]`H6'&I,XE1D)C/3R<61]32DR+J,PT)H^YUWJ2'3=I,R">9DC@]X):.[8
MYYJ&[=H%`L3UMJRWT3IV74-U"^>&)S&EC"`X\;PP;3LV5JH>?Z0[LU\W;<[^
M-.*_WH3U^RKJ#Z5L_P`7(H._:<P7T7=_C(T_I#NS7S=MSOXTXK_>@_95U!]*
MV?XN1/VG,%]%W?XR-/Z0[LU\W;<[^-.*_P!Z#]E74'TK9_BY$_:<P7T7=_C(
MT_I#NS7S=MSOXTXK_>@_95U!]*V?XN1/VG,%]%W?XR-/Z0[LU\W;<[^-.*_W
MH/V5=0?2MG^+D3]IS!?1=W^,C3^D.[-?-VW._C3BO]Z#]E74'TK9_BY$_:<P
M7T7=_C(T_I#NS7S=MSOXTXK_`'H/V5=0?2MG^+D3]IS!?1=W^,C3^D.[-?-V
MW._C3BO]Z#]E74'TK9_BY$_:<P7T7=_C(UE%;]82XRNG%_"^RV^T$EDCX<=:
MSM_:G'4:?;**4K,Z;X825="-?@=Q=="]`HYO"SK!O%W&0QKNKB,[:^6D3Z>:
MJK(O$SI,T[^PR+>OA$+J>2LK:^>BW3B/GI\$,D6TBYLMV-OTN>'WN9=MTY-0
MQWF9*\4L#N,V</PB+578E>I'[.IZD,>OO#;S+M`3;LL;JG]%/2OD[YL._MIV
MJ_67B'Y=71`G?>VU?Z2"M/Q+I=W95=P;5<Y^(&]C\2%MKR'VPO;:>YX4''IN
M0LXOE,US4B[(F*Y:BBR.2>IE[R*KTB.,WRWUYIUKI,OBKR*!HVO##)&/+)%Q
MQCSN4@X;F'HC/N;'BLI:23..QA>(Y#Y(Y.!Y\S5U<,)69("("("("+1')K?:
MIXR[%[A;Z7M#8Y/4[>UU=8S**IDQH=C8HL;ZJH4-QI,PCC-*;>M4N&:^AI09
M>DR&2Z/TU/K#4EKINVE9#/=/<T/<"6MX6.?M`V[FTV=:QW5NHH=)Z=N=0W$;
MIH;9K7%C2`YW$]K-A.S>ZOF4*_\`2'=FOF[;G?QIQ7^]#87]E74'TK9_BY%`
MG[3F"^B[O\9&G](=V:^;MN=_&G%?[T'[*NH/I6S_`!<B?M.8+Z+N_P`9&G](
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M("("("("("("("("("("*NER_P`<5A7)?<V(39MQ;NVC9;#<[>U,A.40(MO-
M=06O7LMY,ELS]:FS,;3Z&N_SAI*S?6KXV&(]G=DM'\4-/G6M>L[4V.J+IGR9
M'B0=O&`X_P`8N'F6FJZR[2+VO5[HOTL-58XY-BRAJVT26JNGW11F!539E\$F
MWU2?M>KW1^F0;5^73+#K*SU[O:]WUBX0P]:HY):A:ZM9VO=U]WUBZ0QJW2O6
MO+&3J:NONBZ1,5OD<L,ENZF8N$;51/*UUE^94N(0E3+1_5Y:5?`Z]DTJFSG"
M_6LMF9=K9&9=SBM$)]9ZF1'\N+J&UCXY3M.X=)_TZU]AMY+A_"P;.D]`7#N9
MY)<YW<'9VI^&PSWMUU:VM2HM='49'X;>I)\5]WM(W73(E.&1="224IQ&[GEO
M)>\D^+T#H`_TWE9);0QVL?`S?TGI/^G0%X\2LT,O9]SU?H#R;&O1SUET"NT,
MO9_2%2R-4[WK.:V#[WV/<%;&RBIGN6P*R'[WI[GI_KBMC8J1[E)MQRVN=P^D
M<R>ZC*8OK^.A$>,\WV/UM.:DO-MN$KVVY$]:4N.)/0TI2@C(E$HAR3\97/.U
MU[J"/E[I>9LNE<1,732L-67-Z`YAX#N=%;-<^-CAL?(^5PXF"-YG7E[IE^+M
M79:];PWUPVC6G>R/8=O4YYH2.@!H-#4+I@:0J2%]EE.NGVQZ-"_07M1D>C[/
MLZ"J8%Z`+)H;?HZ?^05T35[-"RV"U[WH+C$U>[0LSKV?>]/<%TA:JAH77'&V
MI-R_NK92#-%?4HB)/U)?L9*%H/IZ5>#!<+[AG]H3[R/QYES5UD2*LAM@P=CI
M7`CS\,;AY_(OW)L;3M78PV:7B@(HHO.L^CUW6^,^UGRB8\)N\//O3LO4W/L'
MJ&N?GNRO/76_MF*D$.BZY_("("("("("("("("("("+OWBKYE?*KB?95D;%<
M]L,VVZB.--S=J=PIL_(L1<KR4?BQJ!<F0JTPR025J6VY6/,->-VJ?9D((VU1
MAK7E#HK6\+WWMLVVRSALN8`V.7BZ"^@X91T$2!QIL:YIVB2='<UM8Z,E8VSN
M77&+;OMYB7Q\/4RIXHCT@QD"NUS7#8;?G";GMLQS>PQZUP24YCN?X_$C.YWM
M;=R&59%C:WC2S^$8+J$M-9%B[\H^QFPCH21&I*'VX[RB:&A_,3EEJ#ESD!!D
MFB7%RN(AN6`]W)3;PN&WNY`-I8X]9:7-%5NYH#F/@>8%@9L<>ZR4309K=Y'&
MRNSB!V<<9.P/`Z@X-<:+N$1RI!0$0$4=_FP?1Z\EOBQB_P`HF'"5>2/O3P_K
MI/82J,.<WNRRWJH_;Q*AJ.F"YT("("*^5Y3_`-'KQI^+&4?*)F(YG\[O>GF/
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M]5A5A+0A+CCCB6VT$I2W%J)"$)3U4I2E&1)21>L_0*]C0!4[E1O=7<M`9CND
MS%)Z'CB$S9?5*K!U)G!8/T:L(]E4M:3]!]&RZ'JLN@\)[T1C@AVNZ^@?O_N+
MUBM>,\4NQO5T_P#@N9[-NPMYCL^SDO39CQZN/R%&M9EJ9DA/ZUMM&OLH21)2
M70B(660/E>7R$EQ5UCX6-X6"C>Q?5;J.I>S^EH/R(U],B]:-5:&7L_I?U?TA
MZMC7F7K)H59II[/VO0*AL:\7/6<4U-(ER(T2)&>E2Y3S,:+%C-+?D29#[B6F
M6&&6DJ<>>>=624H21J4HR(BU'N3'#&Z:9S60L:7.<2```*DDG8`!M).P#:O'
MTI'B-@)>XT`&TDG<`.DE2M;0<$<ZQ;'*[='<>E:*6V93H>"F9O6M-&0@G8]O
MD<0D*:\=.G?\#2M3D8NTWTDOO;:Y^>)KQ(Y27$3Z0Y425M'M='>7["0_@.QS
M+,BGH$<39+C>0?P&RDRF72/+B>`,S.?9^$!XF0':6]3I1U](9T?+VU:-[#EZ
MI47^D6ID0^A?5Z#">I?U![,"_07OQ6_0*R,+U`640FO0*^)J]FA9A`:][T%R
MB:JAH6;5[/O>@NL+54-"[_V(H#J,*1/=1VR+Z6[.ZEHHH;'[4B)/^U4;:W$^
MZEPAMWRAPYQNE1>R"DUY*9.W@;Z#!YZ.<.QR_,AJZG4MU"5%YH"**+SK/H]=
MUOC/M9\HF/";O#S[T[+U-S[!ZAKGY[LKSUUO[9BI!#HNN?R`B`B`B`B`B`B`
MB`B`B`B`BVALUO+N/L#N/C6ZVU.2S,5S3%9A2J^PBGWL26%^Q-J;:$O6-:TE
MK&-3,J*\E33[2C2HO096;4&G\3JC$S83-PMGQ\[:.:=X/0YIWM>T[6N&T':%
M=\%G<IIO*19G#2NAOX75:X;B.EKAN<QPV.:=A"OG\)>7>%<T-BZ'=C&&VJB_
M945#N+AAR$ORL-S6$PRNQKN_7Q)5-/;=3+K91D1R(3R.]+;Z7F6^9W,30F1Y
M?:DEPEX3):GTX):4$L))X7=CVT+9&_)>#0EI:X]&=`:VL->:>CS-H`RY'H3Q
M5J8I0!Q-[6GXS'=+2*T<'-'78P19L@(H[_-@^CUY+?%C%_E$PX2KR1]Z>']=
M)["51ASF]V66]5'[>)4-1TP7.A`1`17RO*?^CUXT_%C*/E$S$<S^=WO3S'KH
M_81+HOR9]V6)]5)[>52("*E)Z`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`
MB`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`
MB`B`B`B`B`B`B`B`B`B`B`B`B`B`BYYY4[4KWEV+SK#H;'CWZ*\K_%2)*ENG
MDF/J_",",P23Z.6R&G()F9'VHE*/34B&4:,S0P.H[:_D-+;BX)/5O]%Q/VM0
M_P`K5CFK<0<W@+BR8*W'#QQ_;L](`?;;6^1RK!,S5MJ-"^Y"TF:5)41I4E23
MT4E23T-)I/74O48W`=&"*C<M5@\C8=Z^^FQ/3WWH+[/NCR,07IWB^%VQZ'[7
MV>D?IL2_)D7@RY^B5&:B)):F9F>A$7K,SZ:=!4LC7B^1:UOLQB0R6B,E4Y\B
M/0FS)+"5%_9OGKK_`.82OND*MK"T;0J4O!.Q:*R.RN;U2BFR%%'UU3#8U:BI
MZZEW-D9FZI/J-9J,NNF@\I`YVP[EZ,+6[1O6"/5/]K^D*<Q+V$B^D=1_:_U!
M^.Z7[,E%_:*C^U'T1+X9.E>FQ4]2]GW/4/V(E^"]=,;$<6MUM^K1$;",><12
MLR$,VF86Z7H&+5/5/B$]8FTLYLMM"B/X-%0_)T/7L).JBP377,S1_+JS,^H;
MD?/2VL=M'1]Q)OIPQU'"TD$=Y(61UV<5=BOV!TQF=2S=WCHCW`-'2NV1MZZN
MIM/V+:N[**>CCEPSVOX\QXUNAE.8[B^"12LTMXK9*@..-&V^QB]:I3S5'&6E
M:DFX2G);B5&2W>PR0GGWS1YZ:JYC.?8`FQTQ79:QN/I@&H-Q)L,IK0\-&QM(
M!#.(<1V%TMH3$Z::+BG?Y2FV5P^+U]VW;P#MVN/2:;%UBZ[Z>OZGZH@M[UG*
MYMW'V9A7*W[C%4,5]JM2W9-;[+,">M7M*4P?1$*4M7I]#2S/KVGJHX_S^E(;
MPF[QW#'<G:6[FN[1]:?J'LWJAGLP_P!.+8[JZ#^\N495?-K)CT*QBOPY<=9H
M>CR&U-NH47NI41:I474C+4E%U(S(1I+!-;RF&=I9*#M!&W_3ZBMA:6GA<*%?
M<CH]'V?='HP+]A9'$;]`K8VKU:LKA->]Z"XQ-7NT+,H#7O1<X6JH:%M+"\=D
MY)>5=)$+1VPDMLJ<[343#):KD25EZ31'82I9EZR2,KTYAI\[E[?$VW\[/(&U
MW\+=[G'L:T%Q\B]QZ(JI,(4./7PXD"(V346%&8B1FB]#;$=I++2"]'O6T$0W
MIM+6&RM8[.V'#;Q1M8T=36@-`\P"IR:FIWK[0J$0$447G6?1Z[K?&?:SY1,>
M$W>'GWIV7J;GV#U#7/SW97GKK?VS%2"'1=<_D!$!%/+Q/\DC\Z#CUMIOQ^<U
M_`?_`#B5EI9?P5_S,?PE_`_X-R*XH/!_#G^=C'_PAXWX)\7N^!L=OB=NA]O<
M>L^M_$5^ANJKS3/YG^<_-'M;WGSON^/BC8^O!\V?PTXJ?'.ZO31;&:,Y`?I=
MIFTU'^=OF_SICG=W\U[SAX7N93C^<,XJ\-?BC?3HJNB/Z.9_]8W_`-O?_P`\
M!BO[6'_T'_KO_9K)_P!EW_[S_P!%_P"[3^CF?_6-_P#;W_\`/`/VL/\`Z#_U
MW_LT_9=_^\_]%_[M/Z.9_P#6-_\`;W_\\`_:P_\`H/\`UW_LT_9=_P#O/_1?
M^[7QN_5S72:<-CF&VX\3:S9;=X_J9:6Z23-M#CR-ZWUM-J7H1J)"S274DGZ!
M];XL!4<6`(;7;2]K]3YH*_"/*OA\+IH>'.`NIL_Y.GU?G1_<*YJW9\@KE5AT
M&39[8YQMCN^U&2M2:1N988'E<PR2:D%"AY"S(Q8]>TR/QKEDR4:="41F:<OP
M?B=T5?RB',VUY8./RZ-FB'E+")/@B/3NZ<4S/AOUC8QF;$7%I?-'R*NAD/D#
MP8_AE'GZ(;MS]IMS-E<MFX)NQ@V3;?9=7D3C]'E%5)JY;D93CC;-A!4^@F+.
MJE*95X$N,MV,^DNYMQ1=1/N&SF'U#8MR6#N8;JQ=N?&X.%>EIIM:X5VM<`X=
M("@O+X7+8"]=CLU;RVUZW>R1I::=!%=CFFFQS26GH)6O!=5;$!$!%*GY07*N
M7QNY9XSCMO8.L[:;[/UNV6915OFB##N[&;X>`94XVI:&"?I<BEE%<>69)9KK
M*6KJ?:0A7GOHIFKM#S7<#`<OC0ZXB--I8T?AX^NCXQQ`#?)'&.M3%R1UB_2N
MM(K6=Q&)R);!**[`]Q_`R=56O/"2=S'O*O#CG(N@B`BCO\V#Z/7DM\6,7^43
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MMO.ZN1LZ1OV[2VGX-_G:.$G>7-<3O6LO,+!'"9UT\+:6-U61G4'5_"-\SCQ`
M#<US1T+G';?9[=O=R2F+MQ@.2Y47B&TY/@P5,TD9TM/8G9!.5$HH"NOH?D-Z
MC*\MG<)@V<>5N8H=GQ2:O/D8*O=YFE8UC,+F<P[AQEO+**[P*-'E>:-'G(4C
M6V'E8Y?:QRG[O9]`Q7Q&#-G'\08+(+1MQ:%$@K*WF_`ZJ*N.[H:FX[<U#B>A
M.H/J459CG+8PN[K!VSIJ':^4\#?X+15QKUN+"/K2I*Q7*>\F;WF9N&PU'Q(Q
MQN\[C1HIU`.KUA1#[MX)F&U^?Y3MQG+"XU[BMH]72VDD:8DIDB2]`M(/1/C5
M]K`=;DQUF6JF74F>AZD4X87(V&9QD.5QY#K:9@<.L'<6GJ<UU6N'6"H>R]A>
MXG(RXV^%+B%]#U'J<.L.%'`]16I9%>AS4TD7W!<G,!5`'D+P)%3Z?8_2'BZ)
M>H>O(=J.OO/TAY&)?L/7U#J.OO/_`,H_/=+Z9%MG:SCSNGO)8%7[>89:WK:'
MT,3+8F2A8_6*41+,[*\F*8K(BDM:K)LW/&6DM$(4>A'B&K-<:1T/;?.M37T-
ML2VK8R>*9XW?@XFUD=MV$AO"/E$#:KWAL%F<_+W6*@?+0T+MS&_;/-&CKI6I
MZ`5+EL9Y96#8BJ%?[T6S>>W;/8\6)U!R8.&Q'B(C)$Z6M,>XR+PG")1:E"85
MU2XRZGTZ:<P/%/FLHV3':$@./LCL^<2\+[EPZV,]**&NT;Y7;G-<QRFO3O*>
MQM"VYS\@N;@?[-M1$/*=CG_Q!T$."DMKJVIH*R%34=;`IJ>MCHB5U75Q(\"N
M@Q6BT;CPX<5MJ/'907H2A)$0U,O\A>9&ZDOLA+)/>RN+GR2.+WO<=Y<YQ+B>
MTDE2W!!#;0M@MV-C@8*-:T!K0.H`;`.P+^77?3U_4_5%L>]>R\QUWT]?L_KB
MD>]?5YKKOV>Y^J*5[_@181E&+T64L>%;1$K=;291YK6C4V-J>OWI\DF9I,RZ
MH42D'ZR%ER-A9Y%G!<M!<-SAL</(?]1V=B\Y(8Y11XV]?2N>[K;&XIG%NUY_
MA>"7<I*F4]DQM!$I6CL74^\R(M-6S5W'ZB]`PB[P%S:DN@_"0_QAYNFG9OZE
M;WVDC-K?2;]7X%CT9A;:C0M"D+0?:I"TFE25%T-*DGH9&*)C"TT<*."\VA99
M!:]`N$35[M"S2O9]Z+I"Q5+`NZ]@,%54UCF76+/9,MV/!J6UIT4S5&I*URM#
MZI78.(+MZ:^$@C(S)P;3\G=).Q]B[4MZVEU<MX80=[8J@E_ED(%/L`"#1Z/=
M\D+HX3<O-`1`111>=9]'KNM\9]K/E$QX3=X>?>G9>IN?8/4-<_/=E>>NM_;,
M5((=%US^0$0$5\KRG_H]>-/Q8RCY1,Q',_G=[T\QZZ/V$2Z+\F?=EB?52>WE
M4B`BI2>@(@(@(@(N>>2G%S9CEAM[-VYWDQ2+=U[B77*._C(8BY9AUHLD]ESB
M=\IAZ34SD*0GQ$D2X\ILC:D-.M*4@\JTCK/4&B,JW+8"=T<H^.PU,4K?K)65
M`<.K<YI])I:X`K&-5Z0P.L\8[%YV$21GXCQ021.^NC?0EIZ][7#8X$5"H=\L
MN,^:\1]],QV2S993Y%`\Q.Q[(V8JX<'+\1M$J?H,G@,+=D$RW.CI4V^R3KOP
M6:R_'-:E-*,^EVA]88_76F[?46.'"R4$/C)JZ*5NQ\;C05H=K30<3"U]`'!<
MZ=9Z3O\`16H9\!D/2=$06/`H)8W;62`;:5&PBIX7!S:DM*YO&6K%D!%\T>1(
MAR&)<1]Z+*BO-2(TF.ZMB1'D,+2ZR^P\TI+C+S+B24E23)25$1D>H_+V-D:6
M/`<QPH0=H(.\$=(*_37.8X/82'@U!&P@C<0>@A?HR\:=SE[T<>MDMUWW&W)V
MX&UV$93;^$220U>VN/0)%_%(D$E!'#NE/M&22(B-!Z=!R?U?AQI[561PC01'
M:WLT;>UC7N##YV<)\ZZB:4RQSVF<?F7$&2YLXI'=CW,!>/,^H\RW>,<60+'<
MLQ#$\]QZSQ'.L7QW-,4NFFF+G&,LI*W(\>MF6)+,QEFSI;B-,K9[3,N.VZE+
MK2R2XVE1>TDC*KL;^^QETR^QLTMO?1DEDD3W1O:2""6O:0YI()!H1L)"I;VQ
MLLE:OLLC#%/92"CHY&->QP!!`<QP+30@':-X!6AOS*.&GS2.,GY!=J_Q4&3?
MK$Y@?3N8_+;G^L6.?H#H7Z%Q/Y';_P!6GYE'#3YI'&3\@NU?XJ!^L3F!].YC
M\MN?ZQ/T!T+]"XG\CM_ZM/S*.&GS2.,GY!=J_P`5`_6)S`^G<Q^6W/\`6)^@
M.A?H7$_D=O\`U:WSB>(8G@6/5F(X+B^.X7BE*TZQ38QB=)6XYCU2R_)>F/,U
ME+3QH=;`:>ER''5)::02G'%*/VE&9XS?7]]D[I]]DII;B^D(+Y)7ND>X@``N
M>XESB``!4G8`%D=E8V6-M666.AB@LHQ1L<;&L8T$DD-8T!HJ23L&\DK(A2*J
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$7,V^/,
MGB_QP:D?YY-Z\'Q"SCM$\>+_`(3.\S5UM7O%L83CK5ME;S2U="<*'X1'Z5$7
M49AIS0&LM6N'Z/XZYGA)IWG#P0CRS2<,0/9Q5[%B>H-=:1TL#^?;^W@E`KW?
M%QR^:)G%(1V\-.U1C0?/1V7SK??:C9W:?:[,;BAW!W.P[`+;<C-K"NQ&'41<
MIR.OH/PW48U$3?V%I%:.>3FLV15N-H29J;/3M$Q2>&W4.-TU?9_-WMO'<VMG
M+.VWA:Z4N,<;G\#I#P-:3PT]!L@)W'I421^(;`Y'45E@\-9SOMKF[BA=/*YL
M8:)'M9QMC'&7#;7TG1D=(Z%.D-;5L.@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(L3RS`\(SQFMC9OB.-Y?&I[!-
MM5QLEI:^[C0;)#+L=$V-'L8\AEN0EE]1$HDZEKKZ2(RK;+)9#&N>_'SRP/D;
MPN,;W,);4&A+2#2H5'>8^QR#6MOH8IFL=Q-#VAP#J4J`X$5H5DL6+%@QV8<*
M,Q#B1FTLQXL5EN/'8:06B&F6&DH::;070DI(B(4CWOD<7R$N>34DFI)[255,
M8R-H8P!K`-@`H!Y`OG'Y7Z4<'F#</"W^P].X.!5Z#W>P>O<)B*PVDG<YQEDW
M)+^-.&G12KF"M:WZQ9ZDIQ3D=1:/(<9E;EAKO]&;_P#->2<?S'<.VD[H9#L$
MGVIV"0=``</BD.C3F)HS](;+\XX]O_S$#=@'^U8-I9]L-I9VU;\H$5J7V'XK
M[T:2R['DQW7&)$=]M;+[#[*S;=9>:<)+C3K3B32I*B(TF6A]1MHUS7M#V$%A
M%01M!!W$'J6L;FN8XL>"'`T(.P@CH*_N)!E64IB#!B2)\V4XEF-$B,.R94AU
M9Z(:8890MYUQ1^A*2,S'XGFAMXG3W+VQP,%7.<0UK0-Y)-``.LK['')*\1Q-
M+I'&@`!))Z@!M*ZSVUX)[\[CG'E2\9;P&D>-)JM,X6Y52?"T-2S8QY#4C(%N
M=A%V>+'8:6:B^^$6II@_5WB&Y9:6#H8KLY+(-_V=F!**]%9JM@`KOX9'.'UA
M-`<_PO+75>7(D?#\UMC\J:K33LCH9*]56@'KWTD8VH\NS9;!#BV><*F;H7S)
MDX;=NC\&8JTZ6AD;..Q'W7)A)U,E%-E2F5EH?A),:IZU\3^N-0A]KIYL>(QS
MME8SWEP1TUG<`&]8,4<;VGY94O8+E1@,:1-DBZ]NA]=Z,0/9&"2?X;G`_6A=
MRP*^KHZ^-54M;7T]7!:2Q"K:N''KZ^&P@M$,1(<1MF/':070DH21$-:[_(7F
M0N7WE_++/=R&KGR.<][B=Y<YQ+G'M)4FPP0VT38+=C(X6B@:T!K0.P"@`\B_
MAUWT]1;'O7LO,==]/7]3]44KWKZO,==]/7[/ZXI'O7U>:Z[]GN?JBE>_X$7F
MNN^GJ*1[U]7F.N^GK]GNF*5[U]7T%*-1_:%,35?5YLNKKI_69#COJT,B<6V7
MBI(R(C[74Z.IZ$7H,O07N#QD@AE_G&M=Y0OPZ-C_`(P!*\S^"]2G3PD/LZ'K
MJAXU:^GI]^)TM.OW>@I_F%L!1H(\A/\`KJOQW+.BJW/M-M0SE5DF7,9>+'ZU
MY*IC[BEI.>\G1:*UA2";0?<1D;RD]4-GZ24I)B3>76@AJ:^%S=L(PL#P7N-1
MWCMXB:10;=A>1M:T[P7`K\OX6#9\9=V-MH:0AII"&VVT);;;;22$-H01)0A"
M$D24H2DM"(NA$-N&,9&P1Q@-8T```4``V``#<!T!>"_L?I$!$!%%%YUGT>NZ
MWQGVL^43'A-WAY]Z=EZFY]@]0US\]V5YZZW]LQ4@AT77/Y`1`17RO*?^CUXT
M_%C*/E$S$<S^=WO3S'KH_81+HOR9]V6)]5)[>52("*E)Z`B`B`B`B`BK1_6'
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M,XW`R:FP[#\?99D7>2Y#/8K*:J8D2X\%AV=/DK0Q';>F2FVDFHRU6M)>DQ6X
M[&W^7O8\;BX9+B_E)#(V-+GN(!)`:-IH`3Y`J/(9&QQ5F_(9*6."QB`+Y'D-
M:T$@`DG8*D@>4KF?^<%X/_.LV+_*)CW^.#,/U6\QOH3)?B'_`+RQ/]9G+[Z9
MQWXYG[Z?S@O!_P"=9L7^43'O\<#]5O,;Z$R7XA_[R?K,Y??3.._',_?3^<%X
M/_.LV+_*)CW^.!^JWF-]"9+\0_\`>3]9G+[Z9QWXYG[ZZ8PC.<.W*Q6GSC;_
M`":FS'#\@9>D4F2X]/8LZ:U8CRY$%]V#/C+6Q(;9F17&E&DST6A1>DAA^1QM
M_B+V3&Y2&2WOXB`^-[2U[20"`6G:*@@^0K+,?D;'*V;,AC98Y[&4$LD80YK@
M"02"-AH01Y0LJ%$JQ`1`1`1`18#N)NKMGM%1+R;=/<##=NZ!!.Z6V9Y)4XY"
M?6R@EKCQ';67%*;+,E))++/>ZM2DI2DU*(CN>*PF8SMS\SPMK<7=UL]&*-TA
M%>DAH-!VF@&\E6W*9C$X2W^=YBY@M;;ZZ5[6`TZ`7$5/8*D]`49^Y7G:\#-O
MI#T2HS'.-U94=9MOM[:X+.>CI<3W:I9L\WE8/3S4="T<CR'6C[BT4?728,1X
M=N9F4:'SV]M9,.[YQ,T'SMA$SQY'-![%$^5Y_<N<8XL@GN+QXW]Q"2/,Z4Q-
M/E:XCM7)UW]8=V:8\7^#G';<VUT\+P/PWE.*X_XFO;X_B_`&LE\'P]3[-/$[
M]"U[=>F;V_A5U`ZGSO*V;-]>".1_DI7NZ]NZG:L,N/$Y@FU^:XN[?U<<D;/+
M6@DI]6O8O*K/K$>VKKJRN.,V<P&2)/AN5FX-!;.J4:M%DMF5CU*A!)1U(R6K
M4^FA>D>\WA4R[6_\OF+9SOLH'M'PA[_W%XQ>)[%$_A\3<-;]C,QWU"QO[JZ.
MV_\`/AX1Y9)8B97%W?VM4M1)D6.581$NZ9C51_?$NX!?9?=O-)1H:O\`F]*]
M=2))D6IXEE/#1S%L6%]DZPO0-S8YBQY\T[(F`_PZ=JRG&^(O0%ZX,O!?69Z7
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M,-[+24,.K1H:D)<<))GH2E::G>&^$]Q:"_/`/IM`LJBO30_.Q4=M!Y`K2[Q1
M-#CPX,EM=E;RAIVCYJ:>2I\J]2I^L68\\K_GWB;<UR?&;3K4[S0;I7P<S+Q7
M>V9ME0EXR"U[6]>U7K6D>,_A1NF_]-G(WFGRK0LV]&ZX?L[?J%>T/B@MG?\`
M4861HK\FZ#MG3O@9M[/JA;QQ'ZP-Q4M5M,9AM;OEB3KJNTY4&KPK**J.6L@S
M7)?;S&HM>WPT-Z>%"=4:W#(R)*.]6-WWA<UM""ZPO<;.T=!=+&X[MP[IS>O>
M\;!UF@R&R\2VCIB&WUGD(">D-BD:-^\]ZUW5N8=I[*GJ_&O.$\O;(Z6;<+WW
M3CSE=#5-F4V2X+N#7W26T]I>#"C,8Q,CW4Q2E:$S`>E.GH9]NA:C";OD-S3M
M+AMN,9WH>Z@?'-`YGE),@+!VO#0LRM>>'+.ZMW3G(]T6MJ6OAF:_R`",AY[&
M%Q7!N^WU@K;"B.95<=]G\CSZ<@U,LY;N--:PS&DK))FF9"QZK.XR.YB&>B?#
MD.T[NNI]"(NZ2]->%O,W/#/JJ_BM8]YB@!ED\A>[AC8>UHE'^J.M1>);$6_%
M#IBQEN9-PDG/=1^4,;Q/<.QQB/\`KA9W[\T[FSR"5*B7V[]E@.,RB4A6';1%
M(V^I?"<-?BQI-A6S'LNMXCJ%]JF9]G+:-*2]G74SV%TSR6Y=Z6I);6#+J\'^
MUNJ3OKT$-<!$TCK9&T]J@74?.#7^IJLN;Y]M:'_96U864Z02TF1P/4^1P[%'
MJZZZ^ZX^^XX\\\XMUYYU:G'777%&MQQQQ9FM;BUF9F9F9F9ZF)3:T-`:T`-`
MH`.A1D27$N<27$[2O5QR]GXOD-#DU6LF[/';FKO:YQ6II1/J)S%A#69%H9DF
M1'28\+NVBO;66SFVPRQN8[[5P+3]0KVM;B2SN8[N'9+%(U[?*TAP^J%^E/CE
M[`RG'J')JM9N5F14M7>USBM"4N!;P6+"&L].FJH\A)CD5=VTME=RV<VR:*1S
M'?;-):?JA=6+6YCO+6.[AVPRQM>WR.`</J%>T*=>Z`B`B_E:T-(6XXM+;;:5
M+<<6HD(0A!&I:UK49)2E*2U,SZ$0^@$F@VDKX2`*G8`N&=XO,JX1;'/RJ_-.
M0&&S[V&XXP]CN"*G;BW+,QH]'(,UG"8EY%IY:#]\F<]%[3+0S(^@DC`<HN8N
MHVMEQ^+N&VSA4234@80>D&8L+Q]H'*/<YS6Y?Z><8[_)P.N&FA9#6=P/41$'
MAI^W+5P+F'U@7BI4//1\.VPWNS%;1]J)DNLP[%ZN3]\;+NCNR,LM+4F_!-:O
MOL)I7<DD]NBC4F3K#PNZVG:'W]YCK<'H#I9'#RTB:W?3<\]?10QO?>)71T#B
MVQM,A.1TEL4;3Y*R.=NKO:/]8U%*^L38&B0ZF'Q>RZ1%)1DP]*W.IHDAQ'31
M3L9K#YK;*M?43KA?;%]9X4\F6@R9F`/Z0+=Y'F)E%?@"LC_$_C@XB/$3EG03
M<-!^`1&GPE9UCOUA7CQ*?0C*]C-YJ1@_!);U#+PG)G$&I#GCGX,^]Q0E):<)
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MQW+_`%OE[*/)8O%7UQ82@EDC(GN8X`D$AP%#0@CRA8GD-=Z,Q5X_'Y+)V4%]
M$0'QOE:US20"`0345!!\A6*_S@O!_P"=9L7^43'O\<%;^JWF-]"9+\0_]Y4?
MZS.7WTSCOQS/WT_G!>#_`,ZS8O\`*)CW^.!^JWF-]"9+\0_]Y/UF<OOIG'?C
MF?OK?^V6[6V6\^.+R_:?.\7W$Q=JRE4[E_B-O$NZI%K":C/RZ]4R$XZR4N.S
M,:4M&O<E+B3/TD,7S&#S&G[L6&<MIK2]+`_@E:6.X22`ZAVT)!H>PK)<3FL3
MGK4WV%N8;JS#RWCC<'MX@`2VHV5`(J.T+88M2N:`BCIY`^:KPHX[3)U'D.Z:
M,\R^N<=9EX;M+"3G-M'D,'V2(<VWC2H>&5=A&=]AR-,M8\A"]2-!=JM)7TOR
M4YAZKC;<VED;:P>*B6Y/<M(.XAI!E<T[PYL;FD=.T*+]2\XM`Z7D=;W5X+B^
M;L,5L.^<"-X+@1$UPW%KI&N!Z-A4>.0_6']H(TE:<4XY;DW4,G=&W\AR_&,9
MDJ9\-)^(N)6Q,M:0[XIF783RB[2(^[4^TI5M?"KGGLK>Y:TCDIN9%)(*^5QB
M-.VGF48W7B=PC'TL\7=2,KO?+'&:>1HD^"OG7J8Q]88V&F/1TYCL'NW0,K+]
MLNXW<8?EBV%>)H7A-64[#?A"/"]HS-39]W0DGZ1X7GA7U-&TFPR=C*[H$C98
MJ^4M;+3;Y5[6GB;TX]P%]C;V)O26.BDIY`XQ5^IY%(+L;YIO"#?N5"J,;WFK
M,0RB<I#;&*[HQ)&`63C[A:LQ8UI=$G$[.8\O5"&8=E(=4LM"3JI/=%VI.2_,
M;3#'3W>/?/9MWR6Y$[:=)+6?A6@;R71M%.G?22]/<X.7^I'M@M;]D%V[='<`
MPNKT`.=^#<3N`:]QKT;E(4E25))23)25$2DJ29&E23+4C(RZ&1D(K((-#O4F
M@UVC<O\`01`1`1`1`1`1`1`1`1`1`1<&[R^7_L-NCG\_=6?CEE^';0B?R/'J
MFW>I:#)+`G%.R+R3'K6X]DW>32,BD*8E,(DF7B*2;ZEN.9'=\SN9&$TT,5I6
M>`.BKPNDB$DS64V,B+R8Z-^2U\;]_"T@`-6$Y#EYI?+91V5O8G]Z_:]K7EC'
MNZ7.#:.XCTEKA7>1Q$D^AA6U&W.V;*XF#X/CN**T-J0]6U4>/9/]AFDT3K):
M%6<Q2#+3[\ZLR&KFI=9ZOU5.7:GR%W=O:X^A*]W`P[CPQ;(V'K#6-64XS!8?
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MM:C-2E&9F9F8VQQV.LL391X_'QMBM(FT:T?5).\DG:2=I-2354I))J=Z]`5R
M^("("("**+SK/H]=UOC/M9\HF/";O#S[T[+U-S[!ZAKGY[LKSUUO[9BI!#HN
MN?R`B`BOE>4_]'KQI^+&4?*)F(YG\[O>GF/71^PB71?DS[LL3ZJ3V\JD0$5*
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M_G=[T\QZZ/V$2Z+\F?=EB?52>WE4B`BI2>@(@(O%R+(\?Q"AM\IRJ[JL;QN@
MKY5K>7UY/C5=145D)I3TN?8V$QQF+#B1VDFI;CBDI21=3%1:6EU?W,=E91OF
MNY7!K&,:7.<X[`UK14DD[@`O"ZNK:RMWWEY(R*UC:7/>\AK6M&TESC0`#I)5
M:'FWY[$Y4JVV[X70V8\1DWX,W?3*:=,B3*62DEX^W>'W#!QXT=)),DSKJ.ZM
MTEJ),%KM0^K;[EUX:XPQF5YA.)>:$6<;J`=D\K#4G[")P`H*R&I:-4-?^(B0
MO?C-!M`8*@W<C:D]L,3A0#[.5I)KLC%`XUUMP]S=Q=VLDEYAN?G&5;@91-,_
MA%[E][8W]B;?<:D1F9%E(D*BPF->UIAKL9901)0E*2(BVMQ6'Q.#M&V&&MH+
M6S;N9$QK&^4AH%2>EQJ2=I)*U?R>6RF:NG7V7N)KF\=O?(]SW>0%Q-`.@"@`
MV``+!A<E;T!$!$!%ZM)>7>,VT"_QNXM<?O:J2B95W5)82ZJVK9;>OARH%C`>
MCS(<EO7V5MK2HO48\;FVM[R!UK=QLEMGBCF/:'-<.IS7`@CL(7M;W%Q:3-N;
M5[XKAAJU['%KFGK#@00>T%3E<,_/"WEVHEU&%<G6YN]>W!.-1#S1'@HW:QJ,
MMQM)RG9[CD>#GD2*WWJ4U/\`"L7%*U^'&24M'K?S`\.6G\W')D='%N.RU">Z
MV_-I#U!NTPD[-K*QC^CVERV$T)X@L[AGLL-6AU_BM@[W9\YC'63L$P&W8^CS
M_2;**U=M#O)MEOU@=-N9M'F%1F^%WK9G#MZEY2O`DMH;7)J[2$\AJ?374'Q4
MID0Y33,EA1D2T)U(:49W`9C3.3DP^=MY+;(1':UPWCH<TBK7L=3T7M):[H)6
MXV$SN)U'CH\MA)V7%A(-CFG<>EK@:%KA\IK@'#I"V:+.KL@(@(@(OC==:8:<
M??<;999;6Z\\ZM+;333:36XXXXLR0AM"",S,S(B(M3'UK2XAK02XF@`Z5\)#
M07.(#0-I5<GGAYXM?A]A=;5\-T5.2WD%UZON=\K:,Q:8O72V3\-]K;NBD(<A
MY2ZR[JDK2<2JTU-GX,:8TXB06V7+3PXRW\4>:U^7PVS@',LVDMD<#N,[QMCJ
M/]FS\)M])\;@6K5SF+X@XK&63#Z%#);AI+77;@'1M(WB!AV24/\`M'^AL]%C
MVD.5:C='>+=3>W)I&8[M[@99N'DDA3I_A3*KJ;:N16WEDM42L8D.JB5%<@TD
M3<6*VS':2DDH0E)$1;=X7`873MF+#!6L%I:"GHQL#:TZ7$;7.ZW.)<=Y)6J6
M8SF8U!=F^S5S-=71KZ4CBZE>AH.QK>IK0&CH"UL+NK4@(@(@(@(@(@(@(@(@
M(OT"O+KSLMQ^#G&#)C?*2ZUM)C>*2I!+4XIZ?M\T[@-@X\M6JE25SL9<-TS_
M`+IW#EWS6QGYIYCYFSI1IOI)`.IL])VT[*2"G91=*N5^1_.O+[$7=:D63(R>
MLP_@37MK&:]J[0$?+/$!%&MSH\SK8WA7#D8U(66Y6]LF$3]7M;CU@PTNI*0P
M3T*QSZZ2B4UB=:^A:%MLFV]8R6UI6U'-E1O(EWEMR=U)S"D%XT?,].AU'7+V
MGTJ&A;"S897#:":AC2"'.XO1,4\P^;>GM!,-HX_.\^6U;;L</1J*ATSMHC:=
MA`H7N!!#>'TA4RY1>8IRJY9S+"-N)N)/H\%EJ=0QM9@CLO%\!8AK7WHBV-9%
ME+FY6IHRU2]<2)[J#,R0:$GVEO#HSE1HK0\;7XJT;)DFTK<S`23$];7$4C\D
M36`]-3M6F.K^:&L=:/<S)W3H\<[=;PUCA`ZG-!K)Y97/(Z*#8N&Q(ZCU`1`1
M`1`1=%\>^67(/BWD+.0;*;F9#B2/A:)5IC/PI5CA61:&TEUK(<0GF_169OL-
M>%XZF4RV4&9LO-+T46*:IT/I;6=J;745G%.>&C9*<,T?462MH]M#MI7A)^,U
MPV+*-,ZTU-I"Z%S@+N6$<571UXHG_;Q&K'5&RM.(#XK@=JM=\`?-]VQY5RZC
M:[=J'5;1[[2R:BUD9,MU.`[BS>SJWB-A8NN2:2\?<2?93SGG7'=4IC292S4V
MWI)S0Y$9C1+),S@W/OM--J7&GX:`?[UK11[!TRL``V\;&"A.Y7+;G=B-8O9B
M,TUEEJ)VQHK^!G/^[<[:QYZ(GDD[.![S4"900`IT0$0$0$5#7S8/I"N2WQGQ
MCY.\.'3#DC[K,/ZF3V\JYS\Y?>;EO71^QB4=XE51B@(KE_D+?R'[;_3KGO\`
M\.X*-`/$S[QF?Y;#_+F6]?AR]W[_`/,9OY$*EUW'W&PC:/!LFW)W'R.NQ+",
M/K';?(<@M'%-Q($-M:&D))#:7'Y4R9*>;8C1F4.2)4EUMEI"W5H2<%8G$Y'.
MY*'$8F)\^1N'AK&-WN._R```N<XD-:T%SB`"5->4RF/PF/FRN5E;#CX&<3WN
MW`;O*220&M`+G.(:T$D!4V_,`\VS=KE58W.WVU,V\VHX^ZNPOP)#DI@9CN%&
M]IM<S.[6O>4XQ5RT&?;2Q7O@9(5^V52EI0IO?SE?R-P>BHH\IFVQWVJ=AXR*
MQ0'JA:X;7#^E<..OQ`P5!T8YE<Z<UK&63&89TEEIK=P`TEF'7,YIV-/]$T\-
M/CEYH1#^)X4(("("("*2;A7YH/(CAY85="Q;R-S=F&7$,S]J<ML9#T2MA&M)
MN.8+=N)DS<.FM%W&AIHG:UQ2E&[%6LTN(B/F%R:TIKV)]TZ,6>H"*MN8F@%Q
M_P!\S8)1UDTD&RCP-AE707-W4^AY&6S7F[P(-#;R.)#1_N7[3$>H"K#MJPG:
M+E7&#E)M%RXVPKMTMH;W\(5SJD0<@H)Z41<FPS("8;>E8[DU8EQPX<]@G-6W
M$*<C2FC)UAQQI1*/0'66B\[H7,OPN>BX)1M8]NV.5E:!\;NEIZ0:.:?1<`11
M;TZ1U?A-:XAN8PDG%$=CV'9)$^E2R1O01T$5:X>DTD&JZ*&*+*$!$!$!$!$!
M$!$!$!$!$!%B60XE"NB5(:[8ECITD)3][?,BZ)DH+WW0M"67M%]LB(AB&HM(
M66;!N(J0Y&GQP-CNH/'3U<0](=H`"_37$>1:/NJJRI7C9GQUM:F9-O$1JCO$
M7K9>(NU73J9=%%ZR(0CF,1DL--W-_&6@G8[>QW:UVX^381T@+V!!W+%W7?3U
M%@>]?I>8Z[Z>OZGZHI7O7U>8Z[Z>OV?UQ2/>OJ\UUW[/<_5%*]_P(O-==]/4
M4CWKZO,==]/7[/=,4KWKZOH*4:C^T*8FJ^K^!^5\7R,LO2'6V([3C[[RTMM,
MLMJ===<4>B4-MH)2UK4?H(B,S'I%%+/(V&%KGRN-`UH)))W``;23U!%T+@NQ
M\N8IFSS'OA0_9<;I6U]LV26A*+X:\@_VFT?K0DS>/J1FV9=9LTARCN;ES;_5
M%8K;>(`?PCO6$?$'6T>GO!+"-OB^4;F[UU'$B18$9F'"CLQ(D9LFF(T=M+3+
M3:?0EMM!$E)?[HV$MK:WLX&6MHQL=M&*-:T`-`Z@!L"IR:[3O7V![H@(@(@(
M@(HHO.L^CUW6^,^UGRB8\)N\//O3LO4W/L'J&N?GNRO/76_MF*D$.BZY_("(
M"*^5Y3_T>O&GXL91\HF8CF?SN]Z>8]='[")=%^3/NRQ/JI/;RJ1`14I/0$0$
M0$0$0$5*OSJ>4E5R!Y3MX+B%DU:8+Q^K+'!8LV,Z;T*QSN?/;D[AV$)PE>&I
MB-+KX56:DEVN.5:G$J4A:#+H7X>M&3Z7T6<E?L+,EE'MF(.PMA:VD#3VD.?)
MV"0`@$%:%<^]7PZEU@,=8O#\=C&.A!&T.F<:S$=@+6Q]IC)!((4/(GI0<@(M
MG;+[5Y'OANSMWM%B3*G<@W$RZDQ6`LFS=1#*TFM,2[64E)D:8%/!-V7(7J1(
M896HS(B,6?4.:M-.8.[SM\:6MI`^1W;PBH:/LGFC6CI<0%=L#A[K4&:M<)9"
MMS=3LC'9Q&A<>QHJYQZ`"5^C5B&+4V#8EB^$XY&^!X]AV.TF+443V/VK38_6
MQJFKC?>T-M_>(41"?92DNG0B+H.3M_>W&2OILC=GBNKB5\CSUO>XN<?.25U&
ML;.#'V4-A:CAMH(F1L'4UC0UH\P`61"D54H[_-@^CUY+?%C%_E$PX2KR1]Z>
M']=)["51ASF]V66]5'[>)4-1TP7.A`1`17RO*?\`H]>-/Q8RCY1,Q',_G=[T
M\QZZ/V$2Z+\F?=EB?52>WE4B`BI2>@(L?RO*L;P;&;[,LPNZ[&\5Q>IG7N0W
MUM);AUM145D=R5.GS9+ADAIB/';4HS])Z:$1F9$*JRLKO)7D6/L(WS7LSPQC
M&BKG.<:!H'22537EY:XZTDOKZ1L5G"PO>]QHUK6BI)/4`J37F2^9;FW,[+Y>
M&87+M\1XY8W8+1CF)D^[#F9W)AR$K8S+/&&5DB3)<<92[`KU][%8C0R[I!N.
MJZ(\H^4..Y?6#<AD&QSZLF;^$EH"(01MBA)W#;1[Q0R'J91HT$YJ\U[_`%W?
M.L+!SX-+1.]".I!F(.R68#>=E6,-1&.MU7**H34H=0$0$0$0$0$0$0$7:7"3
MF_NKPEW/CYAA<EZ\PFX>C1MQMLYLUYFAS*G0LB4X@NUYNIRBN;-2J^R0VIQA
M>J'$NQW'F'(^YB<N<)S$PQL,@!'D8P3!<``OB?\`4XHW?+C)HX;06O#7#/-`
M<P,SH#+B^L"9,>\@3P$D,E;]7AD;\B0"H.PAS2YIO0\?]_-M>3.U6,;P[4W1
M7&*9-'49LO$TS<4%O&[46N-9'`;>?.LOJ>0KL?:-2D*2:76EN,.-.KYMZHTQ
ME]'YN;`YN/N[V$[Q4M>T_%DC=0<3'C:#OWM<`X.`Z&::U)BM68:'.8:3CLY1
MN.QS'#XT;Q4\+VG81NW%I+2"=SC'U?D!$!%5P\Y[S(+F=D&0<.=CL@=KJ&H2
M]4[]995/K:FWMPO0I.UU;,:[51J2I:]F\4VLUS9*U0%^&S'E(E;F^'WE+;QV
ML6OM1Q!]U)1UE$X5#&=%RX'>]Q_F:BC&@2BKG,+-0N>_-.>2YET-IZ4MMF5;
M>2-.U[NFW:>AC?\`:T-7./=FC6O#ZV@VX6JR`B`BVOM-L5O+OM=+Q[9S;'-=
MR+5CPSFM8GC]A:QJMMWN\)^ZL6&3K:2*X:#)+LMYEHU=.[4R(63.:ET_IJW^
M=9^\M[2`[C*]K2[L8TGB>>QH)[%><+IW.ZBN/FV#M+BZF&\1L<X-[7.`X6#M
M<0%(=CGDG>8%>P$3INV^(XHMQ*%HK\CW+PXY_8LU]IK;Q^ROV&5$A)*-"W$K
M22R(R)1*2F*KOQ$<KK:4QQW<\X'RH[>7A_CM83Y0*;.JA,G6O(+F5<1]Y):P
M0D_)?/%7^(YX'D)KMZZT\G,O)C\P/$8:Y\?:2GS*.RTEV06&[@87/F,D:EH-
M"*RTN::TG.I-*3-,9E]6BR,M=%]OOC_$#RNOY.Z??26[R:#O8)6@_P`)K'M`
M^V(W>2OA?\B.9=BSO&V3)V@5/=31.(_@N<UQ_@@[_+2.+.]N\^VOR&5B6Y.%
M95@.40B2N5C^8T%ICEPTVLS)M\Z^WBQ)*H[Q),VW"2;;B>J3,NHEK&Y7&9FU
M;?8BX@NK-VY\3VR-/9Q-)%1TC>.E1;D<7DL1=&RRMO-;7;=[)6.8X=O"X`T/
M0=QZ%AHKU0H"("*9#@?Y4V*<XMKGMQJ3E-78A9T5L_1YQM^WM6[D618I9D^X
M[5IDR'MP\>9D5.0TR"DPYZ&C:6LG6.TW8[Z40%S+YV7O+C,C$W&%?/#*P/AG
M^<B..1M*.H!`\AS'^B]A-0.%U>%[29SY=<G+/F#B#E+?,-@EC>62P_-^-\;J
M^C4F9@+7M])KP*$U;2K7`264/U>+9B.7_P"Y^1&Y]N>CG6AQ?%,<+4U)\(]+
M!>4]$)(R47ZXS(R-.FAQ#<^*K4#_`/H\59Q_;R22>7XO=_Z=:E>V\,>!;_U>
M4NW_`&D<;/)\;O/].I3-<7>-^'<3=FL=V.P'(,RR/$L8FWTZJF9U/I;&\8/(
M[F9?V,0I%#08W7E"3:V#[C22C=Z?%/N6KTC7_6>K;_7&H)=1Y2*WBOIFL#A"
MU[6'NV!C31[Y'5X6@$\5-FP!3MI#2MCHS!1:>QLL\ME"YY:9BUSQQN+W"K&,
M%.)Q(]&NW:2NA!BJR90O^:CYGD+B;32=E=G)<*TY%9-4(>EV1_!IU?M#1VC'
M=%N[2*OQ6I69645PGJJO>0;;32D39*5,G'9E[!\E>3DFN+@:AS[7,TI#)0-V
MAUT]IVL:=A$33LD>#4FL;"'<3HX'YP\VX]&0'`X)S7ZHE94NV%MLQPV/<-M9
M7#;&P[`*2/'#PM?38NKNXR2WL\@R&UL;V]NI\JTN+FWFR+&TM;*<\N1,GV,^
M6X]*F3)3[BEN..*4M:C,S,S,;^6]O;VD#+6U8R*VC:&L8T!K6M`H&M:*``#8
M`!0+1:XN)[J=]S=/=)<2.+G.<2YSG$U)<34DD[23M*\P>R\D!%_:$+=6AMM"
MG''%)0VVA)K6M:S)*4(2DC4I2E'H1%U,P)`%3L`7T`DT&TE9BYMON(U7)MW<
M"S1NI6XII%HYBUXBN4ZGO[FTS502C*<3X:M2)6I=I^X8MXR^*=+W#;JW,]*\
M/>,XJ>3BJJXXK*"+OS;3B"OQN[?P_#2BPL7!4"`B`B^1IUUAUM]AQQEYEQ#K
M+S2U-NM.MJ);;C;B#):'$+(C(R,C(RU(?'-#@6N`+2*$'I7T$M(<TD.!V%6Y
MO*'\SB=OU%A<9]_KLI.\-%5*5MWG%@\DI.Y]#51S7*IKUYU9'*SZCA->*3Y:
MKM83;CKO[98==DZ+\]N3L>F7NUAIB.F!D?\`AX6C9;O<=CV`;H7G9P[HWD-'
MH.:&;K<D^;4FHV-TGJ22N<C9^`E<=MPQHVM>>F9@VUWR,!)]-KB^?`:QK8]`
M1`14-?-@^D*Y+?&?&/D[PX=,.2/NLP_J9/;RKG/SE]YN6]='[&)1WB55&*`B
MN7^0M_(?MO\`3KGO_P`.X*-`/$S[QF?Y;#_+F6]?AR]W[_\`,9OY$*AI\WCS
M`YO)S=.;LOMI?+/8':NYD0T/ULEPH6Y><0#.)9Y7+4TX<>PH:62EV+2Z=[:V
MO$F$H_A+:6I_Y$\KH]'85NH<Q%_^SWL8-'#;;PNVMC%=K7O%'2[B#2.GH$N@
MKG9S+DU;F'8'$R?_`*W9R$5:=D\HV.D/0YC35L6\$5?\H`0S#8!02@(@(@(@
M(@(NU>!7,+*N&&_N.[B5LB9*P2Y?B8]NQBC*S./DF%29)%)?;CFE2#O<<4X<
MZN<+M63[9LFHF7WDKCSF;H*RY@Z8EQ4P:W)Q@OMI#OCF`V"OUDGQ)!NH>*G$
MUI&>\N=<7F@]2192(N=CI"&7$8W/B)VFGU[/CL.^HX:\+G`W[L?OZ;*J&DRC
M';&/;X_DE16W]%;0U&N)9TUQ"9L:RQBK,DFN/-A2$.(,R(S2HAS$NK6XLKJ2
MRNV&.ZAD<Q[3O:]A+7-/:"""ND5M<P7EM'>6K@^VE8U['#<YK@'-<.P@@A>N
M/!>Z`B`B`B`B`B`B`B`B`B`B^"3&CS&5QY3#4EAPM%M/-I<;5]U*R,M2]1^D
MAX7%M;W<)M[IC)(';VN`(/F*;EJ^[VKKIG>]3RW*UX]3*.\2I,,SUUT2HU%(
M9(]?3JX1>HA&V9Y8X^ZK+B976\I^0ZKX_,?C-^%PZ@O02'I6I+C;[+JTU&=6
MY.:+71ZL5\-)6GI[6$$4PONFT7]:,,IH35./))MC-$/E1'O*_P`$>G\+`O4/
M:5KJ8B1%<4U)9>CNI]+3[:VG$_=0XE*B/]`81<QSV[S%<,?'(.AP+3\!H5^_
M(O'==]/46][U]7F.N^GK]GNF*5[U]7T%*-1_:%,35?5DM5A6679I*LQ^TD(4
M9$3ZHJX\7KZ-9<GP8J?T5ET%_P`=I34F6(%A97#VGY7`6L^[?PL_C+\%[1O*
MVYCVP%O)4V]DEG'K&/94J'7Z39JB_7-K?428<=9>I2?'+[0DO"\F,G.1+G;A
MEO%LJR/TY.T%QHQI[1W@[%YNF'R5T%C."XQB2"_`]:VB2:32Y8R/VS8.D9:*
M(Y+A=S2%%Z4-DA!_V.HFG`:0P&FF?_%P-%Q2AE=Z4AZ_3.X'I:WA;V+Q<YSM
MZRX9,OR@(@(@(@(@(@(HHO.L^CUW6^,^UGRB8\)N\//O3LO4W/L'J&N?GNRO
M/76_MF*D$.BZY_("("*^5Y3_`-'KQI^+&4?*)F(YG\[O>GF/71^PB71?DS[L
ML3ZJ3V\JD0$5*3T!$!$!%AV<;AX#ME12,HW'S;$\"QN+TD7V8Y#4XU4-*TU)
MM5A<2X<7Q5?K4$KN4?0B,Q7XW%9/,7(LL3;SW5V[<R)CI'?<L!-.U4.0R>-Q
M-N;S*7$-M:C>^5[8V_=.('F5<KS#/.OQ^QQR_P!FN&]C/FR;J++ILHWS=A2Z
MEBO@/D4>;"VTA6#4>S=L931N,JN)#+"8R3-<)+BU-2V=LN5?AXNH;N+4&OV-
M:R,A\=G4.+G#:#<%I+0T&A[II=Q'9(0`YCM7.9W/RVEM9,%H5[G/D!;)=T+0
MT'81`'4<7':.]<!P[XP20]M8Q2C49J49J4HS4I2C,S49GJ9F9]3,S&XF[8-R
MU*W[3O7^`B`BM1^1UP/GX;6*YC[I4SD.^RBHE5&R%-8L&W+K,5M&U1[O<)QA
MYLGHTC*8AJA5BM4&JK7(=T6U,946EGB.YEQ9";]`<+('6T,@=>/:=CI&[605
M&PB,^G)O_"!C=CHW!;A^'SEU)81?ISF(RVYF86VC7#:V-VQ\U#M!D'HQ[OP9
M<=H>TJQN-35M&@(H[_-@^CUY+?%C%_E$PX2KR1]Z>']=)["51ASF]V66]5'[
M>)4-1TP7.A`1`17RO*?^CUXT_%C*/E$S$<S^=WO3S'KH_81+HOR9]V6)]5)[
M>52("*E)Z`BJ?^=]SPD9UF,CA[MC=*3A&!V+$G>:P@/*2C*,]@N)?A86XZWH
M3]/@[A)=EM&I2';@R2M"7("%*W=\.?+1F-L!KW,1_P#R-RPBT:X?S<)V&7L?
M-N:=XBV@D2D+33Q`<Q79&^.A\1)_\?;.!NG-/\Y,-HB[6Q;W#<9=A%8PJ\HV
MH6LB`B`BD>X=>5YR7YBQ(N6X]5P-N]IGWW6D[GYVF7$K+8HSJF9:<.I8S2[C
M+%,/MK:-YI+5<3S:VERT.H4@HFU]SETAH&1UC=/==YP`'YO#0N;7:.]>3P15
M%#0DR4(<&$$%2EH;E%JS7+&WMJQMKA22/G$U0UU-A[I@]*2AJ*BC*@@O!!"F
M\P'ZO=QUJX44]R]ZMX<SMFO#7)<Q%G#\!I)*T]AK;_!MG29[:-L+,E%[-@E>
MAEHHC+KKGD_%-JN:1WYGQUA;P'=WIEF>/X37PMK_``*=BV`QOAFTO#&/SM?W
MT\XW]V(H6'^"YDSJ?PZ]JRS)_J_W$2SBK_@SN)OSBUB378PZ]D.$W]9XFJC\
M:57R<#ASGU^T1:-S64Z%Z-=3%%9^*'7<+_\`G+3&315VTCF8[R!PF('G856W
M?AKT3*S_`)2ZR4,M-E7Q/;Y2TP@GS."B<Y7>21R0V$I['--J[6'R&PBL:>E6
M,?&:672;D54-DE..2G<&5+N$W<5EK0C.LFRY2C)2CBH;(U";]$^(K26IKAF/
MS3'8K(O(#3(\/@<3T":C.`G_`'C&MW#C)V*&=9<@-4Z<@??X=[<GCV`EPC86
M3M`Z>YJ[C`_W;W.Z>`!0NJ2:3-*B-*DF:5)41D:3(]#(R/J1D8V#W[1N4#;M
MAWK_``$0$4J7E3\ZY_$+?")C.7VCQ;$;LV5?29[$>>UAXI<O*3"H]Q8K:U$B
M.=0XXEFS-)D;U8I:C2XY'CI*%>=G+6+7>G'7E@P?I+8L<^$@;9&#:^`]?%OC
MKNDH-@>XJ8>3G,231.H&VE\\_H[>O:R8$[(W'8R<=7#NDZXZG:6M5X9"T.H0
MXVM+C;B4K;<0HEH6A9$I"T+29I4E23U(RZ&0YRD$&AV$+H(""*C:"OZ'Q?5R
MGS>Y`EQ@XL[Q;S1U-%>XWC"J_#FW22M+N;9/+C8SB2U,*;>*4Q"O+9F4^WVZ
M*C,.:FE)&HLVY<Z7_3+6EAI]U?FTTW%+3^AC!DEV[*$L:6@_7$;]RPWF!J7]
M$='WV=;3YQ%#2+ULA$<>S;4![@XCZT'=O7Y[MC83[>PG6UK-E6-G9S)-A8V$
MY]R5-GSYKZY,R;,DO*6](E2I#JEN.+,U+6HS,S,QU,BBB@B;!"UK(6-#6M`H
M&M`H``-@`&P`;@N9TLLD\KIIG%TSW%SG$U))-223M))VD]*^F/VOP@(I,?+/
M\ORWYP[H3GLBDS\>V/VZ=KIFXN0PB2W8W,J6X;M=@F-/.$I#5S<QV'')$KM6
MBOB(-Q1&ZY';=B#F_P`T8.7&&:VT#9=1W8<((S\5@'QII!]8PD!K=A>XT'HA
MY;+'*?EI/S!R[G71=%I^U+3.\?&<3\6&,_7.`)+MH8T5.TM#KM.V&U.W&RV&
MU6WNU.&4.!X;3-DF!0X]!1#BDZ;;;3LV8[[<JSM9:64G(F2G'I4A9=SKBU=1
MSMS.;RVH<@_*YNXEN<A(?2>\U/8!T-:*^BUH#6C8T`+?O$8;%X&P9C,-!';6
M,8V,8*#RGI<XT])SB7..TDE;`%K5S0$7.G)CBOLQRTV\F[=[Q8K%N(JFI"\>
MR2*VQ&RW"[5YM*476)WBF79%;,0MM!N-F2XLM"";D-.M&:#RO1^M=0:'RK<K
M@)W1OJ..,U,4K1\B5E0'#?0['-)JQS3M6+ZLT?@=:8QV+SD(D90\#Q021./R
MHWT):=U1M:X;'`C8J(W+?C!G'$'?+*ME<Y6F>]4^!:XQDL>,N)`S+#;1;_X"
MR>!'6Z^<=,LH[C,AGQ'?@LZ.^QWK-HUGTKT+K+&Z\TW!J'&^BU]6R1DU=%*V
MG'&XT%:5!::#B8YKJ"M%SLUKI'(:(U#-@<CZ3F4='(!02Q.KP2`;:5H0X5/"
M]KFU-*KFD9>L40$4AOEB<JY_%/E=@M[-LE1=M]Q)\';?=*(ZZ2(!8YD4]B-`
MR203G<VT[A=XXQ8FZE)O?!&I+"#(I"]8KYQZ)BUMHBYMHV5R]HTW%L:>EWD8
M)=&.L2LK'3=Q%CC\4*3>4FL9-&ZRM[F1],5=.$%P.C@>0`\^J?1]=_"'-'QB
MKYHYG+HR@(N-.>'+B@X8\><GW7G-Q+++9CB<5VRQJ4MPF\ASNUC2G*UN2EG[
M[^"*:+%>L)QDIONC15-)6EUUK7/^6FA;KF#JJ'"1%S+%H[RXD'R(6D<5*_*>
M2&,W^DX.(+6E8+S%UK;:$TS-F9`U]ZX]W!&?ES.!X:T^2T`O?N]%I`(<0J#&
M;9IE.XV7Y)GF;74W(\NR^YL,@R*\L7/%F6=M9R%RIDEU1$E""4ZX9(0@DMMH
M(D(2E*2(NG6.Q]EB;"'&8Z-L5C!&UD;&[`UK10`?ZR=I.TU*YO9"_O,I>RY'
M(2.EO9Y'/>]V]SG&I/[P&P#8-BQ<5BI$!%.UY=_DVY+R'IZ3>CD;*O-O=H+1
M$:SQ/#ZY*(6<[CU3S;4F+<N2I*'DXGA]BVX1L/*:7.GLZK92PRMB4YK7S5Y_
M6FE;B33VDVQW6>82V65VV&!PV%E!3O96](J&,.QQ<X.8-B>6'(NZU/!'GM4F
M2VPCP'1Q-V2SM.T.J:]W$[H-"]XVM#6EKS:$V8XM<>./59%K-FMGL%P4XK!1
MSN*RCBOY5-;Z:JM\PL4S<IN75:%JN7,>5H1%KH1$--=0:TU7JJ9TV?O[FYXC
M7@<\B,?:Q-I&P=C6A;<X'2&F-,Q-BP5C;V_"*<36`R'[:5U9'>5SBM^#&%DB
MYDWWX:\9.2E;.@[P;.89DMA-:<0C+8]4Q29W`<<[3*179K2I@Y)'4AU"%FV<
ME4=XT$3K;B-4GF.FM?ZQTC,V3`W]Q#$T_P`T7%\+NQT+ZQGI%>'B%?1(.U8E
MJ+0NDM51.CSEC!+(X?S@:&3#M;*VCQT&G%0T]($;%5/\Q+RD\[XC1;#=?:JP
MM]SM@4R-;*9+C,+S3;-$AU#41O,6Z]MB+<4;SKA(1<18\=I#ADW(88,VEO[K
M\J>>6-UT]N$S;8[/5%/1`)[JXH*GNN*I:\#:8G.<2-K'.](-TYYG\ELCHICL
MSAG/N]-5](D#O8*F@[WAH',.X2M:T`['-;L+H<!/J@Q`1>]BV49#A&2T.8XE
M;S:#*,7MZ^^Q^[K738GU5Q52FIM?/BND1DEZ-)92HM2-)Z:&1D9D*:]LK7(V
MDMA?1MELYHW,>QPJUS7"CFGL(-%46=Y<X^[COK)[H[N%[7L>TT+7--6D=H(5
M_'@7ROJ>8_&[#MV62B1,NCDK$MSJ2(>C5+N%1Q89W28[)FI3%;=,2V+.$@U+
M4W$FMMJ6I:%F.8?,S1$^@=6W&#=Q.L3^%MWG>^!Y/!4]+F$&-YV5<PD``A=)
M.7.LH=<Z5@S3>%MZ/P<[!N;,P#CH.AK@1(T;:->`22"NRQ'ZSI`14-?-@^D*
MY+?&?&/D[PX=,.2/NLP_J9/;RKG/SE]YN6]='[&)1WB55&*`BG$V@Y<O<:?*
M`R+$,2MCKMU-^=^-SL$QAV*Z3=A2XFWBN`*W"RF.9:.,N1:B:U6L.MJ0\Q,M
M6GVSU9/37+/:%;J_GQ%?WS./"XS&6\T@(]%\O>3]Q&>NK@9"#4%L;FGXRV"P
M>M7:4Y(2V5D_AS&1R,\,=/C-C[N'OI!Y&D,!%"'2-</BJ#L;&K7U=`\?N+6_
M?*/)5XOL=MO>YM*BJ:*WM6$,UV+X\V[U0]D.56KL*@I^]LE*;:>D)?D$@R9;
M<47:,7U1K33&C+/Y[J.[BMV.KPM-72/IT,C:"]W:0WA;7TB!M62Z:T?J35]W
M\ST]:R7#Q\9PHV-E>E\CB&-[`34_)!.Q3%X+]7LWXMJUN5N'OIM?A5@ZT3A5
M6.4V2YTJ.I78:6)DV46&1DOH(U$OP?A#9*3HE:R/N*`\EXI],P3%F*QM[<1`
M_&D?'#7M`'>FG57A/6!N4Y8[PS:CFB#\GD;.WE(^*QLDU.PD]T*]=*CJ)WK!
M=Y/(0Y1X)33+S:[-MO=Z4P6E.KQV(J=@V834I0:U%5P;]4K&I2DDD_8<MV'%
M'H2$K4>A7+`>)O1F2N&VV9M[K'EQIWAI-$/MBRD@\HB(ZR%;L[X<-7XZ!UQB
M+BVOPT5X!6*4_:A]8SY#(#U`J$_+<1RG`LENL-S;'KC%,KQR>]67N.Y!7R:J
MXJ9[&GB19T"8VU(CND2B47<DB4E1*+5)D9[$6-]99.SCR&.ECGL96AS)&.#F
M.:>EKA4']_8H#O;*\QMW)8W\4D-[$XM>Q[2US2.@@T(_T*QT52I4!$!%=;\D
MC?*5NWPJJ,2N9JI=_L;EEQMHI3ZR5*=Q8V(>38<^HD^RF'"K;Q=5'+0E>'5Z
M&1Z=RN>7B*TXS!\PY+ZW;PVN2@9<;-PDJ8Y1Y2Y@D=VR>8;[\@-0OS6@F64[
MN*YQ\SH-N_NZ"2(^0->8QV1^<R_B!U-Z`B`B`B`B`B`B`B`B`B`B`B`B`B^%
MZ.Q)1X<AAE]']@\VAU'_`.%:5$/*6&&=O!.QKV=3@"/@*+PG\.Q.3KXV,T*S
M5IJO\$P4N'IZ/OB6$N?IBS2Z6TU/7O<?9$GI[F.OPAM?JK]<3NLKZR,#PI"N
MXL5H%'UZ.5<-U/7^T=:6DS_0'BW1VE&'B&.LB>V%A'P$$)QNZRO9ATE-7F1U
M]160321$DX<"+&-)%VZ$7@M(T(NTOZA"Z6N)Q5E0V5M;PD?61L9_)`Z@OA).
M\KTQ<%\0$0$0$0$0$0$0$0$0$447G6?1Z[K?&?:SY1,>$W>'GWIV7J;GV#U#
M7/SW97GKK?VS%2"'1=<_D!$!%MO'M_M]\1IH..8IO7NWC&/5;;C5;18]N/F-
M+35S3KSLEUN#5UMS&A1&W)#RW%$VA)&M:E'U,S%CNM,::OKAUW>XZQFNGFKG
MO@B>]U!05<YA)V`#:=PHKU;:DU%90-M;._O8;9@]%C)Y6M;4UV-:X`;23L&\
MKV?SH>3'SB=]/RMY_P#C`*?]#=(?16-_)8/O%[_I=JSZ4R/Y3-]^GYT/)CYQ
M.^GY6\__`!@#]#=(?16-_)8/O$_2[5GTID?RF;[]/SH>3'SB=]/RMY_^,`?H
M;I#Z*QOY+!]XGZ7:L^E,C^4S??K_`!7*#DLI)I5R'WS4E1&E25;M9\:5),M#
M(R/(-#(R#]#=(#:,5C:_V:'[Q/TNU6=AR>1_*9OOUJ:]R/(<HG'9Y-?7.162
MFT-'87MI.MYQM-I)+;9R[!^0^;;:2(DEW:$7H%\MK2ULH^YLXHXH:UX6-#17
MR-`"LMQ=75Y)WUW))++3XSW%Q^%Q)7BBH7@@(O8Q_'<@RRZK<;Q6CN,FR*YE
M(A5%!C]9-N;JUFNZ^'$K:NN8DSITIS0^UMIM2STZ$/"ZNK6QMWW=[)'#:1MJ
MY[W!C&@=+G.(`':2`O>VM;F]N&6EG')+=2&C6,:7/<>IK6@DGL`JK(WEW^2G
M=(N,>WHYE5,6%`KGV+?&MA'UQY\FSD-'XL&9NB['<>@QZYI9(>*D;6ZY(/1N
M>;:">ANZD<U?$-;FWET]H![G2O!;)>BK0T'81;UH2[>.^(`;OBJ>&0;4<L>0
MDXGBSVNF!L;2'1V9H2X]!N*5`;N/=`DG=)0<3#9X:::8:;88;;999;0TRRTA
M+;333:20VVVV@B0AM""(B(B(B(M"&G+G%Q+G$EQ-23TK;8`-`:T`-`V!?(/B
M^H"*._S8/H]>2WQ8Q?Y1,.$J\D?>GA_72>PE48<YO=EEO51^WB5#4=,%SH0$
M0$5\KRG_`*/7C3\6,H^43,1S/YW>]/,>NC]A$NB_)GW98GU4GMY5(@(J4GKD
M/G9R5C<3N+NZ&\+;K)91!J#Q[;N*\VR^F;N'DW=5XL:XKY&S,B5$MU5E+95I
MXD*$\1==!G?+72#];ZSLL"0?F3I..<BHI!'Z4FT;07`=VT]#WM6$\Q-5LT9I
M"\S@(^=M9P0@T-9I/1CV'80TGC<.EC'+\_"TM+&[L[&ZN)TJSMK>=+M+2RFO
M+DS;"QGR')<V=+D.FIQ^5+DNJ<<6HS4I:C,^ICJ-##%;0LMX&M9!&T-:T"@:
MUHH`!T``4`ZES3FFEN)G3SN+YGN+G.)J7.)J23TDDU)ZU]`>B\T!%+?Y2W`:
M+S`W;L,UW)KGG]AMI)%?)RB*:G8[>=99*/X52X&W(0;:SK?@S*I=NIE?BM1?
M!9^]JF-NH@SGCS.?H/!LQV(>!J:^#A&=A[F(;'S4^NJ>&($4+N)VWNRTS5R7
MY;LUOFG7^583IRR(,@VCOI#M9#7ZV@XI*&H;PMV=X"+K]=75]17P:FI@PZNJ
MJX<6NK*RNBL0J^NKX3"(T*#!A1D-1HD.)&:2VTTVE*&T))*2(B(ASQEEEGE=
M/.YSYWN+G.<27.<34N<3M))VDG:3M*WXBBB@B;#"UK(6-#6M:`&M:!0``;``
M-@`V`+[@\UZ("("*KCYVGE\4>)1G^8VS6/QZFKGV[$3??&ZEGP(,>VO9K<6I
MW,A0T$4>(5Q<240K=+1))R;)CR20:WI;HW-\.W-*YOGC0.H)2^9L9-G(XU<6
ML%76Y.\\#07Q5W,:YE:-C:M0N?W+.WLF'7."B#(7/`NV-%`'/-&S@;AQ.(;)
M3>YS7TJ7E5LQMPM5D!$!%=S\F[E+(Y%<3*K%\EG_``S<+8.5"VSR!QYXG9UG
MBS,!+VW>0R2,UN_MFB8<K%..*4Y(E5#[RCU6.=?/[1;=*:X?>V;>'%9-IN&4
M%`V0NI.P=&QY$@`V-;*UHW+?[D7K!VJ-%LL[MW%D\:1`^IVNC`K`\^5@,9)V
MN=&YQWJ6<0<IH4"WU@C+Y55Q<VHPZ,^XRC+M[(<^P2V2B*77XMAV4.?!'E$?
M9X/X3N(KW:9:FMA)D9=ID>S/A<L&3ZSOK]X!,&.+6]CI)8]H[>%CAY">M:Y>
M):]?#I"RL6$@3Y`%W:(XI-A[.)S3Y0.I5#AO8M)D!$!%?$\J39ZLV=X*;%QH
MD9MNUW%QQO=[(YI,FR]9V&XI(O:IY\E)2I9P,2=K82%>A;<5*BU(]3YH\[<]
M-G^962>\DP6DWS6,5J&M@]!P'VTHD>>HN(71;DW@XL'R[QS&`":ZB^<O-*%S
MI_3:3Y(RQHZPT%2+"*%*"`B`B`BKG_6&=KJV7MAL%O4U$:;N*#/+C:Z=.03*
M7IE;EV/6&654249_?WVJV5A,Q;&GL-'+>UZN%KMAX5\U,S,Y33SG$P2VS;D-
MVT#HGMB<1T`N$S`[I/"WJ6KOB;Q$3\1C<^&@3QW+K<G94MD8Z1H/2>$Q.(Z!
MQ.ZU55&ZJT[0$0$7Z+_%?.)6Y?&7CWN!82#DVF9;*[8Y%</*6IQ:KNTPRFE7
M25NK:9-UQNU<>2I?:DE&1F1:&0Y0:UQS,/K#*XN(<,-OD;B-@^P;*\,V;:>C
M3978NH>CL@_+:3QF3E-9I["![C]FZ)I?U5]*NU;[&,K(U2>\YWE,_O\`<K[;
M;VDGF]MWQY.QV\I66G35&G9M\(8/<F]4CJE,DKR$W4D9&:%,5#;B=#<5KT/\
M/NBVZ8T0S*W#:97*\,[R=XAH?F[/)P$R]=92#N"T&Y[ZP=J363\9;NKB\9Q0
MM'09:COW^7C`CZJ1@C>5$,)V4)("*6KRA.%%;RPW_DY3N#4MVFS6R3=5DF6U
MLI*50LLRBP>E'AF&RFG"-,JJE/UDB;8M]JVW(D/X,X1%*2H0=SWYAS:(TN++
M%O+-09$NCB<-\4;0.]E!Z'`.:R,["'/XQ\0J:.26@8M9ZE-YDV!^"Q_"^1IW
M22.)[J(CI:2USWC:"UO"?CA7;&FFF&FV&&VV666T-,LM(2VTTTVDD-MMMH(D
M(;0@B(B(B(B+0ASL<XN)<XDN)J2>E;^@!H#6@!H&P+Y!\7U`1`1>?;5-7?55
MG1W=="MZ6YKYE3;U-E%9FUUI5V,9R'/KK"%)0Y'EPIL1Y;3K3B5(<;4:5$9&
M9#U@GFMIF7-L]T=Q&X.:YI(<US35KFD;000""-H.T+RFAAN87V]PUKX)&EKF
MN`+7-<*%K@=A!!((.PC8J)WF><,RX:\D++'\:CRO\TNXD5_-]K)+YK=*OK)$
MM;5WACLI9&;\K#;17@H-2ENJKGH;KJC<=4.E')SF!^G^DF75X6_GRT<(;D#9
MQ.`JR6G0)6[3N`D$C6BC0N=_-O0GZ"ZI?;6@/YEN@9;<GH:31\5>DQ.V#>2P
ML)-25',)847("*;'R-N2\G:7E&_LM=6)M8/R"JETK,=]WMBP=Q\:CS+;$+!!
MK[DMN6T'X?5&A!)5)D3(O<HR920UX\1^D&9S1@U#;LKD<6_C)&\P2$-E;V\)
MX)*GXK6/I\8J??#WJQ^%U><#.ZF/R;.$`[A/&"Z)W\(<<=!\9SF5^*%<I&@*
MWI0$5#7S8/I"N2WQGQCY.\.'3#DC[K,/ZF3V\JYS\Y?>;EO71^QB4=XE51B@
M(O0DVME+@UU9)FR'JZH*659!6XHXL(Y[_P`)FN,,%HVAZ6\23<7IWK)"$F9I
M0@D^3((8Y'S,:!+)3B/2>$4%3U`;AN%3UE>CII7QMB>XF)E>$=`J:F@ZR=YW
MF@Z@I#?+AX`9/SCW1D,V#]AC.RF!O0)>YF9Q4-E,?.4I;L'"L65(2MEW)KUE
MAPU/&AUFMBI-]Y*EJCL2(KYL\T+/EQA@Z(-FU%<APMXCN%-AEDIM$;"1LJ#(
M[T6D`/<R3N5O+6[YA9<ME+HL!;$&>4;S7=%'79WCP#MH1&WTG`DM:Z[OM/M'
MMML;@E'MIM-A]/@^$X\P3-;24S!MMFX:4%(L+"6\MZ?<7$]2"7*FRW7I<IW5
M;KBUF9CG3G,[E]29*3,9R>2YR,IJY[S\#6@4:UC=S6-`:T;&@!=`,-A,5I['
M1XG"P1V^/B%&L:/A<XFI<X[W/<2YQVN)*V,+2KH@(HE_-;X"8]RNV:N]Q<+H
M([/(7:ZCF76*VE?%)-GGF/5+#\ZSVXM393W6;DU@G':<W"4Y&LB2VA;3,F3W
M3CR2YGW6B=01XG(2DZ5O9`R1KCZ,+W$!L[:_%H:"6FQT=207,92%^<G+:VUE
M@I,I81@:FLXRZ-S1Z4S&@ET#J?&J*F*NUKZ`$->^M(T=%%H"@(@(K&?U=_-W
M8>YG)#;=3ZC8R'!<+S=F,IS5"'<.R"RH9+[+1Z]BG49TTEQ2=.XD()6O:G34
M_P`5>.;)A\1EP/2BN982>R5C7@'R=R:>4TWE;1>&+(.9ELKBB?1EMXI0.V)[
MF$CR]\*^05W!6IQI4MQ$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!%%%YUGT>NZWQGVL^43'A-WAY]Z=EZFY]@]0US\]V5YZZW]L
MQ4@AT77/Y`1`1`1`1`1`1`1`1`19)B5Q2T-_7VF0XE69Q3QG>Z;C-O99!40K
M)KUM+L<8M::XBJ]Q3;Y:>LC%)?6]Q<VKH;6=]M<$;)&M8XM/VLC7L/G"JK*>
MWMKELUU`RX@!VQN<]H</MHW-</,58GX0>:_P0V7;C8[/XB1>-DN6TS73=PMN
M$,[G*FL&IKO=RB]NHT#=,ZMKM-1,$]>N)46I$9K49:I<QN2/,O4)-W%G79=C
M27"">MO0[=D;&%UMQ'KI"/@6S_+_`)R\NL"!:R808I[@&F:"D]1UR/>!<</9
M68_"K'>T.^&T6_F*MYKLWN'B^XF-+<)AZPQNR:EN5TI2?$*!=5R_"M*&R\/1
M9QIK+$@D&2C1H9&>IF=TYG=,7IQV?M9K2\I4-D:1Q#ZYCMK7MZ.)A<VNRJVE
MPFH,)J2S%_@KJ&ZM*T+F.KPGJ<WXS'?8N`=3;1;4%E5X0$0$4=_FP?1Z\EOB
MQB_RB8<)5Y(^]/#^ND]A*HPYS>[++>JC]O$J&HZ8+G0@(@(KY7E/_1Z\:?BQ
ME'RB9B.9_.[WIYCUT?L(ET7Y,^[+$^JD]O*I$!%2D]5:_K">]SDW+MC>.M=,
M_:=#266[V516UI<:=M+Z5.Q/#D2"29^!,JJZHMU]AZ*-FR0HR[5),]S_``L:
M<$=CDM5RM_"2R-M8STAK`)9:=8<YT0KUQD;P5J#XF=0&2]Q^EXG?@XXW7,@Z
M"YY,<5>HM:V0TZG@]2K<C;9:KH"("+]`WR_>.T;C!Q+VBVQ<A%#RAS'H^8;A
MJ4WV27\_S!EFYR)F4KM0;QT;C[=6RLTI4<6`UJ1&1CEUS1U6_66N+_,!W%9B
M4Q0=0@B)9&1U<=#(1]<]RZ5\M=,,TCHNRQ!;PWAB$LW69I0'/!Z^"HC!^M8U
M=FB/UG:`B`B`BPC<K;[&MV-O<VVRS*&4_%L^Q>[Q*^C=K9N*K;VO?KY#L93K
M;J6)L9+_`(K#O::F7D)6G122,7'$92\P>5M\QCW<-[:S,E8?LF.#@#3>#2CA
MT@D'85;\KC+3,XRXQ-\WBL[F%\;Q]B]I::=1%:@]!`/0OSF=T]O;O:7<O<#:
M[)$]M_MWF>2X5;J)M33;T_&KB942)+"%*69Q9:XGBM*)2DJ;6E1&9&1GUAPN
M5M\YA[7,VG_2W=O'*WIH)&AP![16AZB"N768QEQA<M<XBZ_ZFUGDB=T5,;BT
MD=AI4=A6!"YJW("*:#R+][']N.92=MI4HVZ#?;"[S%W8ZWC:BIRG$XDG-<9L
M'"]XY)1#JK*`RD]-5V1D7M&1'K[XDM.MRV@/SNP5NL9<,D!I4]W*1#(WR5=&
M\]D:GCP\Y]V*UU^:GG_ELC`^.E=G>1@RQN\M&O8.UZN=#GXM[E`1]80QF3.X
MT[,Y8RAYQC'=[$T\OPR[FV49-A&3R&I$@B0I2&R?QQ+9+-24$MTDGJI:1L]X
M6KQD>K\A8N(#I<=Q#M[N:,$#S25IOH*]!6MWB8M'R:4L+UM2V+(<)[.\BD-3
MYV4KUFG2%4<&\ZTJ0$0$7Z#GE_9/6Y=PAXI6M4ZV[%B;#[;8PZMMU+R2LL)Q
MF!AERT:TD1$XS;T#Z%I]*%)-)ZF6HY;<T+.:QYC9N"<$/=D[B0;*>C-(Z5A\
M[7@@](VKI?RUNXKWE_AIH2"QN.@CZ_2BC$3O@<P@]6Y=?#`UFZ`B`B`B@`^L
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M2%F[(ES);RY$J2^XK53CS[[BEJ4?4U&9CJ]%%'#&V&(!L3&AK0-P`%`!V`;%
MR]DDDFD=-*2Z5SB23O))J2>TE?4'[7X0$5XOR;MF(>TG!7;:U7#3'R+>"9=[
MK9$^:$>*^W=S55>)I2]VDZJ*G"J:O=2A1FE#S[II]\9GSCY_:@DSO,F\@#JV
ME@UEM&.K@'%+LW5[Y[Q7I`;7<N@O(O`LPO+RTF+:75\Y]P\]?&>&/;OIW36&
MG02:;U*>(64PH"("("("*$OSXMHX>;<.:[<U$1M5ULKN+CMJFQ\%+C[&,9R^
MWA%U7$Z>BF(]A?V-,\LRU)2X;9&7H,MB/#1G9,=KY^'+C\WR-I(WAKL,D([Y
MCJ=):QLH'8XJ`?$7A(\AH9N6#1\XL+ICN*FT1S'NGM[`Y[HB>UH5-D;^K1=`
M199@>97>W.<8=N#C4E4/(L&RG'\OH92%*0J/<8W:Q+BM>):?:3X<R&@^@HLG
MC[?+8VXQ=X.*TN87Q/'6R1I8X?`2JS'7]QB\A!D[0\-U;S,E8>IS'!S3\("_
M2"P+,:G<3!L+W`H5^)1YSB>.YC2N=R5^)4Y-3P[JN7WI(DK[H<U!ZET,<E<G
M83XK)7&+N=ES;3R1/^VC<6.^J"NIN-OH<GCX,E;;;>XA9*W[61H>WZA"RP4*
MK50U\V#Z0KDM\9\8^3O#ATPY(^ZS#^ID]O*N<_.7WFY;UT?L8E'>)548H"+[
M<"!,M)T*LKHSTVPL9<:!!AQT&[(ES);R(\6,PVG53CS[[B4)274U&1#\2RQP
MQNFE(;$QI<XG<`!4D]@&U?N..2:1L,0+I7.``&\DF@`[25^A)PIXU47$WC=M
MQL[5Q8S=U6U$>ZW`LF#0M5]N-=Q8TG+K9Q])J\=E,])1(AFI1MP(L=K4R;(Q
MRSYAZON=<:MN\_,XFW?(60-/R(&$B)M.@\/I.ZWN<>E=,M`Z4M]&:5M<'"`)
MV,#IG#Y<[P#(ZO2*^BWJ8UHZ%U6,)68H"("("+\]3G1MC!V<Y@\BMNZJ*U!I
M:/=/)9=!`8)*6:_'<CE%E&/5[*4:)2U!I;IAI)>HD#J?RVS,N?T'B<K.XNN)
M+*,/<=[I(QW;W'[9["?.N9?,/$1X+7&4Q<(#;>.\D+`-S6//>,:/(UP'F7*`
MS98:@(IMO(-FR(G-K)6&%DEJSV`SJ%,(T)4;D=O,-N;)*$FHC-LREU[2M2T/
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M/'0YA!Z*T)"O6`U%FM,9!N4P5Q);WC>EIV.'UKVFK7M/2UP(Z:5HKEOEO^9G
MA?-FA7A>4Q(>$<@\7ITV&1XLPLTT.7UT=PHTK*L$<D/O2U165K:5-KWC.1!4
M\GM7(9U>+0'FUR?R'+NY_.%DYUSI::3ACD/QXG':(YJ`"IV\#QZ+Z&H:[T5O
M7RLYLV&O[;YA>-;;ZFACXGQCXDK1L,D-230;.-AVLKL+F^DI41"JF%`11W^;
M!]'KR6^+&+_*)APE7DC[T\/ZZ3V$JC#G-[LLMZJ/V\2H:CI@N="`B`BOE>4_
M]'KQI^+&4?*)F(YG\[O>GF/71^PB71?DS[LL3ZJ3V\JD0$5*3U0[\V+/W]P^
M?O(6<J0X]"QC(:?`*QA1&2(3&#XS38]81V25JHFW;^',D'U,C<?49:$9$72[
MDABVXKEABHP`))HGSN/69I'O:3Y&%C?(`N=/.;).R?,G)R$DQPRMA:.H11M8
MX#^&''RDJ.D2NHO0$74/"?;5G=[EQQTV\F1CFU=_NWAJ[Z(39N')QJFMF+_)
MV="2LDDYC]7)(U&1I07M*(R(QAO,3+NP6A<ME8SPS16,O`>J1[2R,_=N;Y=R
MR[0.*;F]:XO&/'%#+>Q<8ZXVN#Y!]PUWDWK]#D<K%TX0$0$0$0$0$5(#SI=O
M&<#Y][DSXD=,6%N/C>";AQV6^SP_&FX]'QJXD))*E+)4[(,6ER'.[0S==49%
MVFD=&?#WE79/EA:1//%):330$]@>9&CS,D:T=@'35<_>?.,;CN9-W(P4CNHH
M9@.TL$;CYWQN)[2>A12";%#:`BWUQ8SQ[:_DML%N"T^<=&([P;>7,U9::.54
M7*JO\,Q7-33]YFU*GF5Z&D^QP]#(]#+&=:8QN9TAE,6X5,]A.P?;&-W`?*'4
M([0LCT?D78C5>-R8-!!?0N/VHD;Q#R%M0>PK]&`<H%U#7%7F&\?)/)OB%O'M
M?3P3GY@="C+<"CMEK*?S3"Y+614]9#U4EM,G(TP7:KN7[*43E'TT)12'RKU2
MS1VN[#,W#N&P[WNICT"*4&-[CV1U$FSI8%@7,W3+]6Z(OL1`WBON[[R$=)EB
M/&UH[7T,>WH>5^?ZM"VEK;<0IMQM2D.-K2:%H6@S2I"TJ(E)4E1:&1]2,=0@
M014;05S7((-#L(7\`OB`BLQ^1=SBH::#*X:;EW+%6]-NY^0[&V=C(0Q#FS+E
M:I>2;<I<<\-J//E69+LJQ!F:IDB5+9(_$^#MN:@>)+EQ<W$C>8&(C+VMC:R\
M:T5(#-D<_:T-I'(?DM:QV[C(VP\//,&V@C.A,M(&.=(7VCG&@)=M?!V$NK)&
M/E%SV[^$&SN-.5ML@(@(OC==:8:<??<;999;6Z\\ZM+;333:36XXXXLR0AM"
M",S,S(B(M3'UK2XAK02XF@`Z5\)#07.(#0-I5'[S=.8E-RPY+?`L"M&[?:39
MJME83A-G',SA9'<2I3<K-LOA*/7OA6MG%9AQ7$&;<F#6L/I(O%,AT9Y%:"N-
M$:0[S)L,><R#Q-,T[XV`4AB/:UI+W`[6OD<T_%7/SG9KB#6>J^[QK^/"V##%
M$X;GN)K+(.QS@&M(V.9&UP^,HJA-:AU`1=)\0M@K7DYR0VFV7K8LA^'EF5P3
MRJ1'[T_@K!ZE1VV9VRWTJ03!P\<A2#:,UH\20;;:3[UI(\1UWJ>#1VDK[4,S
M@)((#W8/RIG>C$VG360MKL-&U)V`K*M$:;FU;JJRP,0)CFF'>$?)B;Z4KJ]%
M&!U-HJZ@&TA?HA,,,QF68T9EJ/'CM-L,,,-H:989:03;3++39)0VTVA))2E)
M$22+0ARJ<YSW%[R2\FI)VDD[R3UKIVUK6-#&`!H%`!L``Z`H:O/9W"<P_@XY
MB\=Y27=U-U\%PZ2RVXE*UUE0BXW#D.N(-:5+BMS\*BH5H2M%NHU+0]2G_P`-
M>*%_S'%ZX>C96,TH/V3N"`#R\,SCY`5!7B(R9L>7QLVG;>7L,1'V+>*8GR5B
M:/*0J7XZ"+0]`1`16G-G_/7XR;6[2;7;8M[-;W/M[<[=83@B'H[6!_!WD8AC
M-9CZ76/$RUE?@N)K]4]R$GVF6I%Z!I=GO#7K#-9R]S!R&.!N[N::A[ZH[V1S
MZ'\$=OI;=I6X&#\1&D\/A;/$BPR!%K:Q0U'<T/=QM9L_"#9Z/4MB_P!(3XS_
M`/@KOI_R6`?CB+3^RSJ_Z1QO_'_JE=/VF=)_^0R/_!_K4_I"?&?_`,%=]/\`
MDL`_'$/V6=7_`$CC?^/_`%2?M,Z3_P#(9'_@_P!:G](3XS_^"N^G_)8!^.(?
MLLZO^D<;_P`?^J3]IG2?_D,C_P`'^M3^D)\9_P#P5WT_Y+`/QQ#]EG5_TCC?
M^/\`U2?M,Z3_`/(9'_@_UJ?TA/C/_P""N^G_`"6`?CB'[+.K_I'&_P#'_JD_
M:9TG_P"0R/\`P?ZU<P<S_.:X_P#)OC%NUL7C^U>[M%=Y_35<.JMKZ/A3E/"G
M5&34F1QW)Z864RY:65.4Y)[FVEK0I1*(C,AF7+[P_:HT=K&QU)=7MA+;6LCB
MYK#-Q$.C?&>&L8%?2Z2`=RQ'7?/;36K=)7NGK:SO8[BYC:&N>(N$%LC'BM)"
M:>CT`D;U6]&VJU90$0$5\KRHLZ>W`\O[CE:2WO%F4>,76"OIT7JPS@&79!A]
M0R9J,R5_S#3Q%EVF9=JB+H9&DN9_.W&MQ?-#+0L%(Y)F3#M,\3)7'[M[AYO.
MNC')K(NR?+7%S/-9(X70GL$,CXFC[AK?]-BD0$5*3E0U\V#Z0KDM\9\8^3O#
MATPY(^ZS#^ID]O*N<_.7WFY;UT?L8E'>)548H"+OGROMLXVZ_/+CCC<]A$BM
MJ<T>S^>AY/?'-&VE':Y]#;DM]BTN,R[3'8[!H41H6;I)5[)F91CSES#\)RSR
MUW$2)GVX@;3?_P`P]L)IVALCG5WBE1M4C\HL2S,\QL7:R`&)EP9C7=^`8Z85
M["Y@%-QKMV*_".9"Z/H"("("("*BSYQ:$-^8[R,2VA*$FK:59I0DDD:W=B]L
MG'%F22(C4XXLU*/TFHS,^ICI+R#)/*7$D[3_`,S_`(RX7/+GD`.:64I__P`W
M^$@498F!1,@(IB/(Q==;YYTB&W'$(?VNW':?2A:DI>:*%7ODVZE)D3C9/,H6
M1'J7<@C])$($\2+0>6<A(!(O8".S:X;/,2/.IQ\/1(YC1@$T-G/7MV-/[H!5
MU(<]5OJ@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(HHO.L^CUW6^,^UGRB8\)N\//O3LO4W/L'J&N?GNRO/76_MF*D$.BZY_("("
M*]9Y56*XO/\`+]XVS)V-T,V6_C63J>E2Z>ODR'E)W"R]"3=?>CK=<,D)(BU,
M^A$0YL\Z[V]BYHY>.*:5K!-'0![@!^`BW`%=#N3EG9R\M<4^2*-SS%)4EK23
M^&EZ2%(/_`G#/^R.,?\`0%5_B@BS\XY#^GF^[=^^I-_-]A_00_<-_>3^!.&?
M]D<8_P"@*K_%`_..0_IYONW?OI^;[#^@A^X;^\G\"<,_[(XQ_P!`57^*!^<<
MA_3S?=N_?3\WV']!#]PW]Y/X$X9_V1QC_H"J_P`4#\XY#^GF^[=^^GYOL/Z"
M'[AO[RQ/+-C=E,\A'6YQM!M?F->I)H.%E&`XK?1>T^[H3%I52FTZ&HS+0B,C
M/45UCJ346,D[['7][;R]<<TC#\+7!45YI[`9&/NLA8V<\75)#&\?`YI44?*3
MR/N,>[M7/N-C4/<?MPR0MZ&FI7.NMM[:21$91[G$Y\IZ33-ND@FT/5,B*W'[
MU.*BR3(D'-NC/$;K'!3-@U(1E,5N/%1EPT=;)6@!]-Y$K7%U*![-ZAO5_A^T
MEFX73Z>!QF3WCAJZ!QZG1DDMZ@8W-#=Y8_<JGN__`!]W5XR;F7.T^\.-/8WE
M=03<EI25_"J>^IY2G"K\AQNU0E,>XH[`FE$V\C12'$+9=2V^TZTC=W2^J<)K
M'#QYS`S":RDV'H<QP^,R1N]KVU%0=X(<TEI:3IGJ73.9TEEI,-G(C%>,VCI:
M]IW/8[<YCN@C<06D!P(&EAD*L*`BS?;?<7,]H\\Q3<S;V]EXWFF%7,2^QZZA
M*+Q8D^&O4DNM+)3,N%+94MF3'=2MF3'<6TXE3:U).W9?$X_.XR?#Y6-LV/N(
MRQ[#N+3]4$&A:X4+7`.!!`*N&*RE_A,C#EL9(Z*_MY`]CAT$?4((J'--0YI+
M2""0K_O#+E!C/+_CWA&]./HC0+&TCJILYQR.Z;O\$\_IVF&\EH-5K<>^")>>
M;E05.&3KU;*CNK)*G#27+_F!HV\T'JFYT]=$NB8>.&0BG>P/KW;^JM`6O`V"
M1KVBH%5TFT)JZTUOIFWSUL`V5XX96#_9S-IWC.NE2',KM+'-<:5HNIAA:S!1
MW^;!]'KR6^+&+_*)APE7DC[T\/ZZ3V$JC#G-[LLMZJ/V\2H:CI@N="`B`BOE
M>4_]'KQI^+&4?*)F(YG\[O>GF/71^PB71?DS[LL3ZJ3V\JD0$5*3U^<QR@O#
MR?DMR'R0W#=/(=\]VKPW5-)84X=MGV03S<-E)$EDU_"->TNB?0.L.C;;YGI#
M%6E*=UC;9G7\6!C=_3N7+K5UQ\[U7D[JM>]R-R_J^-,\[NC>M&#)%CR`BE2\
MEV@1=>89L]+=8<?1C5'NA?F1):6RTO\`S;912,/R4NMK,VVI%T@VS3VK2_X:
MB/H9'"OB#NC;\J[^,$`S26[.FI_YB-Y`\H8:]'#4*8>0UL+CF;8O()$4=P_L
M_F)&`GR%XIVT5X@<Y%T%0$0$0$0$0$52#ZPG2$QR5V3R/PDDJUV-32&^3JS6
MX5!GV73B:4P:C;;2R>2F9+(B4LW#(S,DEIO-X6+CBTAD;2OQ,EQTI]?#$VM>
MWN]W13M6E?B9M^'5>/NJ?'Q_!7[2:0TIV=YYZ]B@$&SZUM0$7]H6MI:'&UJ;
M<;4E;;B%&A:%H,E)6A23)25)46I&74C`@$4.T%?02#4;"%^EYC5HN[QR@NG#
M8-RWI*JT<.+K\%-<^`Q+4<;N<=5X'<[[&JU'VZ=3](Y!7D(MKN6W%:1R.;MW
M^BXC;NV[-NQ=7;28W%K%.:5?&UVS=M`.S?LV[%[8IU4*ICYQ_EN6^W>7Y#RQ
MV2QZ58;:YA/E76[N-4\1Z4[M]EDUQZ7:9FU'CH6MK"<ED*4]+69>'6V"UZJ3
M'D,H9WAY!<VX,M8Q:'U%*UF7MVAEK(X@">(4#8B3OFC&QHWR,`V%S7%VF'//
ME7/B[V76>`B+L5.XNN8V@GN9#4NEH-T4AVN.YCR?DN:&U\QM(M:$!%\C3KK#
MK;[#CC+S+B'67FEJ;=:=;42VW&W$&2T.(61&1D9&1EJ0^.:'`M<`6D4(/2OH
M):0YI(<#L*FTXO>>5R0V6J*_$=XJ&OY$8O6LL1(-M>W4C&MRHD5E)-(;E9FU
M77<?)":;]HW+&"_/>47WR7UU+7;67APTEJ&=]_@)7XJ]>27-8P26Y)V[(BYA
MCKU1O#!T1J?M(^(356!@;99R-N4LV``.>XQS@#KE#7A_E>PO/2]2<4?U@_BI
M(@H<R7:#D'4V1Z>)$HZG;C(8*?9(U=EA/W%QB0YHO4BUBIU+KT]!0]<^%K6S
M9*6E_BWP];W3L/W+8)!_&4M6_B8T<Z.MW8Y-DO4QL#Q]T9XS_%7B9C]86X[P
MH3CFW^Q>]&36)-)-F+F,K!\&A+>^_=S;D^ER#<1]IHNUO191EF?<KV2[2[ZB
MP\+&JY)`,IDL?#%7:8A-,:;/DO9`"=^SB'1MV[*>^\36F(XR<;CK^66FP2F*
M(5V]+'S&F[;PGIV;-L.O,'S;>37+.HL<$0[5;/[3V1.L6.$8&_.78Y)!6M"T
M0\SS&:M-G=1T=II7'B-5D"0@]'XSAD1E/F@N1FC]#SLR1#[_`#C-K9I@.&,]
M<40]%AZG.,CVGXKPH-UQSJU9K.!V.!98X9^QT4)/$\=4LI])PZVM$;'#XS"H
MM!,ZB!`1?/%BR9TF/"A1WYDR8^S%B1(K+DB3*DR'$M,1X[#25NOOONK)*$)(
MU*49$1&9C\O>R-ADD(;&T$DDT``VDDG8`!O*_3&/D>(XP72.(``%22=@``WD
M]`5SSRA_+WF<4=NYV[>Z]247?K=2JBLO54DB.3MO@BUL6$7$W4FDC9R.YEMM
M2K@C,_!6S'C$25,/*=Y]\]N:<>M\JW!81_%IFR>2'#=<3;6F4=<;!5L76"]^
MT.:&[W\D^6;]&XMV:S+*:CO&`%IWP0['"/L>XT=+U$-9L+7%TRX@!3JJX'UB
M:^5'P/B[C!/I2FWR[<Z^.,9.][JL<IL/KTOI41^"28Y92:3)1=QFZ7;T)0VT
M\*=L'Y/,WE-L<%NRO5WCY74Z]O=_4V]"U9\3]R6X[$6E=CY[A].O@;$VO5L[
MSZOE560;HK3]`1`1`1`1`1`1`1`1`1`1`1`17-_(<N56G!N5!-YETL<WLW`I
MDH:,S7'2_4X?D/@R"-2NUY2KXW"+1/WMQ/3UGS]\2]OW/,ALE".]QT#_`"T=
M*RH[/0IY05O;X=)^^Y>NCJ#W60F;Y*MB?0]OIU\A"FC&OBGE4-?-@^D*Y+?&
M?&/D[PX=,.2/NLP_J9/;RKG/SE]YN6]='[&)1WB55&*`BFF\AJD*UYQSYYL*
M>_@SLAG]V3B5)244W[O"\<\=9*,C6E19`;6B=3[G"/T$8U[\3%QW'+AL5:=]
MD8&>6C)9*?Q*^93SX<[?ON8+I*5[K'S/\E7Q,K_'IYU<T'/Y;VH"("("("*B
MYYQWTC_(S_5%\A&V`Z2<@O=+B?[U_C+A<\N>?O3RG]V_PENHR!,*B9`13">1
MI_+UQ_\`T8[D?Y.AB!?$A[LI?[9!_**G#P]^\>+^R3_R0KJPYZ+?9`1`1`1`
M1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`111>=9]'KNM\9]
MK/E$QX3=X>?>G9>IN?8/4-<_/=E>>NM_;,5((=%US^0$0$5\KRG_`*/7C3\6
M,H^43,1S/YW>]/,>NC]A$NB_)GW98GU4GMY5(@(J4GH"("("("("*.+S.^&=
M-R]XXY)'K*AE[>+;2MM<QVGMF62.SD64&)\*M<(\5)$X]7YM"B?!4M*432)Y
M17S_`&'K+/)SF!<:$U;"Z:0C`WCVQ7+2?1#2:-FIT.A)XJ[RSC;\I1;S;T)!
MK;2TK8F`YRT8Z6W<!Z1<!5T7:V4#AIN#^!WR51"'2Q<ZT!$!%8`\@7D!*Q/?
M7<#CQ:3-,?W:Q9[+<;C.+(_"SS`VS?DM0T*6CM_#&&29KLDTDM2OP6P6A))1
MEJ_XG]+LOM-6NJH6_P#-6,XBD/7#-L!/VLH8&[OYQW8MD_#;J5]EJ*YTQ,[_
M`):]A,C!U30[33[:(O+O5M5MH:-+=-1W^;!]'KR6^+&+_*)APE7DC[T\/ZZ3
MV$JC#G-[LLMZJ/V\2H:CI@N="`B`BOE>4_\`1Z\:?BQE'RB9B.9_.[WIYCUT
M?L(ET7Y,^[+$^JD]O*I$!%2D]?F[;XM.L;U;OL/MN,O,[H[@-/,NH4VZTZWE
MELAQMQM9$M#B%D9&1D1D9:&.MFFW!VG;!S2"TV4!!'3^":N6&H06Y^^:X$.%
MY-4?_P"QRU<+RK0@(I@/(W=:;Y[XTAQQM"W]M=R6F$K6E*GG2J8[YMM)49&X
MX3+*UF1:GVH,_01B!_$>UQY93$`D"\MR>P<1&WSD#RE3?X>R!S'B!(J;2>G;
MZ(/[@)5UH<\EON@(@(@(@(@(JH?UAU2?\\_'=.I=Q;89.HTZEW$E65H))F7I
M(E&D]/=T,;M^%4']'\J>CYY'[-::^)P__/8L=/S23VBKPC:I:QH"("+])C:2
M#(J]J=LJR622E5VWN%P9)(42T%(B8W6QWB0LNBTDXV>A^LAR.SDC9LW>3,^(
M^ZE(\AD<0NJ>%C=#AK2)_P`=MM$#Y0QH*V$+6KFO+NWZ:-36LC(WJN/C[5=-
M7>/7;D1JF:J4QW/PBNU<GFF$BN*)W^,;QDUX>O=TU'M;MN'W#&V@>;HO'`&5
M+^*OH\/#MXJTI3;7<O&X=`R![KHL%L&GC+Z!O#3TN*NSAI6M=E-ZHO>977<#
MXN\4N3PMO;B44F?,7G5+15D=W92#8N*<<=>VRR"18M6GP<Y9F2X4:&_2(0HC
M@24,I3'+I'RAEYEOP#6<PHHVT:.Y>]Q^=EO5<,#2VM-SW/$Q/\ZPN)<N>?-:
M+ETS.%^@I'N!<>^8QH^:AW7`\NXJ5WM:TQ`?S;PT!JC:$N**T!$!$!$!$!$!
M%N79+CYO1R-RUC"=E=N\CS^^<<83**GAZ55*S)<-MJ=DE_+5&HL;K361E\)G
M2([.I:$K70A8-1:IT]I.Q.1U#=Q6ML`:<1])Y'1&P5?([[%C7'L5]P&F<]JF
M]&/P%K+<W)(KPCT6`]+WFC&-^R>X#M5M?R\/**P/BI(J-VMXY-1N;OW';;E5
M/@,KD8/MG*4E*O$Q=F<PR_=9-'5J16\AIHV/1%9941O.:-\U>>N3ULR3!X`2
M6>F":.J:37`_WA:2&1G^B:37Y;G#T1NERQY)X[1SF9K.EEWJ0"K:"L4!_P!V
M"`72#^D(%/D-;\8S/#7U3N@(JR7UC/\`_IS_`/Z$_P#X/&X?A/\`_P"__N/_
M`/,6IGBB_P#Z/^^__P`15DAN$M3$!$!%VU5^7!SENZRNN:KC1N3.J[>!$LZV
M:Q!KS9F0)\=N5#E,FJQ29M2([J5IU(CT,1W-S:Y;V\S[>?,6C9HW%K@2ZH<T
MT(/H]!%%G\/*SF%<0MGAQ-TZ%[0YI`;0@BH(]+I!JOO_`,V9SU^:]N=^X:[]
M\AY?K@Y9?3-G\+OO5Z?JGYC_`$1=_`W[Y/YLSGK\U[<[]PUW[Y!^N#EE],V?
MPN^]3]4_,?Z(N_@;]\G\V9SU^:]N=^X:[]\@_7!RR^F;/X7?>I^J?F/]$7?P
M-^^3^;,YZ_->W._<-=^^0?K@Y9?3-G\+OO4_5/S'^B+OX&_?)_-F<]?FO;G?
MN&N_?(/UP<LOIFS^%WWJ?JGYC_1%W\#?OD_FS.>OS7MSOW#7?OD'ZX.67TS9
M_"[[U/U3\Q_HB[^!OWR?S9G/7YKVYW[AKOWR#]<'++Z9L_A=]ZGZI^8_T1=_
M`W[Y/YLSGK\U[<[]PUW[Y!^N#EE],V?PN^]3]4_,?Z(N_@;]\G\V9SU^:]N=
M^X:[]\@_7!RR^F;/X7?>I^J?F/\`1%W\#?OE9[\ES8?=SCWQ8S?#]YL'N-O\
MHN=^<JRN!1WJ&&Y[E!+P';&DBV"FV'GT(:D6-!*0G56I^'KZQIQX@]38+5.M
M+:_T_<QW5E'C(XW/97AXQ-</+=H&T->T^=;;\AM.9K3.C[BQSUN^VO),C)(&
M/I7@,-NP.V$[W,</,I=A!2FQ4-?-@^D*Y+?&?&/D[PX=,.2/NLP_J9/;RKG/
MSE]YN6]='[&)1WB55&*`BG2^K[_RR]S/]F3,_E4V8&MOBC]W]G_G$7^&NUL-
MX:?^^KO_`"F7_$6JN$#0Q;P("("("("*BYYQWTC_`",_U1?(1M@.DG(+W2XG
M^]?XRX7/+GG[T\I_=O\`"6ZC($PJ)D!%,)Y&G\O7'_\`1CN1_DZ&(%\2'NRE
M_MD'\HJ</#W[QXO[)/\`R0KJPYZ+?9`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1
M`1`1`1`1`1`1`1`1`1`1`1`111>=9]'KNM\9]K/E$QX3=X>?>G9>IN?8/4-<
M_/=E>>NM_;,5((=%US^0$0$5\KRG_H]>-/Q8RCY1,Q',_G=[T\QZZ/V$2Z+\
MF?=EB?52>WE4B`BI2>@(@(@(@(@(@(OSKN7>&P]O>57(_":R.W$J<9WQW1J:
M6,T9*1'HX^:7)4K)=I$23;JC9(T_K3(R]0ZM:$R$F5T5B<C,2Z>;&V[GGK>8
MF<9^ZJN8&MK&/&:QRN/A`$,.0N&M'4P2NX!]S1<[#*UC"`B[/\NO,9F#<Y^*
M]U!6\V]-WGPW#EJ8T[SA[B6"=O[!"M7&OO+L#)G4N=3^]FKHKWIQ]S7L(\ER
MWS5O)0M;CY9=O7`WOV]>WBC%.WJWK/.5]\_'<P\/<1U#G7\46SJG=W+O-20U
M[.M?H%CEVNE2CO\`-@^CUY+?%C%_E$PX2KR1]Z>']=)["51ASF]V66]5'[>)
M4-1TP7.A`1`17RO*?^CUXT_%C*/E$S$<S^=WO3S'KH_81+HOR9]V6)]5)[>5
M2("*E)Z_/*YP8PYAW,?E%CZT*;;B[\[I2H:5^(:RK+?,;:XJ36IQ*%+4JKGL
MF:M-%&>I&9&1GU2Y<W@O]`X:Z!J78RV!^V;$UCOXS2N9',&T-CKG+VQ%`,C<
M$?:NE<YO\4A<M#,UB"`BDT\GK)6L:\P[8-4DVDQ;Q6X6-/+<+VTNW&V.8M5I
M,&;S*$NO7"([9Z]^J%J)*34:=(?Y]6;KSE5DPRO''W$@\C;B(NKL.P-XCT;0
M-M*J6.1]VVTYG8TOIP2=]&?*Z"4-IM&]W"/(3LK17IAS:70Y`1`1`1`1`14^
M?K`60L67+[;J@CJ:7_!O8'&_AAI)9.M6%QG6X4U49TS/L-*:U$5U.A:_?CU,
M^FF^?A>M'0Z$N[IU1WV4DIU%K(8!7[KB'F6D'B4NFRZWM;9M/P6-97[9TTQI
M]SPGSJ"L;)+7A`1>M0TTS(KRFQ^O3WS[VVKJ:"CM6OOF6<QF%&3V-I6XKN>?
M26B2-1^HC,>%U<1VEM)=2_S43'//D:"3]0+VMH'W5Q';1?SDCVM'E<0!]4K]
M+J%#C5T*)7PV_!AP(L>'$9[W'/"C16D,,-^(ZI;J^QI!%JI1J/34S,QR$DD?
M+(Z60UD<XDGK)-3NV;UU=CC9%&V*,48T``=0`H-Z\'-LUQ3;C$<CSS.;VOQC
M#\2J)M[D=_:.FS!JZJO94_*DO&E*W7#)"=$-MI6ZZX:4-I4M24G58['7V6OH
ML9C8G37\\@9&QHJ7.<:`#_630`;20`2J;(7]GBK*7(Y&1L-C`PO>]VP-:T5)
M/^H"I)V`$FBI.^8=YGVY_,O(;/#,4E6N`<=:VP4FBP>-(7#M,U;B/$N)D6Y+
MT20XW92WGFTOQZQ*E5]?HWH3\ALY2^A_*ODWAN7]JS(7K676JWM].8BK8JC:
MRW!'H@#8Z2G&_;\5AX!H+S.YN9?7=R^PLR^VTNQWH1`T=+0['SD'TB3M$?Q&
M;/C.'&8KQ-*A]2!<!/+ZW)YU9Q9PJ>>6$[6X<Y#//MR9L!4]J"]-);D/',;K
M3?B)O<HGL-*<\/Q6V(<<O%D+2:X[4B+N9_-+$<ML:R2=OSC-7`/<6X=PD@;Y
M)'4/!&TFE:%SW>BT&CG-DKEORTRO,/(/C@=\WP\!'?3D5H3N8QM1QR.`K2H#
M1Z3CM:'6`LP\@+B7;T\*-A^X.]6&WD.(U&<MI5SB^3P+1Y#1)<GVE/*QBN<^
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MZO8OJ5GD2<ZIZG2E-[.TA-FT2%6>X4EU+Y.&LEJ:_`V-VZB)CM+O[R09]Q=O
M=UT_<WB5Y;1`<!OY*U^+`!3[N1N_HI7MHOQ%X=N8<E>,6,=/KICM^Y8[=VT[
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M,Q`^4R^5SEX[(9BXFNKUV]\KW/=UT!<30#H:*`;@`%-V,Q6,PUHVQQ-O#;6;
M=S(V-8WRT:!4GI)J3TDK-Q;E<$!$!%7-^L14#DC;+C1E!-D;5/G>?4"WO@_<
MIMS),?H;%MLI7]Q)U.*K,V_[KV$?]S&V'A4N@S,9BSKMDMH'TK_1O>W=TT[P
M;>BO:M7?$];%V)Q-W38RXF96GU[&.W]'\WNZ:=BJKC=5:=H"("+]'[C_`&#-
MOL-LE:QDNHCV>T>V]@PA]*$O(9FX;326DO);6XA+J4.$2B2I1$?H,_2.2^J(
MG0:FR,#Z%[+ZX::;JB5X-.Q=2]-2MGTYCYF5X7V4#A7?0Q-.U;<%B5[0$0$0
M$0$0$0$0$0$0$0$5#7S8/I"N2WQGQCY.\.'3#DC[K,/ZF3V\JYS\Y?>;EO71
M^QB4=XE51B@(ITOJ^_\`++W,_P!F3,_E4V8&MOBC]W]G_G$7^&NUL-X:?^^K
MO_*9?\1:JX0-#%O`@(@(@(@(J+GG'?2/\C/]47R$;8#I)R"]TN)_O7^,N%SR
MYY^]/*?W;_"6ZC($PJ)D!%,)Y&G\O7'_`/1CN1_DZ&(%\2'NRE_MD'\HJ</#
MW[QXO[)/_)"NK#GHM]D!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!%%%YUGT>NZWQGVL^43'A-WAY]Z=EZFY]@]0US\]V5YZZW]LQ
M4@AT77/Y`1`17RO*?^CUXT_%C*/E$S$<S^=WO3S'KH_81+HOR9]V6)]5)[>5
M2("*E)Z`B`B`B`B`B_Q2DI2:E&24I(U*4HR)*4D6IF9GT(B(`"30;T)IM.Y?
MG*<F,\B;I<B]^=R:Z2<NKSO>+<K+*=\UFLETU]F-Q94Z6U&I?WEJLD-(;+4R
M)"2(CT(=8]'XR3"Z3QF(E'#-;6%O$X?9LB8U_GX@2>U<N=69%F8U1D<K$>*&
MYOIY&G[%\KG-\W"13L6D1D2Q]`1=!\28,FSY5\9:V&I*)=AR#V8@Q5K6IM"9
M,O<?&V&%+<22E(2EUPC,R(S(NHQ;7,C(=%9B:3^;9B[LGR""0GZBR71<;YM8
MXF*/X[LG:@>4SL`7Z*XY1KJ"H[_-@^CUY+?%C%_E$PX2KR1]Z>']=)["51AS
MF]V66]5'[>)4-1TP7.A`1`17RO*?^CUXT_%C*/E$S$<S^=WO3S'KH_81+HOR
M9]V6)]5)[>52("*E)ZI.^=WM>[M_SORO)$,>%6[O8/@VX4$VT:1R?C5:L!MV
MR66J?A3EIA+DEU)GW%\)2HR(EI,^A_ATS+<IRT@M":S6%S-`>NA=W[?-PS!H
MZ/1(Z"M!?$!B'8WF+-=`4BO;>&8=50WN7>?BB+C]M7I"B'$[*$T!%NGCAN<K
M9??_`&6W8-QQN/M[N?A.5V1-D9JD4M1D$"5>0C(B4HT6%.A]A7;[7:X>FAZ&
M,>U;A_TATOD,'0%]U9S1M['N8X,/\%]"/(K]I;+'`ZEL,S6C;:[BD=VM:\%X
M\[:@^5?HUQY$>9'8EQ'V9464RU(C28[J'X\B.^A+K+[#S2E-O,O-J)25),TJ
M29&1Z#DZ]CHW%CP6O::$'801O!'00NHS7->T/806$5!&T$'<0>D%?,/ROT@(
M@(@(@(J&_FM[H-;J\]N0%I#?\:KQ/(H&V=<DE^(EA6W5+7XK>-H470T.9576
M#NA="-S3KZ3Z7\DL,["<LL7#(*33Q.N'=O?O=(S_`(;F#S+G1SDR[<SS'R4T
M9K##*(&]G<-;&_\`XC7GSJ.T2LHP0$7:/EV;:N[L<WN-&(H85(CL[IT&86;1
M)[D.4VW2W=P+AE\]4]C$FNQEQI1ZD>B_9]K01]S6R[<'RZS%\31QLGQ-/V<_
MX!I':'2`^;;L6><L,4[-<P,39`5:+QDKOM8/PS@>PMC(\_6OT"1R[72I5G_K
M`/)NTKVML^)^-6;D6%>5J-UMT&(YF7X2@M6TFKV]I)+J#T^#LVE+8V$B,O4S
M=:@O:%VH-6W_`(7M'0RNO-;WC`Z2-_S:W)^2>$.G>!UEKV,:X=!D;TFFJ'B4
MU;-$+31EH\B.1GSBX`^4.(MA8>P.:]Y:>D1NZ!6L*-QEJ0@(KUOE#8%0X)P!
MV-72M0_A>;1LFSW)9\3L-=I?7V46S!.S7$)1XDRKI*Z%6GKJI"(*4&9]NHYL
M<]LG<Y/FADA<%W=V[HX8VGY+&1M-!V.>Y\G:7D]*Z'\DL;;8[EMCS`&\=P))
MGD?*>^1PV]K6-8SR,`Z%):(A4KH"("("("("("("("("*';SS-O7LTX)VV0Q
MV/&<VKW.P'.WC0E:GD0IKUGMY)-'9[1M(5G:''"/V"2WWG[PC*>_#?E6X_F5
M':O-!>V<\(ZJ@-G'G_`D#IVTZ5!WB%QCK_EV^Y:*FSNX9CUT)="?;`GR5Z%2
MN'0I:%("("*_OY:F=Q]Q."'%^\CNMN%5[5TF"/$@T:MR-LUR=NWFG$H(NUQ*
ML7UZEW&1D9ZZZGS!YNXU^*YEYFV>"..]?,/)<4G'M%TEY4Y%N3Y=8BX:0>"S
M9"?+!6`^S7<8CA2"@(@(@(@(@(@(@(@(@(@(J&OFP?2%<EOC/C'R=X<.F')'
MW68?U,GMY5SGYR^\W+>NC]C$H[Q*JC%`13I?5]_Y9>YG^S)F?RJ;,#6WQ1^[
M^S_SB+_#7:V&\-/_`'U=_P"4R_XBU5P@:&+>!`1`1`1`147/..^D?Y&?ZHOD
M(VP'23D%[I<3_>O\9<+GESS]Z>4_NW^$MU&0)A43("*83R-/Y>N/_P"C'<C_
M`"=#$"^)#W92_P!L@_E%3AX>_>/%_9)_Y(5U8<]%OL@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(HHO.L^CUW6^,^UGRB8\)N\//
MO3LO4W/L'J&N?GNRO/76_MF*D$.BZY_("("*^5Y3_P!'KQI^+&4?*)F(YG\[
MO>GF/71^PB71?DS[LL3ZJ3V\JD0$5*3T!$!$!$!$!%$)YN?.K'N,VQ>0;3XC
M?M*WZWBQ^7045=6R4G985AMPEZNR'.[/PE>-5J=KRD0ZA7<V\Y8.>.SW(B/]
ML[\B^6UUK#4D6<OHC^C-A*'O<X>C-*VCF0MKL=1W"^7>`P<+J&1M82YU\Q+;
M2>GI<-92#]([Z(L8UI]**)U6OF=TM]&K8]Q+SQ-J&.5*`=#EH,@(@(I!?*PP
M!_<;GSQPJFVC7'Q_,I&?SGO#-QJ*QMY1VN91W7M-/#)ZSIH["%'Z'GD"+N=.
M4;B>6.6F)]*6W$`'69WMB-/(U[B>P%27R>QKLIS(Q4('HQ3F8GJ$+'2BOE<T
M`=I"OJCF6NC:CO\`-@^CUY+?%C%_E$PX2KR1]Z>']=)["51ASF]V66]5'[>)
M4-1TP7.A`1`17RO*?^CUXT_%C*/E$S$<S^=WO3S'KH_81+HOR9]V6)]5)[>5
M2("*E)Z@&\_G8)W,]A=N]_J:"I^RV:REW'\I>9;ZMX/N(N#!:G3%I0HUM5>9
M5U<PR1F1(.T</U]=GO##J=N/U-=Z7N'4AR$(?&#_`$T'$2!VNB=(X]?=A:V^
M)+3;K_3EKJ2!M9;"8LD(_HIZ`$_:RM8!U=X54>&\ZTK0$0$5X_RB.4L#D=Q'
MQ"AL[1N3N3L?$K]LLVA.O=T]ZLJHRF,$R1:%J4^[&N\8BMLK?6>KMA!E_P!B
M.<7/;1<ND]=3W,+",1DG.N(33T0YQK-'U`LD)(`W,>Q=!N2>L(]4Z*@MY7@Y
M7'M$$HKM+6BD,G71\8`).]['J4L0NI@0$0$0$7.7+3D'C_%SCUN;O5?R(J7<
M4QV66,5TE:25D&;62#K\/H&6C6AU_P#"-[(9)_PR4IF(EYXR[&EF66:'TM=:
MSU39Z>M0:3RCO'#Y$+?2E>3N'"P&E=[N%N\A8OK34UMI#3-WG[DBL,1[MI^7
M*[T8F`;SQ/(K3<WB=N!7YXES<6>0W%K?W4UZQN;RRG7%M82#)4B?9V<IV;/F
MOJ224F]*E/K6HR(B[E&.JEO!#:P,M;=H9;QL#6M&YK6@!H'8``%S&GGFNIWW
M-PXOGD>7.<=Y<XU)/:225YH]5Y("*Q7]7VV%>NMR=WN1]M`4=3@^/Q]L<0E/
M(5X#^596Y&N<FD0EI+M.908W71F724>A-71:$9GJG5'Q1ZF;;XBPTE`[\/<R
MFXE`WB..K(P>Q\CG$=L/P[0>&G3CKC*WVJ9F_@;>(6\9.XR24=(1VL8UH/9+
M\%J\:4+<94</.>M9UCYBF]\.6HU1Z&KVGJJLC-XR1!>VCPB\<2DG7%H21V5S
M(/1LD(U/4R[S4I71[P^P1Q<J<=)'\:5]RYV[>+J9G\EC=]3YJ`<^.>\TDO-#
M(,?\6-ENUN_<;:)_\ISMU!YZE1:"9U$"`BLK>2_YCF#8-B\+B%OED$3%(D>Y
MLYVS.;WDQB%CB$Y!-7966WMW825M,4\AZ]E2)E9(>43$AR6[%4MMQ,5#^HGB
M"Y39+)7KM=Z;B=.\QM%W"P$R>@.%L[&C:\!@:V1HVM#0\`@O+=K.0_-+'XZS
M;HG4,K86"1QM97D!GIGB="]QV-)>7.C<=CBXL)!#`ZT&E25))23)25$2DJ29
M&E23+4C(RZ&1D--2"#0[UMT#7:-R_P!!$!$!$!$!$!$!$!$!%IWD+M-`WWV,
MW9V=L5MLL[CX#DV*L2W"(TUUG9U<AJFMB(T.%XE1;^!*3JE1=S1=#]`O^E<Y
M+IK4ECGXJEUI=1R$?7-:X%[?X3:M/E5CU-A8]1:>O<'+0-NK:2,'ZUSFD-=_
M!=1P\B_.9N:>SQZXM:"ZA/5US1V4ZGMJ^01)D0+.LE.PI\)]*34DGHLIA:%$
M1F7<DQUAMYX;J!EU;N#[>1@<UPW.:X`M(["""N74\$UK.^VN&ED\;RUS3O#F
MFA![000O-'JO)`16G?(#Y,UECA.XG%3(;)AB_P`<N)6YNW;$EU+;UICETW#A
M9A3P$J<23JL?N8K,[PTI-U2;-Y?5#2NS2[Q/Z/FBR-IK6U83:RQBWG(&QLC*
MF)SNKC82RNX&-HWN%=P?#9JR&6PNM'73P+F)YG@!.US'T$K1]HX!]-Y$CCN:
M:6/1J6MI4!$!$!$!%Q'YA7*.NXE<6]P]QT6+,3.+:O?PG:N(H^Z1.W"R.'+8
MJ)+#)*1XC.-QFW[:1JI!''@J22N]:$JD7E7HR77.L[7$EA=CHW":Y/0((R"X
M$]<AI$W?Z3P=P)&`<S=7Q:+TA=90/#<@]IBMQTF9X(:0.I@K([=L81O(5*W#
MN=',K`B:;QCD]OA$C,:>!7S]Q<EOZE@DI>1VLT^03[2K:29/J,R2R1*425'J
M:$F70J_Y;:`R=3>8;'.>=[FP1L<=V]S&M<=W7UCI*T)L>8>NL=06F7R#6#<T
MSR/:-^YKRYO3U=1Z`NJ\.\Z7S!<56R5ANMCV<Q6#;[8>8[;X,M"D(6E:FWIN
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M".X=&TO97BX7$`N;Q4'%PFHK05I6@7M"G7NJ&OFP?2%<EOC/C'R=X<.F')'W
M68?U,GMY5SGYR^\W+>NC]C$H[Q*JC%`13I?5]_Y9>YG^S)F?RJ;,#6WQ1^[^
MS_SB+_#7:V&\-/\`WU=_Y3+_`(BU5P@:&+>!`1`1`1`147/..^D?Y&?ZHOD(
MVP'23D%[I<3_`'K_`!EPN>7//WIY3^[?X2W49`F%1,@(IA/(T_EZX_\`Z,=R
M/\G0Q`OB0]V4O]L@_E%3AX>_>/%_9)_Y(5U8<]%OL@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(HHO.L^CUW6^,^UGRB8\)N\//O
M3LO4W/L'J&N?GNRO/76_MF*D$.BZY_("("*XIY<//#B!M1PGV%V]W%W^P+$<
MTQJ@R"+?8Y;2YS=C5R)6<918QVI*&H+K:5.PIC3A:*/V5D-".;7+37F;YB9/
M*XG%W4^/FE862-`X7`0QM)&T;B"/,MX^5G,71&&T#C<9E,E;07\4;P]CB>)I
M,LCA78=X(/G7;O\`.9\"OG0[8_NZQ_>T1U^I_F;]#7GW+?OE('ZV.7'TO:?"
M[[U/YS/@5\Z';']W6/[VA^I_F;]#7GW+?OD_6QRX^E[3X7?>I_.9\"OG0[8_
MNZQ_>T/U/\S?H:\^Y;]\GZV.7'TO:?"[[U/YS/@5\Z';']W6/[VA^I_F;]#7
MGW+?OD_6QRX^E[3X7?>K#LK\VCR^<1C+>E\BJ*X=2E)M0L4QC.\IDR%K2ZI#
M2'*7%Y<)E1DR>IO/-(09I)2B-2=:^RY'<TKYX;'B98V])DDAC`^[D!._H!)Z
M!L*H;SG1RSLF\3\I&]W5''-(3]Q&0-W20!T[PHM>3/U@&O<K+''.*&V=FW:2
M6'8S6Y>Z[,%ANK<6EQI4RBP*IG6:+%]LE$Y&>L9S;2'$D3T)U&J#FC1_A>E$
MS+O6]XPP@U-O;$GB['S.#>$=#@QA)'Q9&G:H@U9XE(C"^UT;:/$Q%._N`!P]
MK(6EW$>EI>\"OQHR-BK=[@;A9ONMF5_N#N-D]OF6:91-587V1WDI4NQL))MH
M9;[UGHAF/%C-(988:2AF.PVAII"&T)26VV+Q6.PF/BQ6)ACM\?"WA9&P4:T;
M_.2222:EQ)))))6J^3R>0S-])D\I,^>_F=Q/>\U<X[O,`*``4#0`````L-%>
MJ%`1`168OJ^O':0J?N_RCO(3C<5J(WL]@#SS:R1*>D/5V2Y]8LI<2E!E#1%J
M(C+[?>2C>EM:I-"B5J!XI-5M$=AHRV<"\N^=3@=``='"T^6LKB#3<P[:A;8>
M&C3#N\OM7W#2&!OS:$GI)+9)G#R4C:".MXV4*L\#3E;;*._S8/H]>2WQ8Q?Y
M1,.$J\D?>GA_72>PE48<YO=EEO51^WB5#4=,%SH0$0$5\KRG_H]>-/Q8RCY1
M,Q',_G=[T\QZZ/V$2Z+\F?=EB?52>WE4B`BI2>M>;M;8XKO1MEG>T^;Q#F8K
MN%B]OBMTTWVE(:BVT1R,4Z"XM*RCV5:\I$B*Z1:LR&D++JDA=<'F+W3V8MLY
MCG<-[:S-D9U$M-:'K:X5:X=+21TJV9K$V>>Q-SAL@WBL[F%T;^NCA2HZG-/I
M-/0X`]"_/"WVV;R[CYN_N#LSG494?)=OLDGT,M[P'([%K#:43]/D%>V]JX=3
MDE,_'GQ%*ZJC2$&?4QU4TUG[#5.!M=08TUL[J%KP*U+2=CV.I\J-X<QWV32N
M8VHL%>Z9SES@<B*7=M*6$TH'#>U[:_)>TA[?L7!:E%\5E0$76O"_EWG_``PW
MKI]U<-)RUJ'FRI<_PEV6J)79OB$A]MV95/N^%(1#LHKK:9$"83:U192",TK:
M4ZTY@_,'0F+Y@Z>DPF0HR<'C@F`JZ&4"@<!45:?BO;4!S3O#@UPS30>MLEH/
M/LS-AZ<!'#-%6C98R:EI.VCAO8ZAX7#I!<#>AXV\HMF.5^WL+<79K+8E[7N-
MLMWE#(6S%RS#K1Q!J<I,MH?&<E5-@TI"B0H^^-*0GQ8[KS*DN*YN:NT9J#1&
M5=B=00.BE!/`\5,4K?KXGTHYIZ1L<T^B]K7`@=#-*ZOP.L\8W*8*9LD1`XV&
M@DB=]9(RM6N'1O:X;6ES:%="#%5DR`BPC<7<G`MH\.N=P-S,MH\(PS'XYR;;
M(<@G-08$5!^RTRA2S\25-E.:-L1F4N2)#JDMM(6M1).XXG$9/.W\>+P\$ESD
M)31K&"KCV]@&]SC1K1M)`%5;\IE<;A+&3)9::.WL(A5SWF@'9VD[@T5<X[`"
M=BI7^9]YBUGS8SZ'BV$%8TG'[;RQE.8=53"5%GYG>FEZ$_N!D,+1*HSKT):F
M:R&YW+@Q''%*[7I+Z$]"N3?*B'EWC'7N1X)-4W;!WKAM;$S81`P](!VR.&Q[
M@*5:QI.A?-SFA-K[)-L\?Q1Z:M7'NFG897[09GCHJ-D;3M8TFM'/<!%8)J4.
MH"+V<<QV\R[(*/%,9K)=UD>2V]=0T-/`;\:;:W-O,9@5M=$:U+Q),R9(0V@M
M2U4HA3W=W;6-K)>WCVQVD,;GO>[8&L:"YSB>H`$E>]K:W%[<QV=HQTEU*]K&
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MJ2VU-&T_,[R`1N--@FAV4)Z.*,MX0=IX'TW;(!1L\M;4!$!%U!M7S5Y9;)UT
M:FVPY!;H8O0P?#^`XVC)YMMC$$FW&W23"QJ]5:4,-*U-$2R;CI)Q/LJU29D>
M&YKEYH?44IN,SB[.:Z=OD[L-D/1MD9PO/95QH=HVK+L/KW6>`B$&(R=Y#;-W
M,[PNC'DC?Q,';1NW<=BWA_.P>85\Y;)_XL;=_B<,<_4CRL^AX?QD_P#6K(/U
MR\S?I:;\7#_5)_.P>85\Y;)_XL;=_B<'ZD>5GT/#^,G_`*U/UR\S?I:;\7#_
M`%2?SL'F%?.6R?\`BQMW^)P?J1Y6?0\/XR?^M3]<O,WZ6F_%P_U2?SL'F%?.
M6R?^+&W?XG!^I'E9]#P_C)_ZU/UR\S?I:;\7#_5)_.P>85\Y;)_XL;=_B<'Z
MD>5GT/#^,G_K4_7+S-^EIOQ</]4LSQKSD_,.QU;!/[X0\FB,:Z0<EVUVQEH<
M[G_'7X]A7XC67;O=J:.LKV4'HGMT3I;[SD#RJNP>'&NAD/3'<7`Z*;&NE<P=
M?Q=^_I5?:<].9UJ1Q9!LK!T200'IKM<V-KS]UNW="[EV?^L);J54B)#WTV.P
MO,:TW&V95WMM:VV%7<>.:T^+-53W[V755O+0WW:,H?K&UJT]M!$>L;Y[PLX6
M9CI--Y*XMYJ5#+AK9F$]7$P1.:.TB0CJ*D+!^)G,0N;'J+'V\\5:%\#G1/`Z
M^%YD:X]@,8/6%.WQ8\P;B]R^81$VJSQ$/-DQER9NV&:,LXWN!#::(E/NQZEV
M3)A9#$CH4E3LBIDSV&26DG5H4?:-:M:<K=9:#<7YNV+L=6@N(B9("3N!<`"P
MGH;*UCC0T!&U;$Z/YEZ1UNW@PUR&W]*FWE`CF'71M2'@=+HW/`J*D'8NUQ'B
MSY`14P?.SXJN['\GWMX<>@*;V_Y%?A#+?$:;TCU>Y<)<=.?UCBDDKM7=/RV+
MI"W%$IYZPDI07;'5IT$\.VM6ZCT:,#=.KE,3PQ;=[K<U[AW\`!T1`W!C"=KE
MHAS^T<[3^KCG+9M,9E.*39N;.*=\W^&2)03O+W@;&J&,;`J"$!%L3:;=7.MD
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MI97A?\ESI#!%:DU`1`1:PW@WFVQV#P.YW+W<S"HPK#J-E3DJSM7R2Y*D&A2H
M]7406R7.N;J<I!ICPXK;LA]?1"#ZB\X'3^8U/DX\1@K>2XOY#L:T;ATN<=S&
M#Y3G$-`WE6C.9W$Z;QTF6S4[+>QC&USCO/0UHWN<?DM:"XG<%1U\PWG?EG.7
M=QK(51)F,[4X2F?4[681)?2Y(@U\Q]M5CDV0>`MR*YEF3?!6%22:4IF*PRS&
M;4YX2GWNCG*OEI8\M\$;4.;-F[CA=<S`;'.`]&-E=O=1U/#7:XESR!Q!K>?7
M,[F+>\PLV+DM=%AK>K;>(G:&D^E(^FSO)*#BIL:`UH)H7.C^$H*-4!%*MY/_
M`!7E\CN6N,9+;UJI.VNQ#];N;F,EZ.;M?,O*^8;FW^+NJ4E<=;]QDD0I;C#J
M5(?KZV6@_26L*<^-:LTGH::T@?3+Y,.MX@#1P8X?AY.NC8SP@C:U\C"IBY(:
M/?JG6D-W.RN*QQ;/*2/1+VG\#'U5<\<1!V%D;PKP@YRKH(@(J&OFP?2%<EOC
M/C'R=X<.F')'W68?U,GMY5SGYR^\W+>NC]C$H[Q*JC%`13I?5]_Y9>YG^S)F
M?RJ;,#6WQ1^[^S_SB+_#7:V&\-/_`'U=_P"4R_XBU5P@:&+>!`1`1`1`147/
M..^D?Y&?ZHOD(VP'23D%[I<3_>O\9<+GESS]Z>4_NW^$MU&0)A43("*83R-/
MY>N/_P"C'<C_`"=#$"^)#W92_P!L@_E%3AX>_>/%_9)_Y(5U8<]%OL@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(HHO.L^CUW6^,
M^UGRB8\)N\//O3LO4W/L'J&N?GNRO/76_MF*D$.BZY_("("("("("("("("(
M"("("("+>/'+C[N'R@W@Q#9G;.N.9D.4S23)L'FW3J<8H8QI<N\JOY#25?!*
M6DAF;CBO?O.&AAHEONM-KQS5FJ<5HW`SZ@S#^&UA;L:*<4CS\2-@Z7O.P=`%
M7.HUKB,@TMIK)ZNSD&!Q+>*YF=M<:\,;!\>1YZ&L&T])-&BKG`']`K8/9/"^
M.FS^!;+[?Q?@V,8%1,5,9Y;;3<NVG+6Y,NL@L_!2EM=MD-S)?FRE)(DF^^K0
MB3H1<N]3ZBR&J\]=:ARCJWEU*7$;:-&YC&U^2Q@:QO8`NE>G,!8:7P=M@<:*
M6EM&&@]+CO<]U/E/<2]W:2MOBPJ]J._S8/H]>2WQ8Q?Y1,.$J\D?>GA_72>P
ME48<YO=EEO51^WB5#4=,%SH0$0$5\KRG_H]>-/Q8RCY1,Q',_G=[T\QZZ/V$
M2Z+\F?=EB?52>WE4B`BI2>@(H$?.TX)2=X\`9Y2;8TYR]Q]IZ-R)N'45[&LS
M+ML8;CTQ5PTTRTI4NZP%;STA6IDIVI6^1J4<:.TK9OP[<RF8#*'1F9DX<3?2
M5@<X[(K@T'"23L9-0-ZA*&[!QN<M<.?W+M^=QHU?B&<64LHZ3-:-LD`J>+9O
M=#4GMC+MIX&A5$QO4M*$!$!%L#;/=;<K9G*HF;[49UE&WN60VUL,WN*7$RGG
M+BNJ;6_`EKB.MHGULE32?&C/I<CO$1$M"BZ"UYC"8C4%D['9NVANK%QJ62-#
MA7H<*_%<.APHX=!"N6)S.6P5X,AAKB:VO6B@?&XM-.D&F]IZ6FH/2%*C@?GJ
M<Z\/@-PKV7M)N>XVV;96.>;?O1)ZBT225.'MUD&`1''$$GWQM&:M3-6I]1"V
M3\-G+6_D,ELV^LP3\6&<$?\`'9.?J^13%CO$/S$L8Q'<.LKL@?&FA(/_``'P
MCZGE7KY3Y\_.'((3D6IK=C<&?6TIM-EBV`WTN:TM6NC[;>;9OF%<;J->A*CJ
M1TZI,4]EX9N7%K('SOR5RVOQ9)F`'L_`PQ.I_"KVKVO/$;S!N8RR%F/MW4^-
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MQT>6_P#)QN&T`BAN".BH/##7HXI*;8W*RV-0EM<@(N>.4_&W!.6.R68;*Y^V
M;5?D,=$JCO6&&7K+$<KKB6[0934^*7276R5FEQ!*1\)B.O1U*)MY8RK1>KLE
MH?45OJ'%FLL1H]A)#98G;'QNIT.&X[>%P:\"K0L8UAI7':ST_/@,D*12BK'@
M`NCD;\21M>EIWC9Q-+FDT<50EY(\<-T.*^Z^1;1;K4RZ^\I'S776T9N2O'\M
MHWC[J[)L7L9#$<K*FL63(R424N,.DMAY#;[3C:>FNDM6X;6N$BSN$DX[:0>D
MTTXXGCXT<C03PO:?,X4<TEI!/./56ELOH[,RX3,Q\-Q&?1<*\$C#\62-Q`XF
MN'G!JUP#@0-##)ECB`B`B`B`B`B`B`B`B`B]&HM[;'[2OO*&TL:2ZJ)D>QJK
MBHFR:VTK+"(ZE^).K["&ZS+A3(KR"6VZVM*T*(C(R,AY3P074+[:Y8R2WD:6
MN:X!S7-.PAS34$$;""*%>L$\UM,VXMGNCN&.#FN:2US7#:"UPH00=H(-0K9W
ME4>:](WVF4_'#DC:Q6]W383$VZW$>)F%&W,:A1=3Q[(R(VX\;/TLL*<8?02&
M;=)&@THF)3\,T>YU\D6::CDU;I%CC@JUG@%2;>I^/'TF"IHYIJ8M]3&3W>Y_
M)SG*[44C-+:J>!FZ4@G-`)Z#XC^@34%0102[J!X''/V-8%LDN5^9?%C$.8>P
M>6[-92IJ!/FI1=X-DRFC>=P_/*IB25!?MH3[;L4OA+L6:TG13]?*?;2:5*2M
M.:\O]:7^@M3P:@LJNB;Z$T=:"6%Q'&SR[`YAZ'M:34`@X?KO1]CKC3<V"O*-
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M8W#+RRD?#=QN#F/8XM<TC<6N:00>T%3%['^>ES`VRA0Z7<2'@^^E1%3X?P_+
M*Y_'<U-E':3+7\)L6<A5TGL01DIV95RY+AZ&MTSU,X#U'X;=!YB1UQB77.-G
M=\F)PDAKTGNY*N'D;(UHZ&J<]/\`B'UOB8VP91MOD8&],C2R6G0.\CHT^5T;
MG'I*["8^L8O)993)X>M.R$M-D^ZQO\N.RX\2")UQEAS9:2MAI:]32A3CAI(]
M#4K34\"=X3VEQ+,\0RNP&RJ:=%3\[%3VT'D"S=OBB<&@/P8+J;:7E!7L'S4T
M\E3Y2M.[F?6#]_+^))B;5;)[:[;JD-NM)L\FN+W<BU@DLW/#?@&TS@]/\+92
M:=#DPI+)J29FT9&1)O\`A_"UIBUD$F;R-Y=@$>C&UENT]CJF9U#]B]I[58\M
MXF-27+"S#X^TM2?E2.?.X=HV1-J/LFN'8H;-]N2V^O)C)&\JWQW+R//[.*<C
M\%QK.0U%H:%N4I"I#&.XS6,P<>H&7S;1XB8D5GQ>Q)K[C(C$_::TAIK1]H;+
M3EG%:PFG$6@E[Z;C)(XE[R-M.)QI4THH+U%JO46K+OYYJ"[EN917A#C1C*[P
MR-H#&`]/"T5IMJM&#)%CR`BS';[`,QW4S;&-N=OJ"?E&:9E<0Z''*&M0E4JP
ML9KA(;1WN*;CQ8K*.YU^0\MN/&80MUU:&T+45!E,I887'39;*2MAQ]O&7R/=
MN:T?5).YK0"YSB&M!)`5=C,;?9C(0XO&1NFOYWAC&-WN<?J`#>7$@-`+G$`$
MJ^OP,X>8SPKV"H=L:]R%;9K9N%DNZ.71633_``DS2:PTB2W$==;;DGCV/QT)
M@UK:TM_>&C>6VE]]\U<R^9FO;SF%J>7,RAS,>P=W;Q$_S<0)I4#9QO/IR$5]
M(\():UM.C?+G0]IH+3<>(B+7W[SWEQ(!\>4C;0G;P,'H,!IL'$0'.=7M(1ZL
M]0$5#7S8/I"N2WQGQCY.\.'3#DC[K,/ZF3V\JYS\Y?>;EO71^QB4=XE51B@(
MITOJ^_\`++W,_P!F3,_E4V8&MOBC]W]G_G$7^&NUL-X:?^^KO_*9?\1:JX0-
M#%O`@(@(@(@(J+GG'?2/\C/]47R$;8#I)R"]TN)_O7^,N%SRYY^]/*?W;_"6
MZC($PJ)D!%,)Y&G\O7'_`/1CN1_DZ&(%\2'NRE_MD'\HJ</#W[QXO[)/_)"N
MK#GHM]D!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M%%%YUGT>NZWQGVL^43'A-WAY]Z=EZFY]@]0US\]V5YZZW]LQ4@AT77/Y`1`1
M`1`1`1`1`1`1`1`1`1;RX_<<-Y.4&?0=N=E\,L<LO9"F5V4MM)QL?QBM<6I+
MEWE5\\15]%4LDA1][JO$?6GPF$.O*0TK'-4:MP&C<8[+:AN&06PKPC>^1WUD
M;!Z3W'J&P#TG%K02,ATUI;.ZNR3<7@8'37)IQ'<R-OU\CSZ+&CK.TG8T%Q`-
MVG@%P"VXX.;<?@^O^!Y3N]E,.*O<K<I<7L?L7T=KY8UC1/I*3589522^]->R
M[,=24B07?X;;'.WF?S/RW,?+=[+Q08&!Q^;V]=C1N[R2FQTKAO.Y@]!FRI=O
MWRVY;8OE]B^ZBX9LW,T=_/3:X[^[CKM;$T[AO<?2=MH&]_B+U)2`BCO\V#Z/
M7DM\6,7^43#A*O)'WIX?UTGL)5&'.;W99;U4?MXE0U'3!<Z$!$!%?*\I_P"C
MUXT_%C*/E$S$<S^=WO3S'KH_81+HOR9]V6)]5)[>52("*E)Z`B_Q24J2:5$2
MDJ(TJ2HB-*DF6AD9'T,C(`2#4;T(KL.Y5+?-5\J"ZVNN,GY(\:<:59;23UO7
MFX&VU#%=>L-L9BS2NSO\=K62==F8!)=-4A]EDM:3N69(*`DCB[Q\E.=UOF8(
M=(ZOFX,XVC(+AY`;<#Y+)'&@$X%&M)_GMFWO3Z>E_.+DU/B)YM5:4BX\*ZKY
MH&`ET!^4]C1OA/QB!_-;=G=CT*_`VB6M*`B`B`B`B`B`B_U*349)21J4HR2E
M*2,S49GH1$1=3,S#=M.Y-^P;U8N\L7R?;K+;+'^0/+;%GJ?"8;C-O@NR^015
MQ[C,9+2FWH-]N%4R$I>JL2:67>S4R$HDV:DDJ2VB%HW-U0YQ\^;>QAETOH:8
M29%P+9KMAJV('860.&QTIW&5M6Q[F$R;8]H>4G)"XO98M2ZUA,>/:0Z&U>*.
ME.\/F:=K8^J-U'2;W@1[)+4[333#3;##;;+++:&F66D);:::;22&VVVT$2$-
MH01$1$1$1%H0TJ<XN)<XDN)J2>E;B`!H#6@!H&P+Y!\7U`1<@<P.;FQ_"W!B
MRG=.[.7D=LS)3A&V]&XQ(S/-)K!&2O@,);B45M'%<,BEV<HVXD8C)!&Y(6RP
M[GF@^76H^862^986/AM(R.^N'U$40/6?E//R8VU<[?L:'.;A&M]?Z?T%C_GF
M8DXKIX/=0,H992.H?)8/E2.HUN[:XM::;/.+S"-WN<^0U3V<5&+8E@N)3K"7
M@F$4-9"F2J`K%"&)3MCFTV"C);N?.C,,IDDE<2N=6PAQ$)I22,;^\N.5F"Y;
MVKVXZ2>?)3M:)IGN(#^':`V$'NV-!)X=CI`"09'`K1;F#S,S?,.Z8[(,AAQT
M#G&&)C02SBV'BE(XWD@#BVM82`1&"N"A)BCE`1`1`1`1`1`1`1`1`1`1??J[
M2RI+.NNJ:?,JKBHG1+2JM*Z2]#L*VRKY#<N#/@S(ZVWXLR'*:2XTXA25H6DE
M),C(C'G-##<POM[AK7P2-+7-<`6N:X4+7`["""00=A&Q>D,TMO,VX@<YD['!
MS7-)#FN::@@C:""*@C:"K]/EW<J/SON+6#;H6CL4\[K%2<&W/CQ$M---9WC3
M40I\Y$9D_#B-9'53(=JADB)+*)Q-ET1J?,7FMHK]`]:7.&A!_-CZ36Y-3^!D
M)H*G>8W!T9/265Z5TAY8:Q_3?1]OEYB/SBRL5P!3^>C`J:#=QM+9`.CCIT+N
M(1PI!48WF/>7#AG-_#&;RC>KL-W[PVNE-87FCL5*8610DI=D-81F[L=I<Q_'
MWYBS5%E))Q^J?<6XVAQMQ]AZ8N4O-K(<N<@;:Y#[C3%P\=[%7;&=@,T()H'@
M?&;L$@`!((:YL2\TN5MAS`L!<6Y;!J.!I[J6FQXVGNI:"I83\5VTQDD@$%S7
M4I]V]H=R=BL]O=LMV<1ML*S7'7_!L::V9)*EM+-7P:QKI;*G85M3V#:?$C3(
MKCL:2V9+;6I/4=#<'GL1J7&1YC!SLN,=**M>T]/2UP.UKV[G,<`YIV$!:$9K
M"973N2DQ.:@?;W\1HYKA\#FG<YKM[7-):X;02M;"[*U("("("("("("+8.UN
MU.XF]>;TFW&U>(W&;9ID+_@5E%2QO'?4E)EX\R6\M3<2MK(2#[Y$N0XU&CMD
M:W%I21F+7FLWBM/8Z3+9J>.WQ\0JY[S0=@`WN<=S6M!<X[`"5<\/ALIG\A'B
M\/!)<7\IHUC!4]I)W-:-[G.(:T;20%<_\M?RS,2X4X^>=9C(A9CR'RJE1`R'
M(8Y*<HL(JY2F9,S$<+)UMMUU#C[393K)Q*7IIM)2VAEGN0OGUS=YP7W,.Z_-
MM@'6^E8).)C#\>9PJ!+-38-A/!&-C*U)<ZA&]_*KE-9:!MOSC?%L^IYHZ/>/
MB1--"8XJ[]H''(=KJ;`UNPRM"$U,B`B`BH:^;!](5R6^,^,?)WAPZ8<D?=9A
M_4R>WE7.?G+[S<MZZ/V,2CO$JJ,4!%.E]7W_`)9>YG^S)F?RJ;,#6WQ1^[^S
M_P`XB_PUVMAO#3_WU=_Y3+_B+57"!H8MX$!$!$!$!%1<\X[Z1_D9_JB^0C;`
M=).07NEQ/]Z_QEPN>7//WIY3^[?X2W49`F%1,@(IA/(T_EZX_P#Z,=R/\G0Q
M`OB0]V4O]L@_E%3AX>_>/%_9)_Y(5U8<]%OLN1^6O)S*>,&,P,RJ./VXF]>+
MQZ+.,FSNZP:?2086W%!A%?5VLFTR15PZA:HMA72Y;K9LDHTHKWNXNJ=<ZT-H
MZRUE>.Q\^4M,=>F6&.%DS7DSOF<YH;'P#>UP:#6FU[>U85K35MYI&T;?0XRZ
MO[,1RR3/B+`(&1-:XN?Q=#FEQ%.ACNQ<.2_.`9J=AFN1U_Q*WBH]KK>ZH:/#
MLAG7^*'!S.9=2<CB/)I7VE+49U3^,OI=)Q"349^SZ!(\?(=T^ICI*USEA)F8
MXWOE8&2UB#!&1Q@_7"04H?*H]?SO;#IP:IN<+?1XA\C&1/+XZ2EQ>#P$?6F,
MUJ/(L_WS\VO979783CKOJ6'9-F<;D933[R@Q*ELZB/;8[%H(]>SE;=W-?-V$
M;V.Y'9-U;A(Z.R4N&@]$*%KTWR-U#J'4^6TU\XAMWXF1K'RO:XMD+RXQ\`&V
MDD;3(*[FTKO"N>H>=.`P.F\7J+N)9VY2,O9&QS0Y@8`).,G95CW",TWNK3<I
M7!"2F1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`11A><)B65
MYQP.W.QS"\9R'+\AEY'MH[$HL7I;+(+F2U$SZADRG(]74QI<UYN-';4XX:4&
M2$)-1Z$1F)DY"WUECN9=G=Y":*"U;#<`OD>UC!6%X%7.(`J=@V[3L41\\+*\
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MZ(ZL^B\C^33?>)^:]R8^;MOI^23/_P`7P_3+2'TKC?RJ#[]/T1U9]%Y'\FF^
M\7R-<6>3K[K;#''+?AYYYQ#3++6T.X+CKKKBB0VVVVC'C6MQ:S(B(B,S,]"'
MQVM-'-!<[+8P-`J2;J#9_'7T:/U:XAK<7D2XG8/FTWWBSNFX%\V+Z3\%@\3^
M0;#O<TCNN=ILUQR-J\HTH/X9D-/5Q.TC3[2N_M0751D1D+9<<S.7=LSCDSF*
M(^PN8I#L[&.<?J;>A7*#ESKZY?P1X;)@_96TK!M[7M:/J[.E=1[=>2_S]SYY
M@[#;"@VUKW^PTVNXN=8U"902^W4WZG&)>5Y0QX:5:J)<`CZ&1$9EH,,RWB#Y
M88QI[J\EO)1\F"&0GS.D$<9\SUEV+Y#\R<D1WMI%:1'Y4\S!\+8S)(/.Q2H;
M`?5]L$HY5?=\DMW[+.ELFT_)P3;2"[BV/.O-J0I<2PS&U5)R*UK7T]R5%%A4
M\DNAI=28A;5'BCR=RQUOI&P9;`U`FN")'TZVQ-I&UP^R?*WK:5,.FO#3CK=[
M;C55\^X(VF&`=VRO4Z5U7N:?L6Q.ZG!3Q[1;)[3;"8A#P/9W`<<V^Q6&2#*M
MQ^"3+DU]"/#^'7-D\I^VO[5Q!:+ESGY$IS]>X8UGSNHLYJ:_=D\_=375Z[Y3
MS6@ZF-%&L;U-8&M'0%L9A,!A=.63<=@[:*VLV_)8*5/6YQJY[NMSRYQZ2MHB
MS*[H"("+@GS/\<R'+N!W(C',4H;G)\AM,<QMJMHL>JYUU<V+K6?8G)=;@U=:
MQ)FRW&X[*W%$VA1DA"E'T(S$F\F[NUL>9F*N[V6.&U9-(7/>X,8VL,H%7.(`
MVD#:=YHHXYN6MU>\N<I:V<<DUR^*/A8QI<YU)HSL:T$G8"=@W!4C_P`U[DQ\
MW;?3\DF?_B^.BGZ9:0^E<;^50??K0']$=6?1>1_)IOO$_->Y,?-VWT_))G_X
MOA^F6D/I7&_E4'WZ?HCJSZ+R/Y--]XGYKW)CYNV^GY),_P#Q?#],M(?2N-_*
MH/OT_1'5GT7D?R:;[Q7</+`QS(<1X'<=\<RNAN<8R&KQS)&K*BR&KG4MS7.N
MY]EDEIN=5V3$:;$<<CO(<23B$F:%I470R,<Z^<EW:WW,S*W=E+'-:OFC+7L<
M'L=2&(&CFD@[01L.\46_W*.UNK+ESB[6\CDAN612<3'M+7-K-(=K7`$;"#M&
MXKO81DI'0$0$0$4)O-+R5-DN0,VWW`V/GP]B-TK%V186,"+7KE;7998O:K<>
ML<>B*1(Q&=*>(C<EU1''U-;CD%YY:G!L1R]\0VHM+1QXO4;79/"L`:UQ=2XB
M:.AKSLE:!N;)Z6X"1K110%KWD)@-2R/R>GW-QV8<27-#:V\CCTN8-L9)WNCV
M;R8W.-56WW]\N3F-QQDS%YYLODUMC<4UJ3G6W\5[/,,=C(Z?#)%IC[4J30,K
M5J246L>O?,R_8]#(SVWTQS9T#JUC1C,A"R[=_L9R(90>H->0'GMC<\=JU6U)
MRNUSI9[CD;"9]J/]M"#-$1UES`2P=D@8>Q</B1E'Z`B`B^U"A3;*7'@5T25/
MG2W4L184*.[*ER7EGHAF/'80X\\ZL_0E)&9C\221PL,LKFMC:*DD@`#K).P+
M]QQR2O$<32Z1QH``22>H`;2I(>//E,<U>04F!*3MA-VEPZ4XTJ1F>\+<K"F6
MXCFCA2*_%I<9>;W)2(^JX[C%<<-T^WND-I42Q$FJN>/+S2S',-XV^OVC9%:T
MF->IT@/<LH=C@9.(;:-)%%*>F.2^O=2O:\6CK*Q)VRW-8A3K;&1WKJCXI#.$
M[*N`-59/X7>45QVXHR*K-\E1_GLWEKU,RXV:996LQ\=Q>>WJHGL(PPWIT&NE
M,+[5-SYKLZ>VXCQ&'(Q*-L:C<PN>NJ];L?CK/_X[3[J@Q1.)DD;U32T!<#TL
M8&,(-'!]*K:K07)/3&C7,R%W_P#(9UM")9&@,C=UQ15(:1T/>7O!%6EFY2P"
M$5,R`B`BT=R2WYQ#C+LCN%O=FZC72X-1N3F:UIU#4O(+R4ZW7X[C5>I9*2F;
M?W<IB*A9D:&O$-Q>C:%&61Z1TS?ZPU%:Z=QW_47,E"ZE0Q@]*21W8Q@<XC>:
M4&TA8]JK4=CI+3]SJ#(?S%O'4-W%[SZ+(V]KWD-!Z*U.P%?G_<@M^]QN3&[&
M5;P[HW+MMDV3S%+;CI6[^"\>IF5N%4XQC\1Q:RKZ*EC+\-AI/51]SKAK><<<
M7U"TMIC$Z/P<&!PL899PMW[.)[S\:1Y^4]YVD^1HHT`#FQJ;4F4U9F9LYF)"
M^[F=N^2QH^+&P?)8T;`/*35Q).EQD"L*D3\M'A'(YL[^-XY>KFP-H]OHD/*]
MUK:$:VI,BM=EJ9IL-KI39I.);YE+CNMI=U2J/"CRGT=SC*&UQ3S?YBLY=Z8-
MW;<+L[=.,5LT[0'4J^5PZ6Q`@D?*>YC30.)$G\J-`.U_J06MQQ-PELT27#AO
M+:T;$T]#I2"*]#&O<*EH!ME;@^5SP*W(@QH=QQNP>B7"AQX4.?@)V^W4]I$5
MA$9AZ2[A5E1M6\I+2"[G)R)2G5>TYW*ZC1_%\YN9N(D,EOE[F0.<26S\,[34
MU(`F:\M%>AA;3<*!;G9/E#RXRL89/BK>,M:`##Q0$4%`3W3F<1[7AU=YJ5P]
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M*.[4RB2C4>G0NIBKM/%<[O`+["#NB=\=UM`^U=!1Q_A-5+=>%]O=DV69/>@;
MGVVPG[9L]6_<N47O)[RFN7_&&JL,MM,3K=T-OJQMZ38YKM3*G9$Q306D$\J9
MD&.S*ZKRJIB,,]RI$HH3T"-V*-<@D]JE3+HWGAH/64[+&&=]GE'D!L-R!&7D
M[*,D#G1N)/Q6\8>ZHHRM0(CU=R8UOI&%U[-"R[QC`2Z6W)>&C?5["ULC0!\9
MW"6-IM=NK&>)?43H"("*R-]7AW+FQ\SY%;.OR5.5UMC&)[EU<-:O8A3<?M9&
M+7TF.@C+VK-C)JY+QF2ND1O3MZ]VI/BJP\;L?B<^T4E9-+;N/6'M$C`?M3')
M3[8[^C:CPQY:1M_E,&XUB?#'.T=18XQO(^V$C*_:CSVE!I@MOD!%S/R;XB;#
M<NL/_@AO5AD>Z5$;>+'LLK5-U>;XA(?[5+E8SD;;+LB&3CC:5.QG4OP9)H3X
M[#I)(AF&CM=ZFT+?_/\`3UP8PXCCB=Z4,H'1)'4`]CA1[:GA<%B>K=$Z<UM8
M_,<_`).$'@D;Z,L9/3&^A([6FK'4'$TJL;R<\B?D9ME*L+SC];5N_6%I-;\>
MF6]!Q/<RN8[NXV)-39RVL=R`HS2B(GH4Y$F2I*C3";U2D]Q-'>)32>88VVU3
M&_&9#<7T=+;N/6'-!D94]#V%K>F0[2M2]6^'?5&)>ZXTT]F1L-X;41SM'46N
M(8^@Z6/#G=$8V!0TY]M?N3M5<+Q_<W`,SV^O&U+2=5FF,W.,SU>&9$I;4:XA
MPW'FM#(R6@E(4DR,C,C(Q/\`C,SB,W`+K#W5O=6Q^5%(R1OG+":'L.U05DL1
ME<//\VRUM/;7`^3+&Z,_`X"OE"P47)6Y`1`19_M_M3N?NQ:E1[7[=9QN)<&I
M*3K<)Q6[RB6WW%KW/LTT&8N.TE)&I2W.U"4D:C,B(S%LRF;PV$A^<YF[MK2#
MZZ:1D8\Q>17R#:KEC<-E\S-\WQ%K<74_UL4;Y#YPT&GE.Q3)\9/(FY&[ERZ^
M\Y!6]9L-A:_"D2*9M^OR[<RQCJ,G$L1JJJEO8YC_`,)9(R4[.G+E15J+O@N&
M2D%`&L?$II/#L?;:6C?D\AN#Z.BMVGK+G`2/H>AC`UPW2#85.FDO#MJC+/;<
M:F>S'6&\MJV2=PZ@UI+&5'2]Y<T[XSM"LU<8>'FP7$+$E8KLKA;%0_.:CIR3
M,K9:+;.LP?C)(D2,DR1QEEY]I+G<XW#CHC5T9QQ9L1VN]6NGNLM>ZGUW??/=
M0W!D:TGNXF^C#$#T1QU(!Z"YQ=(X`<3W4"VSTCH?3>B;+YG@(`QS@..5WI32
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MW0+BUCB0T$@5I2I`Z0IZ\.^"S>,UK=7&2L[JW@.+D:'2Q21M+C/;$-!>T`D@
M$TWT!/0K7XTB6Y:`B`B`B`BI9^;3L-OEFGF";_Y+AVS&Z^68Y9?YJOP=D&-;
M=9?>TD_X'LGMO`E_`K6KIY4"5\%GQ76'/#<5V/-J0K123(NA/([4VF\?RMQ=
MG?Y"Q@NV?.>)DD\3'MK=W#A5KGAPJT@BHV@@[BM"^=&G-0W_`#+R5W8V%Y-:
MO^;\+XX)7L-+6`&CFM(-""#0[""-X4<OYKW)CYNV^GY),_\`Q?$L?IEI#Z5Q
MOY5!]^HN_1'5GT7D?R:;[Q/S7N3'S=M]/R29_P#B^'Z9:0^E<;^50??I^B.K
M/HO(_DTWWBE@\E_9#>C`^;U%D&<;0[H890M[<[@Q7+O*\`RO':AN5)KXB8T9
M=E;U,.&E^0I)DA!K[EF70C$(>(/4>GLGRZDM<;?V=Q<F[@/!'/'(Z@<:GA:X
MF@Z338IFY#Z?SV.Y@1W.0LKN"V%K,..2&1C:D"@XG-`J>@5VJX,-#5N^N<N8
M=79WG$?E+2TM=/N+FXXY;WU=34U<2186=I9V&V>3Q(%=70(C;TJ;/FRGD-,L
MM(4XXXHDI(S,B&6:"FAMM=86XN'MCMX\M9N<YQ#6M:VXC+G.<:`-`!))-`-I
M6+:XAEN-%9BWMVN?._%W;6M:"YSG.@D`:T"I))-`!M)V!0YQ=J,]F^6%Y>."
M6.V^82;RDY3[/SLRP^7B%VY<4^.M;J;C/6TW)*%VO.=6T[-;-0N0[):0RAEU
M*EF25$9SX_-XR/G)JK)17=N+:3"W0BE$K.%\AMH`T1O#J.>7`AH:2200-H4&
MLPV2DY1Z8QTMK.;B/,6QEB,3^)K!<3EQ>SAJUH:027`"A%=A7`>8<#=[,3VR
M\P&EL\0S_*\>X^(Q':7BY1M8[?W#UUCVX7*'#]QKC),'AQ8#\FX=A8A`-=FZ
MQXZ6CM'TJ4KP5*;D^PYF:=OLQI>XAGM8+K*][<Y%YD8P,?!CI8&1S$N`:#*Z
MD8-*]VT@#B%8WON7.?LL3J6":"YFM<9W=MCV!CW%S)K^*=SX@`2XB(5D(K3O
M'`GT32XJ-"%O&@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(M,9_Q
MQX^[K.OR=S-C]I,^F2#-3MAEVW>)9!9^(:%M^.W9V=3)L&9"6W%$3B'$N)(S
MT,AD&+U;JG"-#,/DKZUC&YL4\K&^3A:X-(["**PY+2VF<RXORV/LKF0_*D@C
M>[R\3FEP/:#5<YV_E@\!;OO^&<8=NV?$E*EJ_!!7V/Z.K\75"/P#=5OA12\4
M]&$Z,IT3H@NU.F60<Y.9UO\`S>9NS1M/2X'[/X;';=F_?V[2L7GY1\M[C^<Q
M%J*FOH\;-O\``>W9MW;NS8%Z%+Y:?`VA5'5!XN;5OG&;-MO\-5$K)$J29ZZR
M$Y%.M$RG/[9TEJ+W1Y7'-[F9<U[S-7HJ?D.$?P<`;3S47K!RIY<VU.[Q%F:#
MY32_X>,NKYZKI[!MG]I=KVE,;:;7;=;=LJ(TJ9P;"<:Q)I1&DD&2FZ"LKT&1
MH21>CT%H,.R6>SF9=Q9>]N[MW7--)*?X[G++<=@\+B!PXFSM;5O5#%''_(:U
M;%%I5T0$0$0$0$5=+ZPSNC/J-LN/FST*2XW$S?+\OSJ^::<-'B-8#64]12QY
M22T-V-)EYS(=2D]4^+$)1EJE)C:_PKX:*?,97/2`&2V@BA83USN>YY'40(6C
MR.ITE:O>)O+R08G&8.,T9<3RS/IU0M:U@/83*X^5O8%52&ZRTZ0$5JOZN_;8
M\YM=R1HF&XZ,KAY]A-M:NDX7PM_'K+'K2'0-K9-LC^#Q+*ILS2HE*]I]1&2>
MAJTI\5<%T,SB+EQ/S%UK,UHZ`]LC2_;UEKH_@&_HW%\,4UJ<1E;=H'SQMS$Y
MQZ2QS'!GF#FR?"=W38O&J"VA0$0$0$0$0$0$0$5)KSG^,V(\>>6*+C;ZKAT.
M&[T8FSN&UC]=&3#K*'*BM;&FRV#516DDQ'KITJ$S9);0:4,NSW&FT-M(;2.B
M'A]UA?:JT08,H]TN0Q\Y@+W&KGQ\+7Q%Q.TN`)CJ=I#`22XDK03GQI.RTQK/
MO\8QL=C?PB;@:*-9)Q.;(&C<&D@/H-@+R```%$4)U4*("*=KZOK$D+Y@;I3D
MM&<2-QLRF(\]JGM;D3=S]HWHK1I,^\S>;@/&1D1D78>NFI:ZU^*1[!H.RC)]
M,Y>,@=@M[H'X.(?"MB?#0QQUO>2`>@,5(">TW%L1\-#\"N`#0Y;NH"("("+R
M+S'Z')ZYZHR6DJ,AJ9!I4_5WE;#MJYY2-30;T*>S(C.&@SZ:I/0>]M=7-G*)
M[222*<;G,<6N'D+2"O"XMK:[B,%W&R6$[VO:'-/E!!"Y9R7@#PERUYR3<\6=
MCRD/.^.^_3[?T&-//O&MUQ;S[N-Q*E;SKRWE*<4HS-P]#5KH6F:6?-#F)8M#
M+?-9'@`H`Z=\@`V;!WA=0"FRF[H6'W?+70%ZXOGP^/XB:DMA9&2>L]V&UK7;
MU]*UZUY67E_,SUV2.,F#G(6MU9MNV&7/P"-XE$LD53^2.5;:")7LI2R24'H:
M2+0A=7<Z.:#HNY.8N>#9N;$';/LA'Q>7;MZ5;6\G^6K9>]&)M^(];I"W;]B7
M\/U-G0ME8OP+X68<M#M%Q:V,0^T9J9E6NW&-9'-96:U+[V)N10+66RX1J,B4
ME9&2?9(^WH+1><S.85^"VYS62X3O#9Y(P?*(W-!\X[=ZNMIRYT%8FMOA\=Q#
M<701O(\A>'$?#V+J.HIJ>@@,U=%55M)61B[8]=408M;`83H1:,PX;3,=HM"+
MWJ2&&3W$]U*9KE[Y)CO<XESCY2225E\,$%M&(;=C(X1N:T!H'D`H%Z0\5ZH"
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("*KQ]8JKI:,AXHVQM
M'\`D4N\%<V^1D9?"X<[;F2\TLBZH/P9S9IUT[_:TU[5:;E^%&6,VF;@K^%$E
MJZG81.`?A!\FSK6HGB@B>+K#34_!F.Y;7M!@)'P$>7S*M8-NEJH@(NV^`?,>
M^X4;_5&YD>++NL'NHBL4W1Q6(;)R;S#9LJ/)=?JTR7&HR,AH)L9J9!4I;1.+
M:5'6XAF0Z8COF?H&UYB:7DP[W-CR4;N\MY#6C)0"`'4J>!X)8_8:`AP!<UJS
M_EMKFYT#J1F6:'28^1O=W$8I5\1(-6UV<;"`YFT5(+20UQ5[?:7=W;G?3`<?
MW.VIRNJS+"LFB(E5MQ5/DX2'.U/PFML8RNV5575:ZHVI<*2AJ3%>2;;J$J(R
M'-3.8++:;RDN&S<#[?(PNHYKA\#FG<YCAM:]I+7#:"0NB6%S>+U#C8LOAIF3
MV$K:M<T_"UPWM<T['-<`YIV$`K9`M*NJ`B`B`B`B`B`BI5^=MR`QS>KF"K%\
M/L6K6@V/P^)MO-L(KQ/P)>:_A:UO<P.$ZA9H4FJ?L8]6_P"R1_"ZYTB-2>PQ
MT+\.VE[O3V@OGM^PLNLE<&<-(HX0\+615^V#72#[%[=QJM">?VI;7/ZX^:6+
MP^VQ\`@)!J#+Q.?+3[4N;&?LF.WBBAY$]*#T!%:7^KT[.S*[#M^]^+*(XW&R
MBYQO;/%9"R4WXL?%V)>09:ZTD_V>,_,OJQI+A>R3L1U.IF2B+3#Q3Y^.6_QF
MF87`OACDN)!VR$,B'80&2&G4X'J6W_AEP3XK'):CE:0V:1D$9[(P7R'M!+XQ
M7K:1UJR&-25M.@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(H</.]X_V.\/#YW.\=@.3LCV#R9G<)YIAKQ93N#2X3]+
MG*6BZ&AFMC2(MM(7KHF-5N'H9Z"??#IJB+`:]&-NG!MIDX3`"=@$P(?#YW$.
MB:/KI`H,\0&FI<YH<Y&U:776-E$Q`WF(@LE\S06R./UL95+0="%H8@(@(NF^
M,G,#?[B+E;N4;)YO*HVK!3/\(L2LF_POA&6,L'][:R'&I#B8DA]I'<AJ8R;%
MA'0M9,OMDM6N'ZPT'IC75D++45LV1S*]W*WT9HB?K)!M`Z2T\3'$#B::!9;I
M+7&I-$WAN\!<&-KJ<<;O2BD`^OC.PGH#A1[03PN%2K%&P_U@79_((<.LY$;5
M95MY>DVTU)R7;Y3.:8?)?U^_3':F?)JLHH8QD?LL-%<++3JX8U2U+X7<]:R.
MFTK>P7=M4D1SUBE`Z`'-#HWGM/=#L6S^G/$K@[EC8M3V<UK<4VR0TEB)Z3PD
MMD8.P=Z>U278)YF7`W<1EEZCY/;95?C:EX6=V4O;-YI:4$I:'D;B0<8[.W73
MNU-"C]ZI0B#)<G^9F*<6W.&O'TZ86BX'F[@R?O\`6%*^.YL<N<FT.M\O:,K_
M`$SC`?/WXC_>ZETC3[\[&Y"EE=!O/M/>(DOHBQUT^XN(6:9$IPVR;C,JA7#Y
M.OK-U.B$ZJ/N+0NI#$9],ZDM21=8^^C(%3Q02MH.LU8*#9O650:CT]=`&VO[
M*0$T'#/$ZIZA1QV]BS'^&V&?]KL8_P"GZK_&Q0?F[(?T$WW#OWE7?G"P_IX?
MNV_OK!KWD+L%B[3S^3;X[/XZS'.0E]Z]W+PNH:85$2I<HGG+"ZCH;.,A!FYW
M&781&9Z:"Y6VE=3WI#;/&W\KC2@9;RNK7=3A8=_1UJW7&IM-V8+KO(6,316I
M?/$VE-]>)XW=/4N2MSO->X$[6QY1SM_L=S.QCZDS4;8P[7<&1/<(^K<6UQZ'
M*Q=OH1F2W[!EH_4K4R(\YPW)'F;FG-[O%RV\1WNN"V`-\K7D2>9K">Q87E^<
MO+C$-/>9**>4;FVX=,3Y',!C\Y>!VJ#OF/YZFX6Z=+<;?\7\9M]G<9M&WX4[
M<B^FQ7-T9M<\3C2VZ*)4O2JC!'GV5Z*D,R[":@]%,/QUI[CV.T#X;,5A;B/*
M:RFCO[QA!%NP'YN'#;Z9<`Z8`_)+6,.YS7#8M?=<^(?)YB!^-TC$^QM'@@SO
M(^<%IV>@&DMA)'R@Y[Q\ES3M4`*UK=6MQQ:G''%*6XXM1K6M:S-2EK4HS4I2
ME'J9GU,QM```*#8`M;"234[25_`+XMJ[);,Y]R#W3PW9_;*H5<YCFULW65S)
M]Z(<%A*%R;.[MI#;;IPJ2BK679<Q_M5X4=E:B)1Z).RZBU!C-+86XSV8D[NP
MMF<3CTD[FL:-E7O<0UHZ7$;MZO&G\#DM39B#!XEG>7UP_A:.@#>Y[CT,8T%S
MCT-!W[E^@QQQV*Q+C1LCMULAA1*71X#C[5:JP=1X<F\NI3SUGDF1S4=[A-3,
MBR";)FN-I/PVE/\`AMD3:4I+EMJW4M]J_4=WJ/(_]3=2EW"-S&`!L<8[(V!K
M`=YI4[22NE^EM.V6E-/VNG[#_I[:(-J=[W$ESWGM>\N>1N%:#8`MVC'5?T!$
M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!%]2?`A6L&;5V<2//KK*))@6$&8RW(B384QE<>5$E1W4J:?CR6'%(6A1&E25
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MM+`\1+;]WDENZ2:^@HX9K+Q)4EQMLE&E"34XM"%6'4>IL'I+%OS&?N&6]DP;
MR?2>[H9&WXSWGH:T$[R:`$B]Z?TYF=4Y)F)P<#Y[QYZ!Z+1TO>[XK&#I<X@=
M&TD`W5_+N\NK`^#>%2IK\J+F6]^9UT)K/L\)@TQ(,=M+4E6&X6V^VB1"Q:)8
M)\1QY:42K1Y"'GTH2W'CQ^>?-;FOD^9&1;&UKK?3EN\F&&NUQW=[+389"W8`
M*MC!+6U)>Y^^_+#E?CN7M@9'$3Z@G:.^FIL`W]U%7:(P=I)HZ0@.<``UK9(Q
M$BE1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1
M`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1
M`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1
M`1`1`1`1`1`1>?;5-5?5=C27E97W-+;PI5;;5%M#C6-7:5TUE<:;7V,"8V]$
MFPI<=Q3;K3J%-N(4:5$9&9#U@GFMIF7-L]T=Q&X.:YI+7-<#4.:X4((.T$&H
M.T+RFAAN876]PQLD#VEKFN`<US2*%K@:@@C8010C>H$>6'D.[3[CS9^7\8<K
M:V6R*6IV1(P'(6K"\VQF27.Y?_-,ME4G)L+0Z^LU+2A-I$0DB0Q%826@V;T1
MXE\YB8VV&L8#D+1M`)F%K+@#[(&D<M!NKW;CO<]Q6N.L_#IA<I(Z]TE,+"Z=
MM,+ZO@)^Q(K)%MWT[QHW-8T*!+>SRT.;.P[TYS+-B,MR"A@FXL\NVWC'N)CC
MD-LE&JQ>>Q8K"SI87L'J=E%@K3T[DEW)UV:T[S?Y=ZF:T6.3@BN7?[*X/<25
M^M`DX6O/JW/'4=A6N.?Y4:^TXYQO<=-+;-_VD`[]E/KB8ZN:/6-8>L;EPM(C
MR(C[L64P]&DL.*:?CR&ELOLNH/M6VZTXE+C;B#+0R,B,C$DL>V1H>P@L(J"-
MH(["H\<US'%CP0\':#L(\H7PC]+\H"("("("("+H?9_B7R7W\?BM[0[(;BYM
M%EFDFKV!CDR'B:#49$GX7F5LFOQ2`2]>AOS6R,B,RZ$>F*Y[7&D-,-<<]D;2
MW>W>QT@,OFB;Q2N\S"LGP>B]5ZD<!A,?=7#'?+#"(_/*[AC'G<%-=QF\@/.K
MF579#RKW#KL-I?O4E_;O;*4S>Y;)29-J5`N,PF0UXS0NH7W)<^`LW"5H]X\@
MS[DZ\:P\3^-MV/M=$VC[BXV@3W`+(A]DV('O']G&8J'>T[C/FD_#9D9WLNM8
MW38+?83!`0^0]CI2.[9V\`EKT.&\6.-A^.6RO&;#&\#V1P"DP6A-33]BN`VY
M)NL@G-(4A-GDV0SW)5WD-BE#BDH=EONFRV?AM]C9)06INIM6:AUAD#D]174E
MS=;F\6QC`?DQL;1C&]8:!4[34U*VDTYI;`Z3L!CM/VT=O;;W4VN>?KI'FKWN
MZBXF@V"@H%NT8ZK^@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(HT>=_P#@3OT;?^"L?RX?^*1^P?\`
MZ?\`\T2_RT_G!_W=\8__`(C_`%__`.7G44<Q?YL_]J[A_P#EO)T?ZO,JE')O
M_"+7^15_<OY,G^#_`/O*'_[J_P#2_P#9O$&\FCOBL_[AZ?\`\AO^*?C?ZOLJ
M+2W5OQG_`/X#^X;OC#XO^GQ:KBH2$L"0$0$6Q-KO^M\#_N\_N?\`WH_]4/\`
M#(G^'_\`I?\``^(+5F?^@=_U?]W_`)W<?B_Z;Z*YXC_KF_\`2_WC^:WC?_IN
MJK,?`S_"<?\`H9_\*K_^I'_?S^QI_9O_`&K_`-1_PWBC3_F9\27W@;G?SW_1
M>;LZ^SA6V/+GX\?_`&)O;_-?]9Y^WJ[:JQ<Q^PL_L7[$W^P?L/O"_8?^"_L?
MM#5%WQCOW]._S]JVA;\4;MW1N\R^4?E?4!$!$!$!$!$!$!$!$!$!$!$!$!$!
C$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!%__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
